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IVF in the Netherlands
In Vitro Fertilisation (IVF) is a technique to fertilise oocyte and spermatozoa, literally in glass, 
in a laboratory setting. IVF is applied in couples who have not conceived after a period of 
unprotected intercourse. 
Since the beginning of IVF treatment in the Netherlands (1983), the number of treatments 
have gradually increased from around 1500 cycles per year in the first years (Haan et al., 1991), 
to more than 11,000 cycles in 1996, and well over 16,000 cycles in 2007 (www.lirinfo.nl). The 
technique has also improved, which resulted in a higher chance of success per treatment. 
Initially the ongoing pregnancy rate (the chance of pregnancy, with ultrasound observed 
fetal heart beat, after at least 8 weeks gestation ), was around 15 % per cycle (Haan et al., 
1991), and increased to an average of 25% per cycle in 2007. Today, one in every 39 newborns 
in the Netherlands originates from IVF or ICSI treatment (www.lirinfo.nl). 
The increase in the number of treatments was due to a widening of indications for IVF 
treatment. Initially IVF was developed for women suffering from infertility because of bilateral 
tubal occlusion. Ten years after the introduction, also other female related subfertility causes 
such as: endometrioses, cervical hostility and hormonal disturbances were treated with IVF. 
Reduced semen quality of the partner, and unexplained subfertility became indications for 
IVF treatment as well. In 1992, with the development of Intra Cytoplasmic Sperm Injection 
(ICSI) (Palermo et al., 1992), in which fertilisation takes place by injection of a single 
spermatozoon directly into the oocyt, the indications for assisted reproductive technology 
(ART) increased further. ICSI has become a treatment option for many couples with severe 
male subfertility, who would have no, or only a very low chance of fertilisation with IVF. The 
possibilities of treatments of in particular severe male infertility (ICSI) have expanded with 
surgical retrieved sperm, used in percutaneous epididymal sperm aspiration (PESA) and 
testicular sperm extraction (TESE). 
Furthermore, the mean age at which Dutch women deliver their first child is 29,4 years, one 
of the highest worldwide (Uitstel van ouderschap, www.RVZ.nl). The physiological process of 
biological aging of the ovary results in a decrease of quantity and quality of the oocyte 
reserve and a lower natural pregnancy chance (te Velde and Pearson, 2002). As a consequence 
of postponement of maternity more couple will need ART.
In the Netherlands, the number of IVF centres with a license for an IVF laboratory is restricted by 
the Ministry of Health to 13 (Gezondheidsraad, Herziening Planningsbesluit 1997). Soon after 
the introduction of IVF, the increasing demand for ART exceeded the supply. This was partly 
overcome by the introduction of transport- and satellite clinics: To limit traveling time and 
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inconvenience for the patients, the first part of the IVF treatment is offered in the local hospitals 
by their own gynaecologists. After retrieval at the transport-clinics, the oocytes are ”transported” 
to an IVF centre for the laboratory procedure. Satellite-clinics, monitor the ovarian stimulation 
“at a distance” from the IVF centre. Next, the couple is referred to the centre at the moment of 
oocyte retrieval (Roest et al., 1995). This way, the capacity of the IVF laboratories is used effective 
without overburdening the medical staff of the IVF centre. Concentration of experience and 
expertise, another condition of the ministry, could also be guaranteed. 
In the past 25 years all IVF centres and their laboratories have scaled up. The 13 IVF centres 
start between 300-2000 treatment cycles a year (mean number of treatments per IVF centre 
in 2006 was 1105). The average ongoing pregnancy chance per cycle of IVF or ICSI treatment 
is 25%, but may vary from year to year explained by the differences in population treated 
(patient mix) and by pure chance (www.lirinfo.nl). 
In the early years of IVF in the Netherlands, differences in pregnancy rate between 5 IVF 
centres were found, even after adjustment for patient mix (Haan et al., 1991). It is interesting 
to know if this still holds true today. 
Patient characteristics
Reproduction is a matter of chance. The monthly probability is more or less constant, but 
between couples there is a wide variability in chance (te Velde et al., 2000). Dependent on 
different patient characteristics the chance of pregnancy could be predictable. 
With increasing women’s age the pregnancy chance diminishes. Female fertility is limited by 
a biological age-dependent process and studied in natural fertility populations (Eijkemans, 
thesis, 2004). The decline in fertility is expressed in a decreasing quantity and quality of the 
available oocytes and follicle pool. 
Subfertility, defined as a failure to become pregnant after at least 12 months of unprotected 
intercourse, can be categorized by the cause. With diagnostic examination a distinction into 
female factors, e.g. tubal occlusion, hormonal disturbances, or a male related subfertility can 
be made. In around 30% of all subfertile couples the reason cannot be found. 
For subfertile couples treated with IVF, the impact of female age on the chance of pregnancy 
was found to be the most important determinant of success. The degree of subfertility can 
be expressed in a period of time, or the duration a couple has been unsuccessful at conceiving. 
With a history of pregnancy (secondary subfertility), and in particular when IVF had led to a 
live birth, the chance of pregnancy was higher compared to women with a primary subfertility. 
The influence of the diagnostic category on the chance of pregnancy is less clear (Templeton 
et al,. 1996). 
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A combined influence of the different subfertility related patient characteristics on the 
pregnancy chance with and without treatment, would give a prognosis of pregnancy and 
could be  used to decide whether to start treatment IVF or not (yet).
Lifestyle, such as overweight and smoking as possible confounders on the fertility of a couple 
are studied worldwide on a large scale. Although research on lifestyle factors cannot reach 
the highest levels of evidence for ethical reasons, large cohort studies on the negative impact 
of lifestyle factors on IVF treatment, may lead to more awareness of patients and professionals 
on this subject and maybe to a change of habits.
Besides patient characteristics and lifestyle, the influence of psychological factors on 
subfertility have been an issue of interest for several years. The “evidence” that stress has a 
negative impact on fertility is well known by laymen. Many of them know the examples of 
subfertile couples who finally succeed in having a spontaneous pregnancy after going on a 
holiday, moving to another house, and/or being occupied with something else than the 
fertility problem. The scientific evidence of the influence of distress as a determinant on 
fertility is however contradictory. 
IVF guideline
So far, only for tubal pathology there is scientific evidence of the surplus probability over 
waiting for a spontaneous pregnancy (Soliman et al., 1993). For couples with other reasons for 
subfertility, IVF is still not evidence based. Not only in comparison with spontaneous pregnancies, 
but also compared to other treatment options as Intra Uterine Insemination (IUI).
A spontaneous pregnancy and a naturally conceived pregnancy are used synonymously for 
the situations that a pregnancy occurred without fertility treatment. Although the expression 
naturally conceived pregnancy seems more appropriate, we used spontaneous pregnancy as 
this is most commonly used in the literature. 
The NVOG (Dutch Society for Obstetrics and Gynaecology) developed a guideline IVF 
(www.NVOG.nl) indicating when referral for IVF of subfertile couples is justified. The guideline 
is based on different observational studies and consensus meetings. For the indications for 
IVF and ICSI treatment the different causes of subfertility are classified in the following 
categories: tubal pathology, endometriosis, hormonal and immunologic subfertility 
(including cervical hostility), male subfertility, and unexplained subfertility. The indication for 
IVF treatment is dependent on the cause of subfertility, the duration of subfertility in years, 
and on women’s age. The guideline was updated for the last time in 1998. Validation and 
revision is recommended every 5 years. Meanwhile, IVF and ICSI treatments are established as 
full treatment options although most recommendations are still not evidence based. 
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Prognostic models 
Ideally, a couple should only be referred for IVF treatment if the prospects of a spontaneous 
pregnancy are low and the chance on pregnancy would be considerably higher with IVF 
treatment. IVF treatment is an expensive, physically and emotionally burdensome treatment, 
with risks for complications, and should be withheld for couples with still a reasonable chance 
of a spontaneous pregnancy. Appropriate indication for IVF treatment for subfertile couples 
has been subject for research for many years and have lead to the development of several 
prognostic models predicting the probability of a spontaneous pregnancy in untreated 
couples (Eimers et al., 1994, Collins et al., 1995, and Snick et al., 1997, Hunault et al., 2004, van 
der Steeg et al., 2007), as well as predicting the probability of pregnancy with IVF (Haan et al., 
1991, Templeton et al., 1996, and Stolwijk et al., 1996). The patient characteristics: women’s 
age, the duration of subfertility and the pregnancy history (primary or secondary), appeared 
to be important predicting factors in both spontaneous and in IVF pregnancies.
Several draw-backs on models on the spontaneous pregnancy chance should be considered: 
the prognostic models for a spontaneous pregnancy are largely based on couples who have 
not been treated before. For the majority of women, prior to the start of IVF, some kind of 
treatment, mostly IUI, will have been performed. Since there is a couple-to-couple variation 
in pregnancy chances, couples with lower chances are more likely not to have conceived 
during previous treatment than couples with higher chances. For that reason the average 
spontaneous pregnancy rate for these couples waiting for IVF will be lower than in untreated 
couples and can not be compared with couples who have been referred directly by the 
general practitioner (as in the study of Snick et al., 1997). In the study of  Hunault et al., 2002, 
the predictive value of a Dutch model with data from a tertiary setting (Eimers et al., 1994,) 
was tested reasonable on the data of a Canadian study obtained from tertiary clinics as well 
(Collins et al., 1995). On the other hand, prognostic models developed in tertiary clinics may 
not be applicable in a general Dutch fertility clinic. 
The models for the prediction of the pregnancy chance with IVF (Haan et al., 1991), have 
become outdated with the introduction of ICSI. Moreover, although important for its size, the 
Templeton model only predicted the pregnancy chance for one diagnostic category and one 
cycle of IVF (Templeton et al., 1996). Furthermore, validation of the Templeton model in a 
Dutch academic IVF centre was unsatisfactory: only couples with a very low chance to 
conceive could be distinguished from couples with a very high chance (Smeenk et al., 2000). 
To update the IVF guideline, there is a need of a prediction model for the pregnancy chance 
with IVF and ICSI treatment and a prediction model on the spontaneous pregnancy chances 
before treatment with prospectively collected national data. 
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After termination of IVF treatment, spontaneous pregnancies are still possible, both after 
successful and unsuccessful IVF treatment. Only a few studies, mostly on selective patient 
profiles are available on this subject (Cahill et al., 2005, Ludwig et al., 2008, Osmanagaoglu et 
al., 2002). With the large OMEGA-dataset, a study on long-term health effects related to 
fertility treatment (Klip H. Thesis, 2002), we had an unique opportunity to study patient char-
acteristics and lifestyle on the chance of spontaneous pregnancies resulting in a live birth for 
women who terminated IVF treatment. 
Costs
The profit of a pregnancy with IVF should be balanced between the disadvantages of the 
costs and risks of treatment. Information about the actual costs of IVF treatment in the 
Netherlands is available, but cost estimates differ widely and the costs for ICSI were not 
separately assessed (Goverde et al., 2000, Fiddler et al., 2006). For those reasons, detailed cost 
estimates should be gathered. 
Next to direct costs, there are indirect costs e.g. originating from sick leave due to health 
related problems. Absence from work may result in productivity loss (Fiddler et al., 2006), but 
only a part of the treatment cycle was covered in this study and the cause of absence from 
work was not available. If we would know to what extent physical and emotional complaints 
causes the absence of work by studying the predictors of absence of work, we might be able 
to prevent extremes. 
Study
The Dutch Health Council indicated in 1997 that there is little evidence to support current 
IVF-practice and recommended an effectiveness study on IVF and ICSI treatment to find out 
for which couples, according to the subfertility cause, this expensive, physical and 
psychological burdensome treatment, is cost-effective (Gezondheidsraad, Herziening Plan-
ningbesluit 1997). In 2000, a cost-effectiveness study was published comparing IVF treatment 
with postponing IVF treatment, using the Templeton model for IVF and the Collins model for 
spontaneous pregnancies (Mol et al., 2000). Because of the limited external validity of the 
used models in this study, there was still need of a cost-effectiveness study with randomized 
controlled data among subfertile couples, which should provide the tools for the appropriate 
indication for IVF or ICSI. A comparison between couples with an indication for IVF/ICSI, but 
not to be treated (yet), on one arm of the trial, and couples treated with IVF or ICSI on the 
other arm, would be ideal. For ethical and practical reasons, subfertile couples can not be 
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randomised to wait and hope for a spontaneous pregnancy when the treatment with IVF or 
ICSI, and therefore a presumably higher chance of pregnancy, will be offered to the other 
group. However, the disproportionate supply and demand for IVF seized the opportunity to 
use the waiting lists, which arose in the different IVF clinics, to mimic postponement of 
treatment as proposed in a randomised trial. This way, prospectively collected cohort data of 
couples on a waiting list before treatment were studied on the chance of a spontaneous 
pregnancy prior to IVF or ICSI treatment. Next, the pregnancy chance of couples finally 
starting IVF/ICSI after the waiting period, could be assessed. Comparison of pregnancies 
observed in both groups, those on a waiting list, and those treated, could than provide 
models on the prediction of pregnancies with and without treatment for couples of different 
diagnostic categories, to lead to more evidence on justified indication for IVF/ICSI. 
Aims of the thesis
The main aim of the study was to assess the effect of different patient characteristics: 
women’s age, pregnancy history (primary or secondary), cause and duration of subfertility on 
the outcome of IVF or ICSI in the Netherlands, and on the spontaneous pregnancy rates for 
couples on a waiting list before treatment. Additionally, the differences in pregnancy rate per 
IVF centre after controlling for patient mix were assessed. 
We investigated the impact of other factors, such as lifestyle factors (smoking, body mass 
index (BMI), caffeine and alcohol use), on the pregnancy chance with IVF treatment and the 
spontaneous pregnancy chance after termination of IVF treatment. 
Also the influences of psychological factors on the outcome of IVF/ICSI treatment were 
assessed and a screening tool to identify women at risk for emotional problems after 
unsuccessful treatment was investigated.
The direct and indirect medical costs of an IVF and ICSI treatment were calculated. Results were 
used in a cost-effectiveness analysis of IVF/ICSI for different diagnostic patient groups, at different 
durations of subfertility and at different age, compared to the chance of a pregnancy without 
treatment for couples with comparable profiles, when IVF/ICSI treatment was postponed. 
Study design
All 13 Dutch IVF-centres agreed to participate to a national prospective cohort study on the 
evidence based indication of IVF and ICSI treatment. Over a two year period from 2002-2004, 
all new couples eligible for IVF or ICSI were put on a national “waiting list” before treatment. 
All centres started treatment according to their own waiting list and waiting period. 
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Subsequently, in 2004, the IVF/ICSI registries of 11 centres could be obtained, containing 5962 
couples. The IVF registries were crosschecked with the couples on the national waiting list. 
For 4928 couples the data matched on both registries. These couples were followed from the 
start of treatment up until an ongoing pregnancy, or if a pregnancy did not occur, until 12 
months after treatment start. For 1034 couples on the waiting list there was no match with 
the IVF registries. For these couples the medical files were searched by hand to find the 
reason why IVF/ICSI treatment had not taken place (yet). In case a spontaneous ongoing 
pregnancy had occurred during the waiting period before treatment (in 282 women), the 
subfertility related patient characteristics of the couples were determined.
During the national cohort study, a supplementary study among a subsample of women 
took place in 7 IVF clinics. Validated questionnaires assessing psychological factors were filled 
in by 783 women before a first IVF/ICSI treatment. A second and a third questionnaire had to 
be filled in before oocyte retrieval and several weeks after the pregnancy test. The IVF 
treatment outcomes of these women were obtained from the IVF registries. A daily diary 
about absence from work was kept by 411 women during the IVF/ICSI treatment up until 10 
weeks after the start of treatment.
A large supplementary dataset of the OMEGA-project initiated in 1995 and carried out among 
8457 women who retrieved IVF between 1983-1995, were used and provided information on 
lifestyle factors in relation to pregnancy with IVF. For 9669 women the influence on the 
spontaneous pregnancy chance after termination of IVF treatment was assessed. 
During the cohort study of 2002-2004, the costs of a first IVF or ICSI treatment were 
investigated in 4 IVF centres and one transport clinic. 
Finally two models predicting the pregnancy chance with IVF/ICSI and the spontaneous 
pregnancy chance while waiting on a list before treatment, were integrated with the costs of 
treatment, delivery and neonatal care, leading to a cost-effectiveness study of IVF/ICSI 
treatment for different patient groups. 
The aim of this thesis is to answer the following questions:
1. What is the chance of pregnancy for couples starting IVF or ICSI treatment in the 
Netherlands? 
2. Are there differences in pregnancy rate between IVF centres in the Netherlands?   
3. What is the chance of a spontaneous pregnancy when IVF is postponed, and the chance 
of a spontaneously conceived live birth after termination of IVF treatment? 
4. What is the impact of lifestyle factors on the pregnancy chance with IVF, and after 
termination of IVF? 
5. What is the influence of psychological factors on the outcome of IVF/ICSI? Are 
emotional problems after unsuccessful IVF treatment predictable?  
6. What are the costs of an IVF and ICSI treatment in the Netherlands? 
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Outline of the thesis
The first research question is answered in chapter 2. We described the results of a nationwide 
prospective cohort study of couples that were referred for IVF or ICSI treatment according to 
the Dutch IVF guideline. Subfertility related patient characteristics such as, women’s age, 
pregnancy history (primary or secondary subfertility), cause and duration of subfertility, were 
analysed in a multivariate logistic regression model to predict the ongoing pregnancy chance 
within 12 months after the start of IVF or ICSI. 
The second research question is investigated in chapter 3. We assessed the differences in 
ongoing pregnancy rates between 11 centres, while differences in patient mix and sample 
size variation were controlled for. For this analysis, the IVF and ICSI dataset from chapter 2 was 
used to compare the relative differences with the associated confidence intervals of the 
one-year ongoing pregnancy chance between the IVF centres.
The third research question is dealt with in chapter 4 and chapter 6. In Chapter 4 we 
estimated the chance of pregnancy without treatment for couples eligible for IVF or ICSI, 
with prospectively collected data of couples entering a waiting list before treatment. 
A multivariate logistic regression analysis was used to relate patient characteristics to the 
spontaneous pregnancy chance of subfertile couples before IVF or ICSI treatment. 
The fourth research question is evaluated in chapter 5 and chapter 6. In chapter 5 we 
assessed the impact of smoking and body weight on the live birth rate with IVF treatment, in 
relation to subfertility related patient characteristics with a multivariate logistic regression 
analysis. We used data from a nationwide retrospectively collected cohort study, the OMEGA-
project. In chapter 6 we presented a model for the prediction of a spontaneous conception 
resulting in a live birth after termination of IVF treatment for the population in the 
OMEGA-cohort. The impact of lifestyle factors, subfertility related patient characteristics and 
prior treatment results was studied.
The fifth research question was investigated in chapter 7 and chapter 8. The influence of 
psychological distress before, during and after a first IVF or ICSI treatment was studied. 
Prospective data were collected by distribution of validated questionnaires in several IVF 
clinics. In chapter 7 anxiety and depression levels were assessed and related to the 
cancellation and pregnancy rate with multivariate logistic regression analyses. Subfertility 
related patient characteristics were taken into account. In chapter 8 we tested the predictive 
value of a new screening instrument for the development of emotional problems after IVF/
ICSI treatment. The psychological dataset was matched with the IVF outcome data collected 
in chapter 2. 
The sixth research question is studied in chapter 9, chapter 10 and chapter 11. In chapter 9 
we described the pattern and the average amount of absence from work during a first IVF/
ICSI treatment cycle. The costs of productivity loss in women with paid work were estimated. 
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Additionally, the extent to which general and emotional factors contribute to absence from 
work was studied in a multivariate analysis. In chapter 10 we determined the average, direct 
medical costs of a first IVF or ICSI treatment per treatment stage, per cycle and per ongoing 
pregnancy. Detailed cost data were collected on a representative sample of patients 
undergoing treatment in 5 IVF clinics until, if applicable, the first 8 weeks of pregnancy. In 
chapter 11 we assessed the cost-effectiveness of starting IVF/ICSI according to the IVF 
guideline, compared to waiting one year longer, considering the predictive factors female 
age, duration of subfertility, pregnancy history and diagnostic category. The prospective 
cohort studies on chances of treatment-independent pregnancy (see chapter 4), and chances 
with IVF/ICSI of couples that did start treatment (see chapter 2), and costs estimates of IVF 
(see chapter 10) were integrated into a cost-effectiveness analysis.
In chapter 12, the results of the studies presented are discussed. The research questions of 
the thesis are answered, conclusions are drawn and recommendations given.
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Chapter I 2
Predicting ongoing pregnancy chances  
after IVF and ICSI: a national prospective study
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Abstract
Background: The Dutch IVF guideline suggests triage of patients for IVF based on diagnostic 
category, duration of infertility and female age. There is no evidence for the effectiveness of 
these criteria. We evaluated the predictive value of patient characteristics that are used in the 
Dutch IVF guideline and developed a model that predicts the IVF ongoing pregnancy chance 
within 12 months.
Methods: In a national prospective cohort study, pregnancy chances after IVF and ICSI 
treatment were assessed. Couples eligible for IVF or ICSI were followed during 12 months, 
using the databases of 11 IVF centres and 20 transport IVF clinics. Kaplan-Meier analysis was 
performed to estimate the cumulative probability of an ongoing pregnancy, and Cox 
regression was used for assessing the effects of predictors of pregnancy.
Results: 4928 couples starting IVF/ICSI treatment were prospectively followed. On average 
couples had 1.8 cycles in twelve months for both IVF and ICSI. The 1-year probability of 
ongoing pregnancy was 44.8% (95% CI: 42.1%-47.5%). ICSI for severe oligospermia had a 
significantly higher ongoing pregnancy rate than IVF indicated treatments, with a multivariate 
Hazard Ratio (HR) of 1.22 (95% CI: 1.07-1.39). The success rates were comparable for all 
diagnostic categories of IVF. The highest success rate was at age 30, with a slight decline 
towards younger women and women up to 35 and a sharp drop after 35.  Primary subfertility 
with a HR of 0.90 (95% CI: 0.83-0.99) and duration of subfertility with a HR of 0.97 (95% CI: 
0.95-0.99) per year significantly affected the pregnancy chance. 
Conclusions: The most important predictors of the pregnancy chance after IVF and ICSI are 
women’s age and ICSI. The diagnostic category is of no consequence. Duration of subfertility 
and pregnancy history are of limited prognostic value. 
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Introduction
In 1983, In Vitro Fertilisation (IVF) was introduced in the Netherlands as a treatment for women 
suffering from bilateral tubal occlusion. Later on, couples with other reasons for subfertility 
were treated with IVF as well. With the development of ICSI in 1992, a new treatment option 
became available for couples with severe male subfertility. 
As far as we know, the Netherlands are unique in the world for having a national guideline for 
starting IVF, which considers different diagnostic categories, age of the woman and duration of 
subfertility. All gynaecologists use the “IVF guideline” (Dutch Society for Obstetrics and 
Gynaecology, NVOG-Guideline no 09. 1998). The IVF guideline is based on prognostic models 
regarding pregnancy without treatment (Eimers et al., 1994; Collins et al., 1995; Snick et al., 1997) 
and models regarding pregnancy after IVF  (Haan et al., 1991; Templeton et al., 1996; Stolwijk et al., 
1996). The IVF models were developed on the basis of retrospectively collected data of selected 
populations. The largest study thus far was of Templeton et al. They studied factors as female’s 
age, previous pregnancies, duration and cause of subfertility. Male causes were not included. 
The IVF guideline has not yet been examined on prospectively gathered data. Additionally, 
there is a need for an update of the IVF guideline, since the overall IVF success rates have 
improved, and the models did not include ICSI. To evaluate the IVF guideline we planned to 
develop a model that predicts the ongoing pregnancy rate 12 months after the start of IVF or 
ICSI treatment, using data on patient characteristics and pregnancies. We initiated a study in 
which we prospectively evaluated the probability of pregnancy in relation to age of the woman, 
duration of subfertility, previous pregnancy history, and different diagnostic categories. 
Most fertility studies present the IVF outcome per treatment cycle. However, what really 
matters for a couple is the outcome of the whole treatment. We will therefore notably 
concentrate on the ongoing pregnancy rate per couple treated, from the moment they start 
treatment up until one year later. For comparison with other studies, we also calculate the 
pregnancy rate per cycle.
Materials and Methods
From January 2002 until December 2004, a national prospective observational cohort study 
of IVF-patients was carried out in the Netherlands. In the present paper, we will focus on 
prognostic factors. All 13 Dutch IVF centres and all 23 IVF transport clinics agreed to participate 
in the study. In a transport IVF clinic, the couples are treated from the hormonal stimulation 
up to the ovum pick-up. Subsequently, the couple transports the follicle fluid containing the 
2
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oocytes to the laboratory of an IVF centre. The laboratory phase including the embryo 
transfer takes place at the IVF centre. 
Two IVF centres and 3 transport clinics later withdrew from participation, because they were 
not able to meet the data requirements of the study. 
All new couples consulting a gynaecologist in one of the IVF centres or transport clinics were 
included in the study if they had an indication for IVF (or ICSI) according to the IVF guideline 
(Dutch Society for Obstetrics and Gynaecology, 1998). Couples were treated according to the 
centre specific treatment protocols. Only cycles with “conventional” ovarian stimulation with 
gonadotrophins, combined with pituitary down-regulation through GnRH agonists or GnRH 
antagonists co-treatment, were included. The results of cycles with frozen embryo transfers 
were not used because many IVF treatment registries did not enclose this variable.
All IVF clinics are compelled to register their IVF treatments, but there is no central national registry 
of fertility treatments and the included patient characteristics may differ between clinics. 
Patients
In the period of study, 9016 new couples with an indication for IVF or ICSI treatment consulted 
a gynaecologist. The couples that actually started IVF or ICSI were followed, from the date of 
last menstruation just before the first IVF treatment up until at least 12 months in case no 
pregnancy occurred. In case of pregnancy, follow-up continued until an ongoing pregnancy 
was confirmed by ultrasound (≥8 weeks gestation). For pregnancies ending in a spontaneous 
abortion, follow-up continued until an ongoing pregnancy occurred or otherwise at least for 
12 months. For 4928 new couples, we were able to do a complete follow-up from the start of 
IVF or ICSI until at least 1 year. Figure 1 shows the flow diagram from all patients originally 
included in the study, to those used in the analysis.
Indication 
Whether couples are indicated to start IVF or ICSI treatment according to the IVF guideline 
depends on the cause and duration of subfertility, and on women’s age. Six diagnostic 
categories for IVF are considered. When the subfertility is caused by pathology of the tubal 
function, such as tubal blockage (1) or severe endometriosis (2), IVF can be offered directly. 
In case of relative tubal pathology, the subfertility should be at least of 1 or 2 years duration. 
In case of unexplained subfertility (3), IVF is only indicated after a duration of subfertility of at 
least three years and should be preceded by intra uterine insemination (IUI). Minimal 
endometriosis is treated as unexplained subfertility (3). In case of ovulation disorders, mainly 
caused by polycystic ovary syndrome (PCOS) (4), at least twelve cycles of ovulation induction 
should precede IVF. When there is a disturbance in the interaction between semen and 
mucus (cervical hostility or immunological subfertility) (5), IVF is offered after a subfertility of 
at least two years and is preceded by IUI. An identical advice applies for mild male oligospermia 
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(6): if the multiplication of the volume, concentration and motility (VCM) of the semen after 
analyses is between 1 and10 million, IVF is offered after at least two years of subfertility and 
unsuccessful IUI. For severe oligospermia (VCM < 1 x 106), there is a direct indication for ICSI. 
For all diagnostic categories, IVF can be offered 1 or 2 years earlier if women are over 36 years 
or 38 years, respectively. There is no upper age limit mentioned, but the guideline advises 
not to treat women over 40 years of age, because of poor treatment outcome. The guideline 
for IVF is developed for primary subfertility. One recognises that women with secondary 
subfertility are somewhat different, but this is not taken into account in the guideline. 
Definitions
In case of total fertilisation failure, or if only 10 % or less of the oocytes are fertilized, IVF 
treatment may be changed into ICSI in the next cycle. When the first cycle was an IVF cycle, 
the couple was included in the category “IVF”, regardless whether later they changed into 
ICSI treatment. Primary subfertility indicates that the woman had no pregnancy before. 
Duration of subfertility is defined as the time between the date of active child wish, or the 
date of last miscarriage or delivery date, and the date of first IVF. The end point of the study 
was ongoing pregnancy, defined as a pregnancy with heartbeat of one or more foetuses 
confirmed by ultrasound, at 8 weeks gestation. Ongoing twin pregnancy was defined as a 
pregnancy with heartbeat of two foetuses. 
7024 remaining couples 
 
1062 lost to follow-up = no exact 
dates of start of IVF or ICSI 
1034 couples did not start IVF 
or  ICSI with known reason 
Follow-up of 5962 couples
 
4928 couples starting IVF or ICSI with at least 12 months follow-up  
Excluded 1992: Five clinics
withdrew from participation 
9016 couples in national cohort study  
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Figure 1       Flow diagram of all patients included in this study
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Prognostic variables
Prognostic variables found to be important in previous studies were analysed: women’s age, 
duration of subfertility, pregnancy history (defined as primary or secondary subfertility of the 
woman treated), and all diagnostic categories of IVF, being tubal pathology, unexplained 
subfertility, mild male, hormonal, cervical or immunological subfertility and endometriosis. In 
addition ICSI treatment, applied in case of severe oligospermia, was included as a separate 
category. 
Data analyses 
We used Kaplan-Meier analysis to estimate the cumulative probability of ongoing pregnancy 
after IVF or ICSI. If couples dropped out of the IVF programme within 12 months, their 
follow-up time was allowed to continue until 12 months assuming that they had no chance 
of pregnancy, so no censoring was applied (Daya 2005).
In addition, we analysed the cumulative probability of ongoing pregnancy against cycle 
number. This analysis was done twice, once with the usual censoring of patients who stopped 
treatment without pregnancy (giving the potential cumulative curve) and once with censoring 
as described above, giving the realistic cumulative curve (Stolwijk et al., 2000). In the sequel, 
we will often drop the adjective “cumulative” for brevity.
Multivariate Cox regression analysis was used to estimate the predictive effect of the following 
prognostic variables on the probability of ongoing pregnancy: age of the woman, duration of 
subfertility, diagnostic category and whether the woman’s subfertility was primary or 
secondary. To check for a non-linearity of the effect of the woman’s age, a restricted cubic 
spline curve was used (Harrell et al., 1988), with 5 knots at ages 23, 27, 32, 37 and 42 years.
To assess the internal validity of the resulting prediction model, the bootstrap method was 
used with 200 replications. The optimism corrected c-statistic was assessed, which is equivalent 
to the ROC curve (AUC), to measure how well the model is able to make a distinction between 
pregnant and non-pregnant couples (‘discrimination’). Further, the bootstrap method assesses 
whether the pregnancy chances predicted by the model are reliable, i.e. whether they agree 
with the observed proportion of pregnant couples (‘calibration’).
The results of the Cox regression were converted into a ready-to-use score chart that may be 
used by clinicians to calculate the chance of an ongoing pregnancy within one year for a 
given couple. 
Missing data occurred in women’s age (0.7%), duration of subfertility (6.4%), pregnancy 
history (6.4%), diagnostic category (6.9%), outcome of IVF treatment (pregnant or not) (3.8%) 
and whether a registered pregnancy was ongoing or not (7.0%). These missing items were 
imputed to avoid the loss of data in multivariate analysis and to avoid potential bias. For this 
purpose, single imputation with the AregImpute method in S-plus (MathSoft. Inc., Seattle, 
WA, version 2000) was used.
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Results
Table I gives the characteristics of the 4928 couples starting IVF or ICSI in one of the 11 IVF 
centres or 20 transport clinics in the Netherlands, subdivided by diagnostic category. 
The mean age of the women at the beginning of the treatment was 34.0 years (SD = 4.0) for 
IVF and 32.6 (SD = 4.2) for ICSI. The mean number of cycles in twelve months was 1.8 for both 
IVF and ICSI. The overall 1-year ongoing pregnancy rate was estimated to be 44.8% (95% CI: 
42.1-47.5%) (the upper panel of Figure 2). The ongoing pregnancy chances for couples who 
will sustain treatment for four cycles are as high as 63 %, whereas the realistic chances after 
the fourth cycle are only 42%, (the lower panel of Figure 2). 
In Table II, univariate results of the effect of patient characteristics on the ongoing and twin 
pregnancy rates are shown. With increasing female age, both rates decreased significantly. 
For women under 25, the effect was different. In fact the relationship between age and 
pregnancy chance was non-linear (p < 0.001, Figure 3), with the highest chance at age 30 and 
a slight decline towards younger and older women up to age 35. After 35, the pregnancy 
chance sharply decreased. The curve shown in Figure 3 was calculated for one specific 
patient profile: women with primary unexplained subfertility with a duration of ≥ 3 years. The 
shape of this curve did not depend on the duration of subfertility, pregnancy history and 
diagnostic category  (all tests for interaction had p > 0.05). Thus the level of the curve will 
differ between patient profiles, but not the shape. 
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Table I       Characteristics of 4928 couples starting IVF or ICSI treatment during  
2002-2004 in the Netherlands
Diagnostic 
category
Number
of 
women
Age of the
woman
(years)
Duration of
subfertility (years)
% Primary
infertility
    Mean SD Mean SD
Tubal pathology 837 34.5 4.0 3.6 2.6 50
Unexplained 891 34.8 3.9 4.0 2.1 59
Male mild  (IVF) 709 33.6 4.2 3.7 2.1 69
Male severe (ICSI) 1265 32.6 4.2 3.3 2.2 66
Endometriosis 410 32.8 3.8 3.3 1.9 71
Hormonal 353 33.2 3.9 3.7 2.1 63
Immunological 124 34.4 4.1 3.8 2.4 61
Missing  339 32.8 4.3 3.6 1.8 73
Total 4928 33.6 4.2 3.6 2.2 63
30
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Figure 2       Overall 1-year ongoing pregnancy rate (upper panel) and ongoing 
chances for couples with respect to the number of cycles (lower panel)
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With an increasing duration of subfertility there was a trend of decreasing pregnancy rate, 
but no effect on the twin rate. Pregnancy history did neither influence the pregnancy rate, 
nor the twin rate. There were significant differences between the different diagnostic 
categories: severe oligospermia with ICSI gave the highest pregnancy chances and 
immunological and tubal pathology the lowest ones.
In Table III, the results of the multivariable Cox regression model are shown. The impact of 
woman’s age is presented in Hazard ratios compared to the age 35. For example, a woman of 
38 has a 28% lower chance to become pregnant in 1 year IVF-treatment, compared to a 
woman of 35. Age, duration of subfertility and pregnancy history had a statistically significant 
effect. The chance of pregnancy did not differ between diagnostic categories for IVF. In case 
of ICSI, for severe male subfertility couples had a 22% higher ongoing pregnancy chance. 
The c-statistic, measuring the discriminative ability of this model, was 0.583 and 0.577 after 
correction for optimism. Calibration was very good, the correction factor needed to make 
the model predictions agree with observations was 0.94, i.e. very close to unity (= no 
correction necessary), (Harrell et al., 1996). 
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Figure 3       Relationship between age and pregnancy chance
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In Figure 4, a score chart is presented that may be used to calculate the predicted ongoing 
pregnancy rate for a given couple. For example, a couple with female age of 39 years (11 points), 
duration of infertility of 4 years (11 points), a regular indication for IVF (0 points) and primary 
infertility (0 points) has a sum score of 22 points and therefore a prospect of achieving an 
ongoing pregnancy within a year from start of IVF treatment of 28%, as can be read from the 
curve. Had the woman instead been 29 years (49 points), the sum score would have been 60 
points and the predicted pregnancy chance 50%. 
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Table III      Multivariable analysis with HRs for ongoing pregnancy with IVF and ICSI
HR 95% CI P-value
Age (years) <0.0001
25 0.99 0.83-1.18
27 1.14 0.98-1.32
29 1.21 1.08-1.35
31 1.20 1.14-1.28
33 1.14 1.12-1.16
351 1
37 0.82 0.75-0.91
38 0.72 0.64-0.80
39 0.58 0.51-0.66
40 0.46 0.39-0.54
Duration of subfertility (per year) 0.97 0.95-0.99 0.01
Primary subfertility 0.90 0.83-0.99 0.03
     Diagnostic category 0.11
     Tubal pathology2 1 --
     Unexplained 1.10 0.95-1.27
     Male mild 1.06 0.91-1.24
     Male severe (ICSI) 1.22 1.07-1.39
     Endometriosis 1.05 0.88-1.26
     Hormonal 1.07 0.89-1.30
     Immunologic/cervical subfertility 1.04 0.78-1.40
1 Hazard ratios for age are expressed relative to a reference age of 35 years.
2 Tubal pathology was taken as the reference category. 
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Age Points Duration Points Treatment 
modality
Points Type of 
infertility
Points
25 39 1 15 IVF 0 Primary 0
26 43 2 14 ICSI 7 Secondary 6
27 46 3 12
28 48 4 11
29 49 5 10
30 49 6 8
31 48 7 7
32 47 8 5
33 45 9 4
34 43 10 3
35 40 11 1
36 35 12 0
37 29
38 20
39 11
40 0
Sum 
score: 
…  …   …   … … 
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Figure 4       Score chart with corresponding curve to calculate the 12-months 
predicted ongoing pregnancy rate for a patient of a given age, indication, 
duration and type of infertility
35
Discussion
This large prospective study on prognostic factors predicting the chance of pregnancy with 
IVF is the first one, in which all diagnostic categories that are considered in the IVF guideline 
are studied. The most important predictive factor is women’s age. Duration of subfertility, 
and pregnancy history are also of concern for the couple’s prospect of achieving a pregnancy 
with IVF or ICSI. Both in univariate and in multivariate analyses, the effects of duration of 
subfertility, pregnancy history and diagnostic category are modest. Only for women older 
than 35, pregnancy chances become much lower, and for ICSI, in case of severe oligospermia, 
chances are higher than for IVF. The chance of pregnancy for other categories is not very 
different from the chance for tubal pathology, the IVF indication par excellence.
We think that the pregnancy rate with ICSI is not higher because of the technical procedure 
see also Bhattacharya et al., 2001, but because women selected for ICSI have themselves, in 
most cases, no factor of subfertility. The ICSI indication is indeed  primarily due to the severe 
fertility problem of their partner. This does not explain the lower twin rate for this group. 
Presumably these women more often had elective single embryo transfer; unfortunately we 
could not check this in our data. 
We emphasize that after 35 the pregnancy rate strongly declines. In this respect, the IVF 
guideline advises not to treat women over 40 because of poor treatment outcome. However, 
in our sample, women in the oldest age group (40-45) had a fair 1-year ongoing pregnancy 
chance of 24%. Probably, women over 40 with positive prospects were selected by 
pre-screening of the ovarian reserve by ultrasound based antral follicle count and serum 
basal follicle stimulating hormone (Klinkert et al., 2005).
It seems contradictory that women in the youngest age group (< 25 years) had lower 
pregnancy rates than women in the subsequent age group, but Templeton et al. (1996) and 
Human Fertilisation and Embryology Authority data (NICE guideline 2004) showed a similar 
trend for live birth rates per cycle for this age group. Despite the relatively small number of 
patients in this age group, this repeated finding suggests that it may be a real phenomenon, 
not a chance finding. The relationships between child wish at young age, lower social class 
and detrimental lifestyle habits such as smoking and overweight may be the reason for the 
lower pregnancy rate.
The IVF guideline advises on when to start IVF, depending on the diagnostic category. 
This advice is based on prognostic models for pregnancy chances without treatment (Collins 
et al., 1995, Snick et al., 1997). For couples with unexplained subfertility, the spontaneous 
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conception rate during the first three years of subfertility is substantial (Pandian et al., 2005). 
Therefore, the advice is to wait at least three years before starting IVF treatment. We found 
that the overall cumulative ongoing pregnancy rate with IVF for couples with unexplained 
subfertility is comparable with the pregnancy rate of other diagnostic categories, which 
according to the guideline, can be treated sooner. This means that the differences in duration 
of subfertility as formulated in the Dutch IVF guideline are probably appropriate. Whether 
unexplained subfertility can be seen as a separate diagnosis is under debate (Gleicher and 
Barad, 2006). It is most likely a mixture of potentially good prognosis couples and women 
with a low chance to become pregnant e.g. because of imminent premature ovarian failure. 
It would be ideal if we were able to differentiate for unexplained subfertility, between couples 
with a fair chance and couples with a low chance of conception without treatment. We would 
then be able to counsel individually when to start IVF, or maybe sometimes to advise not to 
start treatment at all.
The fertility treatment history of a patient is also of importance for the overall IVF treatment 
outcome. Before starting IVF, ovulation induction or ovarian hyperstimulation and/or IUI will 
be the main treatment options. Only the unsuccessful couples, probably a selection with 
lower pregnancy chances, are referred for IVF. Regrettably, we do not have data on the 
treatment history and can only suppose that the patients in our study were referred for IVF 
according to the IVF guideline and that in case of mild male, hormonal and unexplained 
subfertility, the conventional treatments had preceded IVF. 
We compared our results with those of Templeton et al. (1996). The impact of duration of 
subfertility was comparable. They found that only after a very long duration of subfertility 
(>13 years), the impact on the IVF-pregnancy chance is substantial. However, we did not have 
couples with such an extreme duration of subfertility. It was difficult to compare the value of 
pregnancy history. Since we did not have detailed information on the previous pregnancy, 
we could only distinguish between primary and secondary subfertility. According to 
Templeton et al. (1996) and Stolwijk et al. (2000) it is of supplementary prognostic value if the 
previous pregnancy has led to life birth and if this life birth has been due to IVF. Diagnostic 
categories cannot be compared as Templeton et al. had only tubal pathology in their 
model.
In the period of our study, the first three IVF treatments were reimbursed by health insurance. 
Economic reasons for delaying or dropping out of the programme are therefore not plausible. 
The reason for dropping out is often related to the outcome, although earlier research is 
contradictory (Roest et al., 1998, de Vries et al., 1999, Smeenk et al., 2004). We assigned a zero 
probability of pregnancy to couples that discontinue treatment, see Daya (2005). The resulting 
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curve is the one that couples should expect when they start treatment. We named this curve 
“realistic” instead of “pessimistic” (Stolwijk et al., 2000), as it represents what really happened, 
and therefore what is relevant for patients. Because patients might also want to have 
information on the cumulative chances after a given number of cycles, we made a separate 
curve of the cumulative chances against cycle number, in which dropouts are censored. This 
curve gives chances that could potentially be realised, given that a patient is able to sustain 
treatment for that number of cycles. We were not able to correct this curve for informative 
censoring, so the predicted chances will be too optimistic (Stolwijk et al., 2000).
Lifestyle like smoking, body weight, and psychological factors influence the outcome of IVF 
(Klonoff-Cohen 2005, Lintsen et al., 2005, Smeenk et al., 2001), but are not investigated in this 
study. 
Unexpectedly, most registers we received did not include an accurate registration of the 
cryopreserved embryos. We regret that the lack of the relevant information of pregnancies 
obtained from frozen embryos could not be included in the model, although according to de 
Jong et al., 2002, the  supplementary pregnancy chances by using cryopreserved supranu-
merical embryos are of limited size. 
Five IVF clinics did not deliver their IVF treatment registries. The Dutch society of Obstetricians 
and Gynaecologists website (www.NVOG.nl) reports on the number of IVF and ICSI treatments 
and the average ongoing pregnancy rate of every IVF centre. These results are not on an 
individual level and could therefore not be used in our analyses. Using the per centre 
information we could conclude that the results of the missing clinics were in the same range 
as the included clinics and that their dropout therefore will not have biased our results. 
Over 1000 women were lost to follow-up because of incomplete or sometimes incompatible 
registration files. To carry out a large prospective study as we did, a national registration of all 
fertility treatments is ideal. Only compelled uniform registration, can overcome the problem 
of loss.
The advantage of the present study in relation to earlier research is that the analyses were 
based on complete data with a long follow-up, and that, next to results per cycle, we also 
analysed the results per woman/couple treated. The pregnancy chances are therefore easier 
to interpret for counselling. Contrary to others (Dor et al., 1996; Stolwijk et al., 1996; Templeton 
et al., 1996; Hunault et al.,  2002),  we studied all causes of subfertility and both IVF and ICSI. A 
clear description of diagnostic categories and restriction of treatment to couples that comply 
with the IVF guideline, has led to a well-defined group of couples with subfertility. 
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In the present study we estimated the predictive value of patient characteristics on pregnancy 
chances with IVF and ICSI. Female age has an eminent influence on the pregnancy prospect 
of a couple. The woman’s pregnancy history and the duration of subfertility have a modest 
but significant effect on the ongoing pregnancy chance. The diagnostic category does not 
influence the pregnancy chance, except for severe male subfertility treated with ICSI. With 
these patient characteristics, we developed a prognostic model to predict the cumulative 
ongoing pregnancy chance within one year after the start of treatment.
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Can differences in IVF success rates  
between centres be explained by  
patient characteristics and sample size?
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Abstract
Background: Pregnancy rates cannot be used reliably for comparison of IVF clinic 
performance because of differences in patients between clinics. We investigate if differences 
in pregnancy chance between IVF centres remain after adjustment for patient mix. 
Methods: We prospectively collected IVF and ICSI treatment data from 11 out of 13 IVF 
centres in the Netherlands, between 2002 and 2004. Adjustment for sampling variation was 
made using a random effects model. A prognostic index for subfertility-related factors was 
used to adjust for differences in patient mix. The remaining variability between centres was 
split in random variation and true differences. 
Results: The crude 1-year ongoing pregnancy chance per centre differed nearly a factor 3 
between centres, with hazard ratio’s (HRs) of 0.48 (95% CI: 0.34-0.69) to 1.34 (95% CI:1.18-1.51) 
compared to the mean 1-year ongoing pregnancy chance of all centres. After accounting for 
sampling variation, the difference shrank since HRs became 0.66 (95% CI:0.51-0.85) to 1.28 
(95% CI: 1.13-1.44). After adjustment for patient mix, the difference narrowed somewhat 
further to HRs of 0.74 (95% CI: 0.57-0.94) to 1.33 (95% CI: 1.20-1.48) and 17% of the variation 
between centres could be explained by patient mix. The 1-year cumulative ongoing 
pregnancy rate in the two most extreme centres were 36% and 55%.
Conclusions: Only a minor part of the differences in pregnancy chance between IVF centres 
is explained by patient mix. Further research is needed to elucidate the causes of the 
remaining differences.
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Introduction
Since 1996, reports on the ongoing pregnancy rate per IVF and ICSI treatment are publicly 
available for all 13 IVF centres in the Netherlands. The National Infertility Registration (LIR, www.
lirinfo.nl), publishes the annual ongoing pregnancy rates per started cycle, per embryo transfer 
after cryo-preservation, and the number of multiple pregnancies per IVF centre. Confidence 
intervals of the ongoing pregnancy rates per centre indicate the year-to-year variety caused by 
chance alone. Variability in characteristics of patients treated (patient mix) may explain 
systematic differences in pregnancy rate per centre. Information on patient mix, and on the 
proportion of elective single embryo transfer (eSET), is lacking in the LIR survey. Thus, for several 
reasons, the pregnancy results of the Dutch IVF centres cannot be compared directly. 
Since the early years of IVF in the Netherlands, the success rates per centre have been subject 
of interest (Haan et al., 1991, Kremer et al., 2002, 2008, Lemmers et al., 2007). Haan et al. (1991), 
adjusted for a standardized good prognosis group, but differences in pregnancy rates 
between the five centres studied remained. In the UK, Marshall and Spiegelhalter (1998) 
ranked 52 IVF centres in a league table after adjustment for patient mix. There were wide 
confidence intervals for the ranks associated with the pregnancy rate, in particular for the 
small-sample-sized clinics, leading to the conclusion that the usefulness of ranking is 
questionable. Castilla et al. (2008) compared different graphical classification methods of IVF 
clinics on crude IVF data of 58 IVF clinics in Spain. The relative differences between IVF clinics 
were dependent on the method used, which again limits the value of ranking. 
The situation for IVF clinics in the Netherlands differs from the UK and other European 
countries in several respects. In the Netherlands there are no private or really small clinics and 
there is a national guideline in which duration and cause of subfertility, pregnancy history 
and women’s age determine the moment of referral for IVF. The uniform circumstances in 
which the Dutch IVF centres operate suggests that the real inter-centre differences in 
pregnancy chance between centres can be measured after adjustment for patient mix and 
sample variation. The purpose of this study is to examine if differences in pregnancy rates 
between IVF centres remain after controlling for the variation in patients treated.
Material and Methods
Patients and prognostic variables
From January 2002 until January 2004, a national cohort study on the prediction of pregnancy 
of subfertile couples was carried out in 13 IVF centres in the Netherlands. Prospectively, 
subfertile couples starting a first IVF/ICSI treatment were registered on a national waiting list. 
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During 2004, the waiting list was cross-checked with the IVF treatment registries of the IVF 
centres. Only couples that actually started IVF treatment during this period were included in 
this study. The purpose of the national cohort study was bipartite: first to estimate the chance 
of pregnancy without treatment for couples on the waiting list before IVF (Eijkemans et al., 
2008) and second to predict the ongoing pregnancy chance of a couple within 1-year after 
the start of IVF or ICSI treatment (Lintsen et al., 2007).
Although there is no uniform registration, IVF centres are compelled to register the following 
items: the number of IVF treatments started, the outcome until ongoing pregnancy 
(pregnancy with fetal heartbeat confirmed by ultrasound after at least 8 weeks gestation) 
and patient characteristics such as women’s age, the duration of subfertility, pregnancy 
history before IVF (primary or secondary subfertility) and the diagnostic category. Two out of 
13 centres were not able to deliver their IVF registries during the study period. 
If couples failed to conceive after the first treatment, subsequent treatments were counted 
up until 1 year after the start of treatment. Per couple, the mean number of IVF cycles 
performed within 12 months was 1.8. If couples discontinued treatment they were considered 
to have no chance of pregnancy, as drop-outs are often related to the prospect of treatment 
(see the ´realistic” approach Lintsen et al., 2007). For the majority of treatments, the pituitary 
down-regulation was carried out in a long protocol and preceded the ovarian stimulation 
with gonadotrophins. A maximum of two embryos (double embryo transfer, DET) was carried 
out by all centres. During the study period, eSET was not a common option of treatment. The 
registration of the number of embryos transferred per cycle and the number of frozen 
embryo transfers was incomplete, we therefore assumed DET for every cycle and did not 
include cycles with cryo preserved embryos.The average ongoing pregnancy rate for all 
participating clinics, after the first cycle was 24%, the overall ongoing pregnancy rate within 
1 year of treatment was 45% (for further details see Lintsen et al., 2007). 
The indication for IVF or ICSI is described in six diagnostic categories in the guideline IVF (Dutch 
society for Obstetrics and Gynaecology, NVOG guideline no. 09, 1998): With both sided tubal 
occlusion or with severe male subfertility, to be treated with ICSI, couples can be referred 
immediately. In case, no cause of subfertility is found, the chance of a spontaneous pregnancy 
is estimated to be high enough to justify postponement of IVF for the first three years of 
subfertility and should be preceded by intrauterine insemination (IUI). When the woman is 36 
years old, IVF is indicated 1 year earlier, and even sooner when she would otherwise reach the 
age of 40. For endometrioses, the minimum subfertile period before referral for  IVF depends 
on the severity of the pathology. With hormonal disturbances, IVF is indicated after repeated 
attempts of ovulation induction. With cervical hostility, and mild male subfertility, IUI is the first 
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treatment option and has to precede IVF.  The guideline has no absolute age limit, but gives an 
emphatic advice not to treat women over 40 years of age.
The following fertility related prognostic variables on the 1-year ongoing pregnancy rate in IVF 
and ICSI treatment were studied in a multivariate prediction model in Lintsen et al. (2007): women’s 
age, pregnancy history, duration and cause of subfertility. The 1-year ongoing pregnancy rate 
decreased with older age and increasing duration of subfertility, was lower for women with a 
primary subfertility compared to those with secondary subfertility, was independent of the cause 
for IVF treatment, but was higher for couples primarily treated with ICSI because of severe male 
subfertility. We used the same variables as used in the prognostic index, but estimated the 
coefficients for the models in this paper once again, for each centre separately and compared the 
1-year ongoing pregnancy chance to the mean chance of all centres. 
After crosschecking the IVF databases with the waiting list, we included those couples that 
matched on both registries. The period on the waiting list differed per centre. For IVF centres with 
a long waiting list, the period of  matching couples was shorter compared to centres with a short 
waiting time. This varied between centres from 3 to16 months. For this reason, the number of 
patients per centre included in the study did not correspond with the actual size of the centre. 
For the interpretation of the uncertainty of the results, sample size is of importance. Smaller 
samples can more easily take on extreme values because of sampling variability. In a new 
sample (e.g. data from a following year), the value is likely to be less extreme, the well known 
phenomenon of regression to the mean (Bland and Altman, 1994). Random-effects models 
(Laird and Ware, 1982) implicitly account for this fact by shifting results from small clinics to 
the overall mean. A test for proportional hazards was performed on the scaled Schoenfeld 
residuals as described previously (Grambsch and Therneau, 1994).
In agreement with the study protocol the IVF centres are compared while anonymity of the 
centres is preserved.
Data analyses 
Patient characteristics per centre were presented in categories and differences between 
centres tested by chi-squared tests. Adjustment for patient mix was established by Cox 
regression, with the prognostic factors female age modeled as a restricted cubic spline with 
knots at ages 23, 27, 32, 37 and 42, duration of subfertility as a linear effect, and diagnostic 
category and primary versus secondary subfertility and the centres as a categorical variable. 
The relative differences of the 1-year ongoing pregnancy chance between the centres were 
expressed in hazard ratio’s (HRs) with the associated confidence intervals (CI) and compared 
to the mean 1-year ongoing pregnancy chance of all centres during the study period, using 
3
differences between ivf centres
46
classical sum contrasts for the centre variable. The intervals indicate the margin of uncertainty 
about the estimated relative pregnancy rate. Random-effects analysis was performed with a 
normal distribution assumption for the between-centre variation in log-HR and produced an 
estimate of the variance. The differences in the estimates of the random effects variance 
between an unadjusted model and an adjusted model is a measure of variation explained by 
differences in patient mix. The Coxme function was used in R version 2.6.2
Missing data occurred in on average 5% of the following variables, women’s age, duration of 
subfertility, pregnancy history, diagnostic category, outcome IVF (pregnancy or not), and 
whether the pregnancy was ongoing or not. Single imputation with the AregImpute method 
in S-plus (MathSoft Inc., Seatle, WA, version 2000) was used to avoid the loss of data. 
Results
The 1-year ongoing pregnancy rates of 4928 couples starting IVF and ICSI treatments from 
2002 to 2004 were analysed per IVF centre. The distribution of patient characteristics per 
centre are presented in Table I. The range for women < 30 years of age was from 15% to 25%, 
for women ≥ 35 from 29% to 54 %. The range of couples with a relatively short duration of 
subfertility < 3 year was from 35% to 59% and for a long duration of subfertility ≥ 6 year was 
from 6% to18%. Centres differed in the percentage of couples with a primary subfertility 
ranging from 57% to72%. The range per centre for ICSI treatment was from 19% to 59%. 
The differences in patient mix between centres were statistically significant with p < 0.001. 
Table II presents in column A the crude HRs per centre with the associated 95% CI, of the 
ongoing pregnancy chance per couple after 12 months of treatment, compared to the mean 
chance of the centres. The results after accounting for sampling variation are shown in 
column B, and subsequently adjusted for patient mix, in column C. The matching figures 
(Figure 1) give a graphical representation of the estimates. The size of the spot corresponds 
to the size of the sample, but not with the actual size of the centre. The unadjusted HRs 
demonstrate a significantly low relative pregnancy chance for centre no. 1, HR 0.48 (95% CI: 
0.34-0.69) and relative high pregnancy chances for centres no. 4, 3, 10 and 11 with HRs 1.34 
(95% CI: 1.18-1.51), 1.30 (1.10-1.54) 1.29 (CI: 1.16-1.44) and 1.13 (CI: 1.01-1.26), respectively. After 
accounting for the sampling variation the estimates with their CIs shrunk towards the mean 
for most centres. Then after adjustment for patient mix, the relative 1-year ongoing pregnancy 
rates raised for centre no. 1, 2, and 10. This means that these centres have treated relatively 
more patient with a poor prognosis. The rates decreased for centre no. 3, 4, 5, 7, 8, and 9 after 
adjustment of patient mix, which suggests that they treated relatively more good prognosis 
patients. Finally, the lowest estimates were for centre no.1 and 8, with HR 0.74 (95% CI 
0.57-0.94) and 0.85 (95% CI 0.75-0.97), respectively. The relative 1-year ongoing pregnancy 
chance was highest for the centres no.10, 4 and 11 with HRs 1.33 (95% CI: 1.20-1.48), 1.22 (95% 
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CI: 1.08-1.38) and 1.13 (CI: 1.01-1.27), respectively. With the adjustment for differences in female 
age, duration of subfertility, diagnostic category and primary versus secondary, 17% of the 
variation between centres was explained. The 1-year ongoing pregnancy chance of the 
centre with the lowest and the highest HRs were 36% and 55%. 
In Table III, we give a similar presentation of the ongoing pregnancy rates in odds ratios (ORs) 
per first IVF cycle to account for differences in time span between attempts for the different 
centres. Figure 2 is corresponding to the table. The estimates per centre after random effects 
and patient mix adjustment were comparably related to the average of all centres, as in the 
HRs of the 1-year ongoing pregnancy rates.
Figure 3 presents the relationship between the real size of the centres by the number of IVF 
cycles started in 2003, obtained from the public LIR data (www.lirinfo.nl), and the HRs of the 
relative 1-year ongoing pregnancy rates after adjustments. The slope of the line shows a 
positive association with centre size and pregnancy rates, although not significant p=0.34. 
Discussion
Differences in 1-year ongoing pregnancy rates between IVF centres in the Netherlands exist, 
even after adjustment for sampling variation and patient mix. The estimated HRs for the 
1-year ongoing pregnancy chance was 36% for the centre with the lowest estimate and 55% 
for the centre with the highest estimate. 
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Table II       Centre success rates after 12 months of treatment, in HRs, relative to  
the average of all centres
Centre
A B C
Unadjusted
Random effects, 
unadjusted
Random effects, 
adjusted
HR 95% CI HR 95% CI HR 95% CI
1 0.48 0.34 0.69 0.66 0.51 0.85 0.74 0.57 0.94
2 0.89 0.74 1.07 0.89 0.75 1.06 0.90 0.76 1.08
3 1.30 1.10 1.54 1.22 1.03 1.44 1.12 0.95 1.31
4 1.34 1.18 1.51 1.28 1.13 1.44 1.22 1.08 1.38
5 1.05 0.89 1.24 1.02 0.87 1.20 1.01 0.86 1.18
6 1.11 0.79 1.55 1.04 0.80 1.37 1.04 0.80 1.36
7 0.95 0.83 1.09 0.93 0.82 1.06 0.89 0.78 1.02
8 0.87 0.76 1.00 0.87 0.76 0.99 0.85 0.74 0.97
9 0.95 0.83 1.09 0.94 0.82 1.07 0.92 0.81 1.05
10 1.29 1.16 1.44 1.24 1.12 1.38 1.33 1.20 1.48
11 1.13 1.01 1.26 1.09 0.98 1.22 1.13 1.01 1.27
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The average ongoing pregnancy chance after the first cycle for all centres was 24% (Lintsen 
et al., 2007). The ongoing pregnancy rate per cycle after adjustment for patient mix was 12% 
in the centre with the lowest odds ratio (0.45), compared to 28% for the centre with the 
highest odds ratio (1.25) (data for patient mix adjustment only are not shown). Substantial 
differences between clinics were also seen in the study of Marshal and Spiegelhalter (1998). 
The per cycle “live birth” rate after adjustment for patient mix ranged from 5% to 24% per IVF 
clinic in the UK. The absolute differences between success rates of clinics in the UK and 
between centres in the Netherlands seem to be comparable. On the other hand there is an 
apparent relative difference between the success rates of clinics in both countries. Almost a 
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Figure 1       The first graph gives the unadjusted ongoing pregnancy chance after 
12 months of treatment, per centre. The second graph presents the 
estimates per centre adjusted for sampling variability. The third graph 
gives the estimates after adjustment for patient mix. The size of the spot 
corresponds with the size of the sample, but not with the actual size of  
the centre
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factor 5 difference for the “worst” compared to the “best” performing clinic in the U.K., 
compared to a factor 2.3 difference for the two extreme centres in the Netherlands. Data 
collection took part with a time difference of 10 years between the two studies and IVF 
outcome has improved during the past years. Further, non-privatized centres and adherence 
to a national guideline will lead to uniformity between centres and more or less equality in 
chance per couples treated. The IVF guideline intents to hold back couples with still a high 
chance to conceive spontaneously by determining a minimum for the duration of subfertility 
and discourages couples with a very low chance to conceive by maintaining a maximum 
women’s age for treatment. We examined the adherence to one of the recommendations in 
the guideline IVF: “IVF should be withheld for couples with unexplained subfertility when the 
duration of subfertility is less than 3 years and the woman’s age is under 36” (Table IV). When 
comparing only centres with a reasonable number of participants in this category, we 
conclude that the adherence to the guideline was low for centre no. 4, and no. 7. This “early” 
reference for IVF may increase the overall pregnancy rate. The variation in adherence to the 
guideline-based indicators between Dutch IVF clinics has been studied by Mourad et al.
(2008); they found the median adherence to the guideline IVF was high: 86%. In case of 
unexplained subfertility the adherence was fairly high 79% (range 67-92%). 
Large differences in size of the centres adds to an important difficulty in comparison between 
centres, but in the Netherlands there are no real small IVF centres. The number of treatments in 
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Table III       First IVF cycle success rates, in ORs, relative to the average of all centres
Centre
A B C
Unadjusted
Random effects, 
unadjusted
Random effects, 
adjusted
OR 95% CI OR 95% CI OR 95% CI
1 0.39 0.22 0.67 0.77 0.60 1.00 0.80 0.61 1.05
2 0.87 0.66 1.15 0.95 0.77 1.17 0.95 0.77 1.18
3 0.96 0.73 1.27 1.01 0.82 1.24 0.94 0.76 1.16
4 1.24 1.04 1.48 1.22 1.05 1.43 1.20 1.02 1.40
5 0.74 0.56 0.99 0.87 0.71 1.08 0.87 0.70 1.08
6 1.17 0.68 2.01 1.05 0.80 1.38 1.07 0.80 1.42
7 0.93 0.76 1.13 0.98 0.83 1.16 0.96 0.81 1.14
8 0.87 0.70 1.07 0.94 0.79 1.12 0.92 0.77 1.10
9 0.98 0.81 1.19 1.02 0.87 1.20 0.99 0.84 1.18
10 1.13 0.98 1.32 1.15 1.01 1.32 1.25 1.09 1.44
11 1.11 0.94 1.30 1.13 0.98 1.30 1.17 1.02 1.36
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2003, of the centres included in the study ranged between 589 and 2059 cycles per year (mean 
1314; www.lirinfo.nl), In comparison, in British IVF centres, the number of cycles ranged between 
68 and 1453 (mean 469), cycles per year (Marshal and Spiegelhalter, 1998) and between 10 and 
3054 cycles in Spanish IVF centres. (Castilla et al., 2008). The fact that all Dutch centres were 
equally big in size and for that reason, dexterity does not play a role, might explain why we did 
not find a relationship between centre size and success rates in Figure 3. 
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Figure 2       The first graph gives the unadjusted ongoing pregnancy chance after 
the first cycle, per centre. The second graph presents the estimates per 
cycle after adjustment for sampling variability. The third graph gives 
the estimates after adjustment for patient mix. The size of the spot 
corresponds with the size of the sample, but not with the actual size of 
the centre
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Table IV      Duration of subfertility for women with unexplained subfertility  
aged ≤ 35 at the start of IVF, per centre
Centre Duration of subfertility
< 3 years (n) ≥  3 years( n) ≥  3 years (%)
1 3 5 63
2 1 9 90
3 7 35 83
4 50 60 55
5 6 31 84
6 3 6 67
7 28 51 65
8 6 27 82
9 11 47 81
10 25 102 80
11 8 48 86
Total 148 421 74
Figure 3       The relationship between the actual size of the centres by the number  
of IVF cycles started in 2003 and the estimates of the pregnancy rates  
per centre after adjustment for random effects (p=0.34)
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Nevertheless, despite the guideline, size, and only state-funded IVF centres, the confidence 
intervals around the relative 1-year ongoing pregnancy rates are wide, expressing that there 
is still a great uncertainty about the true estimates. After adjustment for patient mix, the 
relative rates per centre did not change substantially, indicating a minor role for patient mix 
as registered in the IVF databases on the outcome per centre. On the other hand, the patient 
characteristics included in the prognostic index may not adjust for all patient related factors 
present. Sharif and Afnan (2003) suggested that comparison of clinics on a valid basis could 
be solved by comparing the IVF outcome of a standard patient group. This was rebutted by 
Johnson et al. (2007). They found that in the same clinic, two standardized patient groups, 
who were selected based on the area of residence, had a significant difference in outcome. 
Most known variables to influence IVF outcome were adjusted for, but patients differed in 
ethnicity and lifestyle, and also cause of subfertility. 
To be more complete, at least lifestyle should be included in the registration. For this study, 
a centre that excluded overweight women and/or smokers could for this reason have a higher 
1-year ongoing pregnancy chance compared to the others.
The random effects approach relies on the assumption that the centres in our study form a 
sample of the ‘population’ of centres, at least in theory. More important, the relative hazards 
in this population are assumed to follow a normal distribution, after logarithmic transforma-
tion. The fact that the per-centre estimates are shrunk towards the mean by the random 
effects model for most of the centres is a direct consequence of this assumption: it assumes 
that the centres vary around a central mean. If in reality there are two types of clinics, one 
type with on average low success rates, the other one with relatively high success rates, a 
distribution with two peaks would have been more appropriate. An example would be a 
country with a dual healthcare system, partly state-funded and partly commercial. In the 
Netherlands, all IVF centres are non-commercial. The clinics operate in a level playing field 
making the assumption of variation around a central mean plausible. With this statistical 
computation used, differences in the 1-year ongoing pregnancy rates between centres are 
presented in a way that the margin of uncertainty is adjusted for sampling variability and 
patient mix. The mutual position of the centres did not change after adjustment, indicating 
that the influences of patient mix are not as strong as often suggested. Further, the variation 
without adjustment was only slightly larger than the variation with adjustment, and a modest 
17% of the differences between centres can be explained by patient mix.
Several validation studies have concluded that differences in pregnancy outcome rate 
between clinics have important limitations for the reproducibility of prediction models 
(Stolwijk et al., 1998, Smeek et al., 2000, Hunault et al., 2007). By chance alone, pregnancy rates 
may vary from year to year and natural variation causes fluctuations in results (Kremer et al., 
2008). 
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In this paper we intentionally avoided to present performance data for centres, as league 
tables and control charts. These ranking methods are critically discussed by, Winston (1998), 
Adab et al. (2002), Marshall and Rouse (2004), Lemmers et al. (2007) and Castilla et al (2008). 
Data used for comparison may never contain all relevant factors, but the impact of any kind 
of ranking on health providers, consumers and media is high. Instead, we aimed to quantify 
the absolute difference in the 1-year ongoing pregnancy rates per centre taking account of 
sampling variability and patient mix. However, important outcome measures of IVF treatment 
as multiple pregnancies, pregnancies from cryo-preserved embryos, risks of ovarian hyper-
stimulation syndrome and psychological burden after unsuccessful IVF is lacking. According 
to the LIR registration of 2003, on average the centres had a 19% chance of ongoing twin 
pregnancy (range 10-29%), and 9% of all ongoing pregnancies were derived from frozen and 
thawed embryos (range 1,5-25%). Another limitation of this study is that not all patient 
 characteristics could be adjusted for e.g. ethnicity, socio-economic variations and lifestyle.
With this study we can conclude that there are remaining differences in pregnancy rates for 
the IVF centres in the Netherlands, with the extremes of the 1-year ongoing pregnancy 
chance laying between 36% and 55%. To find the explanations for the differences between 
IVF centres, we recommend further investigation of factors that could influence the 
pregnancy chance, e.g. lifestyle, but also to look beyond patient related factors as e.g. 
differences between IVF laboratories.
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Abstract
Background: The effectiveness of IVF over expectant management has been proven only 
for bilateral tubal occlusion. We aimed to estimate the chance of pregnancy without 
treatment for IVF patients, using data on the waiting period before the start of IVF. 
Methods: A prospective cohort study included all couples eligible for IVF or ICSI treatment, 
registered in a national waiting list in The Netherlands. The cumulative probability of treat-
ment-free ongoing pregnancy on the IVF waiting list was assessed and the predictive effect 
of female age, duration of infertility, primary or secondary infertility and diagnostic category 
was estimated using Cox regression. 
Results: We included 5962 couples the waiting list. The cumulative probability of treatment-
free ongoing pregnancy was 9% at 12 months. In multivariable Cox regression, hazard ratios 
were: 0.95 (p < 0.001) per year of the woman’s age, 0.85 (p < 0.001) per year of duration of 
infertility, 0.71 (p = 0.005) for primary versus secondary infertility. Diagnostic category showed 
hazard ratios of 0.7, 1.6, 1.2, 1.7 and 2.6 for endometriosis, male factor, hormonal, immunological 
and unexplained infertility respectively compared with ‘tubal infertility’ (p < 0.001). The 
12-month predicted probabilities ranged from 0% to 25%. 
Conclusions: The chance of an ongoing pregnancy without treatment while waiting for an 
IVF or ICSI is below 10% but may be as high as 25% within 1 year for selected patient groups. 
Timing of IVF should take predictive factors into consideration. 
chapter 4
59
Introduction
The indications for IVF have been widened considerably since its introduction in 1978. 
Whereas in earlier days,  bilateral tubal occlusion was seen as the only reason to perform IVF, 
nowadays IVF is used for virtually any diagnostic category of infertility. Yet, it is only for the 
tubal indication group that convincing evidence from a RCT is available (Soliman et al., 1993). 
For patients with patent tubes, another RCT showed that IVF was superior to expectant 
management (Hughes et al., 2004) over a 3 months time horizon. Combining these studies, 
Pandian et al. (2005) found a significant advantage for IVF over expectant management for 
unexplained infertility, but numbers were low and the duration of follow-up was considered 
to be inadequate. The evidence base for other diagnostic categories is entirely lacking.
The alternative treatment options for the other categories are not many: for tubal pathology, 
endometriosis, and for severe male infertility the choice is between waiting for a pregnancy 
or start IVF or ICSI. For idiopathic, mild male or cervical subfertility, intra uterine insemination 
(IUI) is the only treatment option prior to IVF. The usefulness of IUI, is however, being debated 
(Pashayan et al., 2006) and instead, a waiting time before IVF treatment could be indicated to 
profit from a remaining pregnancy chance. Therefore, an evidence-based comparison of 
expectant management versus IVF is needed for all diagnostic categories. Within the current 
practice, a randomized comparison would not be feasible. Instead, the waiting period before 
the actual start of IVF could be used to estimate the treatment–free pregnancy chances of 
couples that are going to start IVF. A study in this direction has been published, but not on a 
large scale, nor in a prospective cohort manner (Evers et al., 1998). 
In the Netherlands, a nation-wide prospective cohort study has been performed of all 
couples who were indicated for IVF. The global aim was to determine the cost-effectiveness 
of IVF compared with waiting for a longer period. The aim of the current study was to assess 
the remaining chances of pregnancy without treatment of couples who are being indicated 
for IVF according to national guidelines and to asses the predictive effects of female age, 
duration of infertility, type of infertility and diagnostic category on these chances.
Materials and Methods
Patients
A national cohort study was started in 2002 that prospectively registered all patients in IVF 
clinics in the Netherlands at the moment of indication for IVF by their gynecologist according 
to the Dutch IVF guideline (Dutch Society for Obstetrics and Gynaecology, 1998), from 1 
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January 2002 to 31 December 2003. In this way, a national waiting list for IVF was esthablished. 
During 2004, the waiting list data were cross-checked with the IVF treatment registries of the 
IVF clinics, to find out whether the patients had actually started IVF or not. Patients who 
could not be identified in the IVF registries were traced by hand searching the patient files: 
detailed patient data were collected, and the reason for not starting IVF was registered, 
including the occurrence of a pregnancy without treatment. 
The primary outcome of the study was an ongoing pregnancy without treatment, defined as 
an ongoing pregnancy occurring after inclusion on the waiting list, but before treatment was 
started. Criteria for ongoing pregnancy were fetal heart activity on ultrasound after at least 8 
weeks gestation. Some patients of the waiting list received other forms of fertility treatment, 
such as IUI or hormone injections. Pregnancies resulting from these treatments were not 
included in the primary outcome.
Indication
Whether couples are indicated to start IVF or ICSI treatment according to the Dutch “IVF 
Guideline” has been described previously (Lintsen et al., 2007). In brief, for tubal blockage (1) 
or severe endometriosis (2), IVF can be offered directly. In case of relative tubal pathology, the 
subfertility should be at least of 1 or 2 years duration. In case of unexplained subfertility (3) or 
minimal endometriosis, IVF is only indicated after a duration of subfertility of at least 3 years 
and should be preceded by IUI. In case of ovulation disorders (4), at least12 cycles of ovulation 
induction should precede IVF. When there is a disturbance in the interaction between semen 
and mucus (cervical hostility or immunological subfertility) (5), IVF is offered after a subfertility 
of at least 2 years and is preceded by IUI. An identical advice applies for mild mal subfertility 
(6): if the multiplication of the volume, concentration and motility (VCM) of the semen 
analyses is between 1 and 10 million. For severe male subfertility (VCM < 1 million), there is a 
direct indication for ICSI.  For all diagnostic categories, IVF can be offered 1 or 2 years earlier 
if women are over 36 or 38 years, respectively. 
Data analysis
The analysis of the chance of treatment-free ongoing pregnancy was carried out by the 
Kaplan-Meier method and Cox regression. The time variable in these analyses was the time 
from admission to the waiting list until the date of the last menstruation before pregnancy. If 
no treatment-free pregnancy occurred, the couple was censored at the end of follow-up, 
which was defined as the date of the start of the first IVF cycle or the last known date for 
couples who neither became pregnant, nor started IVF. 
Multivariable Cox regression was used to analyse the impact of prognostic factors on the 
chance of treatment-free pregnancy. Factors considered were the age of the woman, the 
duration of infertility, the diagnostic category mentioned as the indication for IVF and 
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whether infertility of the couple was primary or secondary. The internal validity of the 
resulting model, i.e. how well does the model predict the pregnancy chances, cannot be 
assessed on the same data that were used to construct the model. Instead, validity was 
assessed by taking samples with replacement from the original data (i.e. bootstrapping) 200 
times, mimicking the situation that the study had been repeated multiple times. In each 
bootstrap sample, the model development was repeated and the resulting model was 
subsequently tested in the original data set. From this procedure, the amount of over-fitting 
of the model may be assessed and a ‘shrinkage’ factor may be derived; for optimal prediction 
in future patients, the hazard ratios of the model should be adjusted with this shrinkage 
factor (van Houwelingen and Le Cessie, 1990). The discriminative ability of the model was 
measured by the c-statistic, and a correction for optimism was applied, determined from the 
bootstrap procedure. The c-statistic measures the proportion of cases in which the model 
can correctly separate a high chance couple form a low chance couple (Harrell et al., 1996). 
The outcome of a pregnancy (whether it was ongoing or not) was not in all cases available 
from the patient files. Therefore, for some cases, the primary outcome of the study was not 
known, although we know that the couples had become pregnant. Leaving these patients 
out of the analysis would lead to a biased estimate of the ongoing pregnancy chances. 
Therefore, we used an imputation method to fill in the missing values (Little and Rubin, 1987; 
Schafer, 1997), the “aRegImpute” function (Splus 7.0, 2005 Insightful Corp.) with single 
imputation. Missing values in patient characteristics were imputed in the same manner. The 
amount of missing data was as follows: 1.5% of patients had a missing follow-up time or 
missing pregnancy outcome and 16% of patients had missing values in one or more charac-
teristics. The number of missing values relative to the total number of data points was 4.3%, 
justifying the use of single imputation (Schafer and Graham, 2002).
Results
There were 7024 patients included on the waiting list. Of  803 patients, IVF data were found, 
but with starting dates that were partly before the date of inclusion on the waiting list. These 
patients were therefore removed from the waiting list. For 259 patients, no data could be 
found in the IVF centre, and these patients were considered lost to follow-up (Lintsen et al., 
2005). For 5962 patients, the follow-up could be established, and they form the basis of 
analysis (Figure 1). Their characteristics are shown in Table I, overall and subdivided by 
diagnostic category.
Of these women, 4928 started IVF and 316 became pregnant in the waiting period before IVF, 
resulting in an ongoing pregnancy in 282 cases, (89.2% of pregnancies). The remaining 718 
women had not started IVF and had not become pregnant at the date of last follow-up. 
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The time on the waiting list before starting IVF is shown in Figure 2. The total treatment-free 
follow-up was 33,813 months (median 4.6 months), with a median duration of follow-up of 
2.5 months for the pregnant patients, 4.5 months for the patients that started IVF and 6.2 
months for the patient who neither started treatment nor became pregnant. The overall 
(Kaplan-Meier) 1-year cumulative ongoing pregnancy rate was 9.1 % (95% confidence interval: 
7.5% – 10.7%), as shown in Figure 3.
The ongoing pregnancy chances differed markedly between diagnostic categories  (Figure 4): 
chances with tubal infertility and endometriosis were lowest, whereas male factor and 
immunological infertility had double these chances. For unexplained infertility, chances were 
more than tripled compared with tubal infertility. The multivariable Cox regression confirmed 
these results (Table II), although the differences between diagnostic categories are less 
9016 couples in national
cohort study  
1992 Excluded:
Five IVF clinics withdrew from participation
 
 
7024 remaining  
803 Excluded start of  IVF or ICSI treatment
before registration on the waiting list  
1034 couples did not start IVF or ICSI 
with known reason
 
Follow-up of 5962
couples 
 
4928 couples starting IVF
or ICSI  
6221 remaining  
259 Lost to Follow-up: patient could not be 
traced or no date of last Follow-up known 
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Figure 1       Description of the recruitment of couples for IVF or ICSI treatment in  
the Netherlands from January 2002 to December 2004. In the grey area: 
Study population, 5962 couples admitted to the waiting list, with known 
follow-up
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extreme than in the univariable case. As expected, pregnancy chances are lower with higher 
age of the woman [a hazard ratio (HR) of 0.95, i.e. a 5% relative decrease in monthly chances 
with each year older], longer duration of infertility (HR = 0.85, a 15% relative reduction per 
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Table I      Characteristics of 5962 couples on a national waiting list for IVF during  
2002-2004 in the Netherlands
Diagnostic category N
Age of the woman, 
years
Duration of 
infertility
% Primary 
infertility
Mean SD Mean SD
Tubal pathology 1059 34.0 4.0 3.2 2.5 49
Endometriosis 500 32.4 3.8 3.0 2.0 70
Male 2545 32.3 4.4 2.9 2.1 66
Hormonal 462 32.7 4.0 3.3 2.3 59
Unexplained 1236 34.5 4.0 3.6 2.1 58
Immunological 160 34.2 4.0 3.4 2.3 61
Total 5962 33.1 4.3 3.2 2.2 61
Figure 2       Number of couples on the waiting list for IVF or ICSI, who have not yet 
started treatment, against time since registration on the waiting list. 
Kaplan-Meier estimates, censoring for treatment-free pregnancy and for 
termination of the active childwish
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Figure 3       Cumulative chance of an ongoing treatment-free pregnancy, against time 
since registration on the waiting list for IVF or ICSI. Kaplan-Meier estimates, 
censoring for start of treatment and for termination of the active childwish
Figure 4       Cumulative chance of an ongoing treatment-free pregnancy, against 
time since registration on the waiting list for IVF or ICSI, separately for 
diagnostic categories. Kaplan-Meier estimates, censoring for start of 
treatment and for termination of the active childwish
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additional year) and for primary compared to secondary infertility (HR = 0.71, a 29% relative 
reduction). The 12 months chances of pregnancy without treatment predicted by the Cox 
regression model are shown in Figure 5. Predictions range from 0% to about 25%, with 8.3% 
of patients having a predicted chance of 15% or higher. The discriminative index of the model 
(c-statistic) in these data was equal to 0.66, and 0.65 when corrected for optimism, indicating 
that the model will be able to separate a high chance couple form a low chance couple in 
65% of cases. The shrinkage factor determined by the internal validation procedure was 0.91, 
showing only slight overfitting. 
Discussion
We conducted a large-scale cohort study in patients on the waiting list for IVF and found that 
on average 9.1% of the couples would have an ongoing treatment-free pregnancy within 1 
year. Further, we found that ongoing pregnancy chances were higher than average with 
younger female age, shorter duration of infertility, secondary versus primary infertility and for 
couples with unexplained, male or immunological infertility compared with other diagnostic 
categories. A multivariable prediction model was able to identify couples with a 1 year 
chance up to 25%.
The level of the ongoing pregnancy chance within 1 year is lower than in other studies on 
infertile couples (Eimers et al., 1994; Collins et al., 1995; Snick et al., 1997; Hunault et al., 2004). 
4
chance of pregnancy on waiting list
Table II     HR for ongoing pregnancy without treatment of 5962 patients on the waiting 
list for IVF
HR 95% confidence interval lower –upper
Age (per year) 0.95 0.93- 0.98
Duration of infertility (per year) 0.85 0.79- 0.91
Indication
Tubal pathology 1* -- --
Endometriosis 0.73 0.37- 1.46
Male 1.57 1.06- 2.32
Hormonal 1.19 0.67- 2.11
Unexplained 2.64 1.75- 3.98
Immunological 1.69 0.75- 3.84
Primary vs. secondary infertility 0.71 0.56- 0.90
* Reference group
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Since most of the studies excluded ‘poor prognosis’ diagnostic groups, such as azoospermia, 
tubal pathology or ovulation disorders, and were conducted in a non-IVF setting, we might 
expect to find a lower pregnancy chance in our data. Nevertheless, even the Collins study, 
which included all diagnostic groups and which was based on patients in a tertiary care 
setting comparable to a modern IVF setting, found on average almost twice the pregnancy 
chance within 1 year that we found: 16.1%. 
As far as we know, apart from Denmark (danish Fertility Society (www.fertlitetsselskab.dk), the 
Netherlands is the only country that has a central guideline for the indication for IVF, with a 
recommendation for each diagnostic category, depending on the duration of subfertility. For 
instance, in case of unexplained or mild male subfertility, it is advised to perform 3-6 cycles of 
IUI. This might explain for a part the low chances on the IVF waiting list: patients who did not 
become pregnant with the forgoing treatment and who thus turned to IVF are probably a ‘low 
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Figure 5       Histogram of the predicted 12-months chances of a treatment-free 
pregnancy, as determined by the prognostic model based on female age, 
duration and type of infertility and diagnostic category
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chance’ selection with respect to treatment-free pregnancy chances. Nevertheless, the overall 
pregnancy rate in our study was higher than in the waiting list study of Evers et al. (1998), and in 
contrast to that study we did not find a higher pregnancy rate during the first 3 months of the 
waiting period. In a 5 year follow-up study from Denmark (Pinborg et al., 2007) compromising 
818 couples starting with assisted reproduction treatment (ART), 156 (19.1%) had delivered from 
a spontaneous pregnancy, mostly after start of treatment (134 women). Very few pregnancies 
occurred before the start of treatment, mainly due to the fact that patients were included only 
at the start of treatment. Nevertheless, this study shows that considerable spontaneous 
pregnancy potential may be present in a population starting ART.
The prognostic effects of the factors in our data are comparable with those found in the 
other studies on infertile couples. Further, the discriminative ability of our model, c = 0.65, is 
very similar to that found by others (Eimers et al., 1994; Collins et al., 1995; Snick et al., 1997; 
Hunault et al., 2004). Such a low discriminative ability appears frequently in the reproductive 
medicine literature and indicates that it is very hard to determine who will become pregnant 
and who will not, based on the age, duration, type of infertility and the diagnostic category. 
Perhaps, additional predictive ability may come from markers of ovarian reserve such as the 
basal Follicle Stimulating Hormone (FSH) and the antral follicle count (AFC) or from the 
treatment history of the patients, as stated above. Unfortunately, we were unable to collect 
data on any of these factors, and we recommend that future studies take these factors into 
consideration. Despite these facts, the model was able to identify a subgroup of patients 
with relatively high chances for whom postponing IVF might be a realistic option: a recent 
RCT (Steures et al., 2006) showed that, after the initial fertility work-up, expectant management 
was the best option for “average-to-good prognosis” patients, who were selected by a 
prediction model with even less discriminative power (Hunaults et al., 2004).
The main research question of this study was: what are the pregnancy chances of couples 
that are indicated for IVF in a usual care setting using guidelines and clinical judgement? If 
there are patient groups whose chances of pregnancy without treatment are sufficiently 
high, it might be cost-effective to postpone treatment for them, e.g. by 1 year. An important 
issue is whether the current study design can give representative data to answer this question; 
the loss to follow-up, inherent to this type of study, was limited (259 out of 5962 = 4%), and is 
considered not to be a threat to validity. However, the waiting list design may be questioned: 
are the pregnancy chances of couples who get an indication for IVF, but who have to wait 
because of a waiting list, comparable with couples who would have been asked to wait 
longer before being indicated for IVF? An issue of concern here could be that patients who 
get the indication for IVF might experience stress relieve that could positively influence their 
pregnancy chances. On the other hand, couples might feel that they do not have to try 
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themselves to become pregnant anymore, because IVF will take care of it. We have collected 
data on psychological questionnaires during the study that could be used to test these 
hypotheses.
Our findings may have implications for the indication for IVF. Depending on the prognosis 
with IVF and on treatment costs, we could determine the duration of infertility at which 
waiting is no longer justified based on cost-effectiveness considerations (Mol et al., 2000). 
That duration may differ between diagnostic categories, between age groups and between 
primary and secondary infertility. As an example, in case of unexplained infertility, the treat-
ment-free prognosis may be so good, particularly in young women, that IVF might be 
postponed for a longer time than in the case of tubal infertility. 
We conclude that the chances of ongoing pregnancy without treatment are on average low 
for subfertile couples who are waiting for IVF. Nevertheless, prognostic factors may identify 
‘high chance‘ groups for which it might be cost-effective to postpone IVF and take advantage 
of pregnancy chances without the costs and burden of treatment.
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Abstract
Background: We investigated the separate and combined effects of smoking and body-mass 
index (BMI) on the success rate of IVF for couples with different causes of subfertility. 
Methods: The success rate of IVF was examined in 8457 women. Detailed information on 
reproduction and lifestyle factors was combined with medical record data on IVF treatment. 
All IVF clinics in the Netherlands participated in this study. The main outcome measures were 
live birth rate per first cycle of IVF differentiated for the major predictive factors.
Results: For male subfertility the delivery rate per cycle was significantly lower than for 
unexplained subfertility, OR of 0.70 (95% CI: 0.57- 0.86); for tubal pathology, the delivery rate 
was slightly lower, OR = 0.86 (95% CI: 0.70 – 1.01). Smoking was associated with a significantly 
lower delivery rate, OR = 0.72 (95% CI: 0.61 - 0.84) and a significantly higher abortion rate 
compared to non-smoking, delivery rates of 21.4% and 16.4%, respectively (p=0.02). Women 
with a BMI of ≥ 27 kg/m2 had a significantly lower delivery rate, with an OR of 0.67 (95% CI: 
0.48 – 0.94), compared with normal weight women (BMI ≥ 20 and < 27 kg/m2). 
Conclusions: Both smoking and overweight unfavourably affect the live birth rate after IVF. 
The devastating impact of smoking on the live birth rate in IVF treatment is comparable with 
an increase in female age of > 10 years from age 20 to 30 years. Subfertile couples may 
improve the outcome of IVF treatment by life style changes.
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Introduction
The improving success rates of IVF, initially developed as a technique to assist reproduction 
in women with bilateral tubal obstruction (Steptoe and Edwards, 1978), have extended its use 
to other subfertility diagnoses. For women with severe bilateral tubal occlusion evidence for 
the effectiveness of IVF has been available for years (Corabian and Hailey, 1999). Recently a 
randomised controlled trial (RCT), although small, suggested the efficacy of IVF for subfertility 
causes other than tubal pathology (Hughes et al., 2004). Other studies on the success rate of 
IVF by cause of subfertility have shown inconsistent results (Alsalili et al., 1995; Tan et al., 1996). 
However, in the largest study on IVF effectiveness (Templeton et al., 1996), carried out in the 
UK between 1991 and 1994 and including 36,961 cycles, no significant differences were 
observed in live birth rate comparing tubal pathology, endometriosis, unexplained subfertility 
and cervical and uterine subfertility. The prognostic model developed by Templeton et al. did 
not give additional predictive information for the majority of IVF patients in the Netherlands 
in the study by Smeenk et al. (2000). Life style factors were not included in these studies.
The main goal of the present analyses was to explore possible predictive factors such as 
duration of subfertility, and female age, for subfertile couples with different causes of 
subfertility. As there is evidence of an overall detrimental effect of female smoking on natural 
and assisted fecundity in the literature (Hughes and Brennan et al., 1996; Feightinger et al., 
1997; Augood et al., 1998; Hassan and Killick, 2004) and indication for an unfavourable effect 
of extremes of BMI on the outcome of fertility treatment (Norman and Clark, 1998; Wang et 
al., 2000; Wang et al., 2002; Nichols et al., 2003), we also studied smoking and BMI as possible 
prognostic factors. Like the Templeton model we distinguished the major causes of 
subfertility, and added male subfertility and life style factors. We executed this study with 
data from a large Dutch nationwide retrospective cohort study (the so called “OMEGA study”) 
including 19,840 women who underwent IVF treatment between 1983 and 1995. 
Materials and Methods
Patients
The study population, study procedures and data collection methods have been described 
elsewhere (Klip et al., 2001, 2003; de Boer et al., 2003). In short, the OMEGA-study, initiated in 
1995 to examine the late effects of hormone stimulation in IVF treated women, comprised 
19,840 women treated with IVF in a nationwide cohort study. Women with subfertility of ≥ 1 
year duration were included if they had completed at least one IVF treatment cycle between 
January 1, 1983, the start of IVF treatment in the Netherlands and January 1, 1995.  A 23-page 
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questionnaire was sent to 19,242 women between January 1997 and January 2000 to obtain 
information on gynaecological disorders before and after subfertility treatment, reproductive 
risk factors for hormone-related cancers and several other lifestyle factors. Figure 1 gives a 
graphical presentation of the study population. As there was no national registry of IVF 
treatments, data from both the patient records and pregnancy follow-up were collected by 
trained research assistants, who abstracted data from the medical files on gynaecological 
history, subfertility diagnosis, fertility hormones used prior to IVF treatment, and detailed 
information about each subsequent IVF treatment, the number of retrieved oocytes, 
occurrence of complications and whether or not the treatment resulted in a pregnancy. 
Additional information on pregnancy outcome, reproductive and lifestyle factors were 
obtained through the mailed questionnaire.
For the present analyses, all ICSI attempts were excluded because of the small number. 
Unstimulated cycles, other IVF related treatments such as zygote intra fallopian transfer 
(ZIFT), gamete intra fallopian transfer (GIFT), gamete and embryo donation and frozen 
embryo transfers were also excluded from the study (in total 1568 cycles). 
In the Netherlands three IVF cycles were covered by health cost insurances in the period 
under study, leading to a low drop out rate in the first three cycles. Eighty-seven percent of 
the women completed at least three cycles, or became pregnant in the first two cycles. 
As continuation of IVF depends on predictors of success observed in the first cycle, such as 
number of oocytes, fertilization rate and embryo morphology (Stolwijk et al., 1996) we 
restricted all analyses to the first attempt. Leaving 8457 first cycles for analysis.
Definition of variables
Subfertility diagnosis was based on medical record information and divided into 4 categories: 
tubal pathology, male subfertility, unexplained subfertility and other known subfertility 
causes, mainly women with polycystic ovary syndrome (PCOS) or endometriosis. Each 
woman was only categorized once, the one assumed to contribute most to the subfertility. 
For 831 first cycles there was no cause of subfertility known and were therefore not analysed 
in detail. Duration of subfertility was determined by the period between the start of the 
involuntary childlessness, as reported by the woman, and the date of first IVF attempt. Primary 
subfertility was defined as having no pregnancy before the IVF treatment.  Education level 
was divided into low (those without completed vocational training), middle (with vocational 
training) and high (with high vocational training or academic degrees). Women were defined 
as smokers when they smoked more than one cigarette a day for ≥1 year at the time of the 
first oocyte retrieval. Underweight was defined as having a BMI <20 kg/m2, normal weight as 
a BMI of 20-27 kg/m2 and overweight as a BMI ≥ 27 kg /m2, as there were not enough women 
with a BMI ≥ 30 kg/m2 for analysis. The BMI was calculated with the women’s weight at the 
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time of first visit to the gynaecologist for her fertility problem. The woman’s age at the IVF 
attempt was computed by subtracting the date of birth from the IVF attempt date. IVF 
attempts obtained from the medical records were linked with livebirths as reported by the 
women on the questionnaire. Conception dates were calculated by subtracting the reported 
 
19,840 IVF treated women (OMEGA-project) in the Netherlands between 1983 and 1995 
Not approached (n=598):
   •  Deceased (n=39) 
   •  Incomplete, foreign addresses (n=240) 
   •  Emigration (n=290) 
   •  Privacy reasons (n= 29) 
 
5076 non-responders or did not want to 
participate (n=468) 
- Gave no permission to abstract from the medical
   ﬁles (n-259) 
- Only ﬁlled out an informed consent (n=270)
- Data from medical records not (yet) obtained 
  (limited project funding) (n=3227)  
9046 women with 25,461 IVF cycles
Excluded are: ICSI, GIFT, ZIFT, frozen embryo 
transfers and gamete- and embryo donated 
cycles (n=1598)  
8457 eligible women with ﬁrst IVF cycles 
Detailed data on ﬁrst cycles missing (n=589)
9942 IVF treated women with available questionnaire and medical record data, 
completed 27,029 cycles  
 
13,698 women returned questionnaires (respons rate 71%) 
19,242 IVF treated women, received questionnaire 
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Figure 1       Description of the recruitment of eligible women and cycles. GIFT= 
gamete intra fallopian transfer; ZIFT= zygote intra-fallopian transfer
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duration of pregnancy from the delivery date, as reported by the women. If an IVF attempt 
had started within 4 weeks of the estimated conception date, the pregnancy was considered 
to be the result of the IVF attempt, unless the medical record stated that a spontaneous 
pregnancy followed the IVF attempt. The implantation rate was defined as the number of live 
born children per embryo transferred. The live birth rate was the delivery rate with at least 
one live born child per cycle. Total fertilization failure (TFF) was defined when none of the 
oocytes were fertilized after IVF. An abortion was defined as a pregnancy loss between 6 
and16 weeks of amenorrhoea. The following complications were registered: ovarian hyper-
stimulation syndrome (OHSS) leading to hospitalization, other medical problems resulting in 
admission and ectopic pregnancies. 
Statistical analyses 
The statistical program SAS: The SAS system for windows 8.2, SAS Institute Inc. Cary NC, USA, 
was used for statistical analyses. Univariate frequencies and means were calculated to 
describe the women and their first IVF cycles. The results are given in Tables I and II. 
All analyses were done first on all women, including those with unknown cause of subfertility, 
and then by cause of subfertility. 
Contingency tables were used to calculate live birth rates per cycle, live birth rate per oocyte 
retrieval and live birth rate per embryo transfer as well as the implantation rate for categories 
according to the cause of subfertility, age, smoking, period of IVF and BMI (Tables III and IV). 
This figure was then averaged across cycles. 
Multivariate logistic regression was done to study the independent and combined effects of 
potential determinants on the live birth rate. We included cause of subfertility, smoking, BMI 
(continuous and in three categories) and period of IVF in the model, together with factors 
that have previously been reported in the literature to predict the success rate of IVF. These 
factors were: primary versus secondary subfertility, age at treatment (continuous and in two 
categories) and duration of subfertility. We corrected for period of IVF by adding a factor 
indicating whether the IVF was before or after January 1, 1990. In univariate analyses, we 
found higher pregnancy rates after 1990 than before that date; however, differences in live 
birth rates over time were small. The results for the other variables included in the model did 
not change according to whether we included age and BMI as categorical or continuous 
variables. We included the results for the categorical variables in Table V and added the 
estimates for the continuous variables per unit change to the text. The resulting regression 
estimates were transformed to present odds ratios (OR) for those in a category as compared 
with the reference category, with all other factors equal. 
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Table I      Characteristics of women in the OMEGA cohort at first IVF cycle
All  
women  
in first 
cyclea
Tubal 
pathology
Male  
subfertility
Un-
explained 
subfertility
Other 
known 
subfertility 
causesb 
No. of first cycles 8457 3008 (35.6) 2179 (25.8) 1828 (21.6) 611 (7.2)
Age (years)
Average (SD)  32.8 (3.9)  32.8 (4.0)  32.4 (3·9) 33.3 (3.7) 32.5 (3.9)
 
20-24   187 (2.2)     80 (2.7)     48 (2.2)   22 (1.2)    19 (3.1)
25-29 1833 (21.7)   653 (21.7)   553 (25.4) 326 (17.8) 135 (22.1)
30-34 3915 (46.3) 1361 (45.3) 1014 (46.5) 862 (47.2) 290 (47.5)
35-39 2262 (26.7)   821 (27.3)   520 (23.9) 556 (30.4) 151 (24.7)
≥40   235 (2.8)     86 (2.9)     40 (1.8)   59 (3.2)    4 (2.3)
Unknown     25 (0.3)       7 (0.2)       4 (0.2)     3 (0.2)     2 (0.3)
Duration of subfertility 
(years)
Mean (SD)  5.35 (3.0) 5.11 (3.3) 5.34 (2.9) 5.60 (2.7) 5.83 (3.2)
Median (IQR)  4.65 (3.3) 4.33 (3.7) 4.64 (3.1) 4.89 (2.8) 5.08 (3.6)
Unknown 1286 (15.2) 434 (14.4) 245 (11.2) 140 (7.7)   50 (8.2)
Subfertility
Primary 4009 (47.4) 1090 (36.2) 1246 (57.2) 1044 (57.1) 366 (59.9)
Secondary 1944 (23.0)   974 (32.4)   305 (14.0)   460 (25.2)   90 (14.7)
Unknown 2504 (29.6)   944 (31.4)   628 (28.8)   324 (17.7) 155 (25.4)
Level of educationc
Low 2323 (27.5)   862 (28.7)   567 (26.0) 478 (26.1) 194 (31.8)
Middle 4085 (48.3) 1421 (47.2) 1095 (50.3) 888 (48.6) 255 (41.7)
High 1865 (22.1)   651 (21.6)   475 (21.8) 423 (23.1) 152 (24.9)
Unknown   184 (2.2)     74 (2.5)     42 (1.9)   39 (2.1)   10 (1.6)
Smoking at 1st IVF
Yes 3617 (42.8) 1536 (51.1)   841 (38.6)   673 (36.8) 229 (37.5)
No 4706 (55.6) 1423 (47.3) 1306 (59.9) 1127(61.7) 371(60.7)
Unknown   134 (1.6)     49 (1.6)     32 (1.5)    28 (1.5)   11 (1.8)
BMI (kg/m2) at 1st IVF
Average (SD) 22.27 (3.3) 22.36 (3.3) 22.25 (3.1) 22.04 (3.1) 22.46 (3.6)
<20 1752 (20.7)   607 (20.2)   433 (19.9)   409 (22.4) 134 (21.9)
20-25 5132 (60.7) 1818 (60.4) 1357 (62.3) 1127 (61.7) 351 (57.4)
25-27   602 (7.1)   228 (7.6)   144 (6.6)   110 (6.0)   52 (8.5)
>27   619 (7.3)   231 (7.7)   153 (7.0)   117 (6.4)   46 (7.5)
Unknown   352 (4.2)   124 (4.1)     92 (4.2)     65 (3.6)   28 (4.6)
Values in parentheses are percentages unless otherwise specified. a Including those with unknown subfertility  
cause. b Including polycystic ovary syndrome 16.5%, other ovarian problems 28.8%, endometriosis 34.4%, other 
causes 21.3%. c Low= not completed vocational training, middle = with vocational training, high = high vocational 
training and academic training. SD = standard deviation. IQR=interquartile range. 
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Table II      Characteristics and various outcome measures of first IVF cycles of women 
in the OMEGA cohort 
All 
subfertility 
Tubal 
pathology
Male  
subfertility
Un-
explained 
subfertility
Other 
known 
causes
No. of cycles (% of all 
first cycles)
8457 3008 (35.6) 2179 (25.8) 1828 (21.6) 611 (7.2)
With oocyte retrievals 7529 (89.0) 2636 (87.6) 1995 (91.6) 1644 (89.9) 530 (86.7)
Median no. of oocytes 
(IQR) (25-75)
      8 (5–12)       8 (4–12)       8 (5–13)       8 (5–12)     8 (5–13)
With embryo transfers 6286 (74.3) 2388 (79.4) 1389 (63.7) 1437 (78.6) 469 (76.8)
Median no. of 
embryos (IQR) (25-75)
      2 (1–3)       3 (2–3)       2 (0–3)       2 (2–3)     2 (2–3)
No. of pregnancies a 1664 (19.7)   580 (19·3)   369 (16.9)   418 (22.9) 140 (22.9)
No. of abortions bc   313 (18.8)   118 (20.3)     57 (15.5)     84 (20.1)   30 (21.4)
      
Deliveries a 1282 (15.2) 439 (14.6 ) 296 (13.6 ) 326 (17.8 ) 103 (17.0)
No. of singletonsd   915 (71.4)  312 (71.1) 205 (69.3) 228 (69.9)   79 (76.7)
No. of twins d   310 (24.2)  101 (23.0)   81 (27.4)   84 (25.8)   21 (20.4)
No. of  triplets or 
more d
    57 (4.4)    26 (5.9)   10 (3.4)   14 (4.3)     3 (2.9)
Complications
TFF 1164 (13.8) 221 (7.3) 590 (27.1) 194 (10.6) 57 (9.3)
OHSS   206 (2.4)  58 (1.9)  58 (2.7)   49 (2.7) 25 (4.1)
Other   154 (1.8)  77 (2.6)  24 (1.1)   33 (1.8) 15 (2.5)
Ectopic pregnancies c     56 (3.4)  35 (6.0)   7 (1.9)    8 (1.9)   3 (2.1)
Values in parentheses are percentages unless otherwise specified.
a Percentage of cycle.
b Between 6-16 weeks of pregnancy. 
c Percentage of pregnancies.
d Percentage of deliveries.
IQR = interquartile range; TFF= total fertilization failure; OHSS=ovarian hyperstimulation syndrome.
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Table V      Multivariable Logistic Regression Model of the probability of a live birth 
after first cycle of IVF 
Per cycle 
Per  
oocyte retrieval
Per  
embryo transfer 
Intercept 
Pregnancy rate (%) a
-1.4426
19.1
-1.2229
22.7
-0.9500
27.9
Smoking
    No
    Yes
1
0.72 (0.61 – 0.84)
1
0.74 (0.63 – 0.87)
1
0.73 (0.62 – 0.86)
Age
    < 35 yrs
    ≥ 35 yrs
      
1
0.80 (0.67 – 0.96)
      
1
0.83 (0.69 – 1.00)
     
1
0.83 (0.69 – 1.00)
Body mass index (kg/m2))
   20-27 
   < 20 kg/m2
   ≥ 27 kg/m2
1
0.99 (0.82– 1.19)
0.67 (0.48 – 0.94)
1
0.97 (0.80– 1.17)
0.72 (0.51 – 1.02)
1
0.97 (0.80– 1.18)
0.73 (0.52 – 1.03)
Unexplained subfertility
Tubal pathology
Male subfertility
Other known factor
1
0.86 (0.70 – 1.01)
0.70 (0.57 – 0.86)
0.92 (0.68 - 1.23)
1
0.86 (0.71 – 1.05)
0.69 (0.56 – 0.85)
0.94 (0.70 – 1.27)
1
0.81 (0.66– 0.99)
0.93 (0.75 – 1.16)
0.92 (0.68 – 1.25)
Secondary subfertility 
Primary subfertility
1
0.96 (0.81 – 1.15)
1
0.96 (0.81 – 1.15)
1
0.99 (0.83– 1.16)
Period of IVF
   < 1990
   ≥ 1990
1
1.54 (1.18 – 2.02)
1
1.36 (1.03 – 1.79)
1
1.24 (0.4 – 1.5)
Duration of subfertility
   < 8 yrs
   ≥ 8 yrs 
    
1
0.79 (0.62 – 1.00)
 
1
0.84 (0.66 – 1.08)
  
1
0.90 (0.70 – 1.16)
Values are odds ratios (95% confidence intervals) unless otherwise indicated.
a Calculated pregnancy rate.
The final model to calculate the pregnancy rate (PR) is shown below. All variables are indicators:  
ln ((Pr / 1-Pr)) = -1.4426 – 0.3285 smoking – 0.2231 age ≥35 – 0.010 BMI <20 – 0.4005 BMI ≥27 – 0.1508 tubal 
pathology – 0.3567 male subfertility – 0.0834 other factor – 0.041 primary subfertility + 0.0432 treatment  
≥ 1990 – 0.236 duration of subfertility ≥ 8 years.
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Results
Population
The study population consisted of 8457 women who underwent their first cycle of IVF. 
The characteristics of the women are presented in Table I. Education was comparable to the 
Dutch population of women of childbearing age in the period studied and the different 
education levels were equally represented in all subfertility categories. There was no 
difference in duration of subfertility before the first treatment between the major subgroups 
we analysed. Of all women, 43% smoked during the first IVF attempt. Fifty-one percent of the 
women with tubal pathology smoked at the time of the first attempt, which was significantly 
more than in the other diagnostic groups. No significant differences in the distribution of 
extreme over- or underweight women between diagnostic categories were observed. 
Women with tubal pathology were significantly more secondary subfertile. 
Cycles
The characteristics of the first IVF cycles of our population are described in Table II. The 
outcome of the first cycles in women with a main diagnosis of tubal pathology (3008 cycles), 
male subfertility (2179 cycles) and unexplained subfertility (1828 cycles) were analysed, using 
various outcome measures. Cycles with other known causes of subfertility (611), were also 
examined. The proportion of first cycles with TFF was 27.1% in the male subfertility group. 
This was significantly higher than for unexplained subfertility and tubal pathology, (10.6 and 
7.3%, respectively). The abortion rate was significantly lower in the male subfertility group 
compared to both other indication categories. The overall proportion of first cycles with 
complications after IVF treatment (excluding TFF) was 4.9%. Ectopic pregnancies occurred 
significantly more often in the group with tubal pathology, compared to the other groups. 
The percentage of cycles with OHSS leading to hospitalization was significantly higher in the 
“other known” indication group (including PCOS) compared to the main indication 
categories.
The average number of embryos per transfer was 2.2 [0-7, median 2]. The overall live birth 
rate per cycle was 15.2%. The live birth rate per first cycle for the unexplained subfertile 
couples was higher (17.8%) in comparison with tubal pathology (14.6%) and male subfertility 
(13.6%). The live birth rates according to age and diagnostic categories are shown in Table III. 
For male subfertility there was no significant difference in the live birth rate per embryo 
transfer, in comparison with the unexplained subfertile couple (21.3% and 22.7%). Tubal 
pathology was associated with the lowest live birth rate per embryo transfer (18.4%). 
The overall implantation rate per cycle was 10.7%. 
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For the three major subfertility causes analysed, we found evidence of a clear and signifi cant 
(p < 0.001) trend of declining live birth rates with increasing female age (Figure 2). The overall 
live birth rate per cycle decreased with 2% (p=0.03) for each additional year of the female age. 
We compared the effects of smoking and BMI per diagnostic category in Table IV. In all 
subgroups according to subfertility diagnosis, the delivery rate for non-smoking women was 
significantly (p< 0.0001) higher than for smoking women (Figure 3). The effect of smoking 
was the largest for women with unexplained subfertility; smoking decreased the live birth 
rate with 7.3% compared with decreases of 3.0% and 2.5% for women with male subfertility 
and tubal pathology, respectively. Overall we found a non-significant difference between the 
mean number of oocytes for non-smokers (9.6 oocytes per cycle) compared to smoking 
women (9.0 oocytes per cycle) (95% CI: 0.35-1.0). Although the mean number of embryo’s 
replaced for smoking women was higher (2.2 embryo’s per transfer) compared to non-smoking 
women (2.14 embryo’s per transfer), this led to lower pregnancy rates for smoking women. 
The abortion rate per pregnancy was significantly higher for smoking women compared to 
5
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Figure 2       IVF live birth rate by cause of subfertility, for three age groups; 
% = proportion of fi rst cycles resulting in a live birth. P-value for age eff ect 
p< 0.001
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non-smoking women respectively 21.4% and 16.4% (p=0.02). The ectopic pregnancy rate for 
both smoking as non-smoking women was not significantly different, respectively 3.8% and 
2.9% per pregnancy (p=0.3).
There was a significantly higher live birth rate per cycle in women with normal weight (BMI ≥ 
20 - 25 kg/m2) and slight overweight (BMI 25 - 27 kg/m2) compared with women with evident 
overweight with a BMI ≥ 27 kg/m2. The unfavourable effect of overweight was largest for 
women with unexplained subfertility. Underweight women had similar live birth rates 
compared to women of normal weight. 
Table V shows the results of multivariate analyses of predictors of the live birth rate as a result 
of the first IVF cycle, after successful ovum pick up and after embryo transfer. The first row 
gives the intercept, and the corresponding live birth rate for those with reference values for 
all variables. In the other rows, odds ratios are presented. These can be interpreted as follows: 
the live birth rate of smokers decreased with 28% compared with the live birth rate of 
chapter 5
Figure 3       IVF live birth rate for smoking and non-smoking women, by cause 
of subfertility; %= proportion of fi rst cycles resulting in a live birth. 
P-value for smoking eff ect p< 0.001
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non-smokers, adjusted for the following confounders: age, BMI, indication for IVF, previous 
pregnancies, duration of subfertility and calendar period in which IVF took place. There was 
only a significantly lower live birth rate per treatment cycle by cause of subfertility for couples 
with male subfertility. We found that the adjusted effect of smoking on the live birth rate was 
even stronger than an increase in female age with > 10 years, from age 20 to 30 years, with 
an OR of 0.78 (95% CI 0.63-0.96). The strength of the association with smoking differed 
between the subfertility groups. As in in the univariate analyses smoking was most deleterious 
to the couples with unexplained subfertility, and least to those with tubal pathology (Table 
IV). Overweight women (BMI > 27 kg/m2) had a 33% reduced chance of a live birth in their first 
IVF cycle. As for smoking, the association with overweight was strongest in women with 
unexplained subfertility. BMI and age were both also included as continuous variables. 
The effect estimates were similar for live birth rate per cycle, per ovum pick-up and per 
embryo transfer: BMI per unit OR = 0.98 (0.95-1.00) and age per year OR = 0.98 (0.96-1.00). 
Women with primary subfertility had the same live birth rate as women with secondary 
subfertility. The duration of subfertility did not influence the live birth rate for the three major 
subfertility categories, even after 8 years of subfertility no significant decrease in live birth 
rate could be detected. 
Discussion
In this large nationwide dataset we found that the live birth rate for male subfertility was 
significantly lower compared to unexplained subfertility and tubal pathology. Advancing 
female age had an unfavourable effect on the success rate of IVF for all subfertility causes. 
Smoking and overweight during IVF treatment had deteriorating effects on the live birth 
rates. Women who smoked had a significantly higher abortion rate than non-smoking 
women. Furthermore the effect of smoking was comparable to an increase in female age 
with 10 years, from age 20 to 30 years.
When interpreting our results the strengths and limitations of our study must be considered. 
Advantages of our analyses include the large size of the study population and the availability 
of near complete information on details of IVF treatment from the medical records and 
outcome of all pregnancies from the women themselves. A limitation of our study is that the 
analyses had to be based on women who responded to the questionnaire (a 71% response 
rate). Women who had a live birth after IVF were possibly more likely to participate to the 
OMEGA project, than those who remained childless. From two participating hospitals, a 
non-responder analysis to the questionnaire was performed. Indeed, we observed a higher 
response rate among women who had a live birth after IVF, compared to women who did not 
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(response rates of 73% and 64%, respectively). This might have resulted in a slight over-
estimation of live birth rates after IVF in Tables II-IV. However, assuming that non-response 
was not associated with life style factors, the estimate of the OR is unbiased. For 3227 IVF 
treated women who returned the questionnaire, data from the medical files could not yet be 
obtained. Since this was due to limited project funding resulting in a random sample of 
records not yet completed, it is highly unlikely that this has led to selection bias. Another 
restriction of our study is that we should take into account that the success rates in these 
older data might differ from the success rates today (Kremer et al., 2002). Unique of our 
analyses is that we were able to study the separate and combined influences of smoking and 
BMI for a very large number of IVF treatments.
Most of our results correspond with the results of the study of Templeton et al. (1996). We found 
that only male subfertility was associated with a significantly lower delivery rate per cycle 
compared with tubal pathology and unexplained subfertility. If we considered the delivery 
rates per embryo transfer, i.e., after fertilization had occurred, we did not observe a difference 
between unexplained subfertility and male subfertility. The abortion rate was significantly 
lower in the male subfertile group. These results imply that the receptiveness of the women 
with unexplained subfertility and male subfertility was at least the same, and probably better 
in the male subfertile group. For tubal pathology the delivery rate was significantly lower given 
an embryo transfer, compared to unexplained subfertility and male subfertility. The explanation 
for this difference could be the negative effect of tubal pathology on the implantation processes 
and the embryotoxicity of hydrosalpinx fluid (Johnson et al., 2002). 
Individual studies comparing smoking and non-smoking women undergoing IVF treatment 
do not always indicate a decreased live birth rate with smoking. A meta-analysis (Augood 
et al., 1998) showed that women who smoked had significantly lower pregnancy rates per IVF 
treatment compared to non-smokers. However, in none of these studies, a subdivision was 
made according to the indication for IVF and each of the studies reported different 
confounding factors and calculated odds ratios using different statistical methods. In a review 
(Zenzes, 2000) on the genetic damaging effects from smoking and its components on 
germinal cells, evidence was found that smoking affected the quantity and quality of oocytes 
and that it leads to an early age of menopause. Our results show a lower live birth rate and 
higher abortion rate for smoking women unless they had a higher mean number of embryos 
transferred. This might explain the lower quality of these embryos.
We studied the effects of both smoking and age on the live birth rate and found a trend of 
decreasing live birth rates with increasing age, which was consistently lower for smokers. 
Among women with tubal pathology, the diagnostic group with significantly more smokers 
than in the other subfertility causes, we found that the deteriorating effect of smoking on the 
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live birth rate per embryo transfer was not as strong as among women in the other diagnostic 
categories. The difference in influence of smoking on the outcome of pregnancy per 
indication category was not statistically significant (Breslow-Day test for homogeneity of 
odds ratios p=0.19). 
There is a clear association of an increased BMI, risk of complications during pregnancy and 
a higher chance of abortion and subfertility (Norman and Clark 1998; Wang et al. 2000; Wang 
et al. 2002). After multivariable logistic regression modelling, we also found a significant 
effect of overweight (BMI ≥ 27 kg/m2) on the live birth rate per cycle, with an OR of 0.67 (95% 
CI 0.48 – 0.94). 
Besides dependency on calendar period, prognostic models for IVF depend on the success 
rate of the treating hospital (Haan et al., 1991; Templeton et al., 1996; Kremer et al., 2002) 
patient characteristics and the number of previous IVF cycles (Tan et al., 1996; Templeton et 
al., 1996; de Mouzon et al., 1998). Publications suggest constant success rates for each of the 
first three cycles (Haan et al., 1991; de Vries et al., 1999). Some attribute this to active censoring, 
which leads to withdrawal of couples with poor prognosis (Land et al., 1997). In our study, 
continuation of IVF treatment depended on indication, due to the differences in fertilization 
rate. Twenty-five percent of the couples diagnosed with male subfertility did not complete 
three cycles and remained childless as compared with 13% of couples with unexplained 
subfertility and 5% of couples with tubal pathology. For reasons of comparability we therefore 
restricted our analyses in the present study to the first IVF treatment cycle only. 
Our historical cohort study enables us to assess the differences in success rates of IVF between 
the various subfertility causes. However, to study the efficacy of IVF in various diagnostic 
categories, a long-term clinical trial will be the best option, comparing the pregnancy rates 
of IVF or ICSI treatments with no treatment. A second best option is the comparison of the 
spontaneous pregnancy rate in subfertile couples on the waiting list for IVF or ICSI, with the 
results of IVF or ICSI treated couples. We are expecting results from such a study in the 
Netherlands in the near future. 
In conclusion, we observed differences in success rate between subfertility causes in favour 
of unexplained subfertility. Smoking had an unfavourable effect on the outcome of IVF and 
was comparable with an increase in female age of more than 10 years from age 20 to 30 
years. Overweight had a strong harmful effect on the live birth rate after IVF. The effect of 
smoking and overweight was largest among women with unexplained subfertility. These 
results suggest that women, and in particular those with unexplained subfertility, may be 
able to improve the outcome of subfertility treatment by quitting smoking and losing weight. 
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Chapter I 6
Spontaneous pregnancies after IVF: 
influence of patient characteristics  
and lifestyle
94
Abstract
Background: To predict the chance of a spontaneous conception leading to a live birth after 
IVF, based on prior subfertility treatment and lifestyle factors.
Methods: Historical cohort study of 8669 women who received IVF treatment in one of the 
12 IVF centres in the Netherlands between 1983 and 1995. The probability of a spontaneous 
conception leading to live birth within 12 months after an unsuccessful last IVF, or within 12 
months after an IVF live birth. 
Results: In total, 1065 women had at least one spontaneously conceived live birth after a 
median follow-up of 5 years. Within the first year after IVF treatment, or 12 months after an 
IVF pregnancy, or IVF live birth,  613 women had a spontaneous pregnancy leading to a live 
birth. For women with no pregnancy after last IVF treatment, the chances of a spontaneously 
conceived live birth decreased with older age (OR 0.94 per year, 95% CI 0.91 - 0.98), with a 
duration of subfertility ≥ 6 year (OR 0.80, 95% CI 0.61 – 1.1), and with the number of IVF 
attempts ≥ 4 (OR 0.71, 95% CI 0.49 – 1.1), but increased with male, unexplained, or other 
subfertility causes (OR 1.5, 95% CI 1.0 – 2.2), (OR 2.0 95% CI 1.3-3.2), and (OR 1.9, 95% CI 1.3 - 
2.8), respectively, compared to tubal pathology. Several lifestyle factors unfavourably affected 
the chances of a spontaneously conceived live birth: BMI ≥ 27 kg/m2  (OR 0.47, 95% CI 0.31 – 
0.71), smoking (OR 0.72, 95% CI 0.54 - 0.94), ≥ 4 units of caffeine/day (OR 0.72, 95% CI 0.55 - 
0.93), and ≥ 3 units of alcohol/week (OR 0.57, 95% CI 0.42 – 0.78). 
Conclusions: Within one year after last IVF, or within one year after an IVF pregnancy or an 
IVF live birth, 7% of all women had a spontaneous conception leading to a live birth. The 
impact of subfertility-related factors and lifestyle on the chances of pregnancy before and 
during IVF, also applies to the chances of a spontaneous conception after IVF treatment. 
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Introduction
A spontaneous pregnancy is still possible after a long period of subfertility, even after 
unsuccessful IVF or ICSI. So far, studies on spontaneous pregnancies after IVF or ICSI treatment 
had small sample sizes. Most studies consisted of selective observations, because only 
couples with IVF resulting in a live birth were included (Hennelly et al., 2000, Shimizu et al., 
1999). Other studies investigated only one cause of subfertility, such as severe male subfertility, 
after discontinuation of ICSI (Almagor et al., 2001, Osmanagoaglu et al., 2002, Ludwig et al., 
2008). To our knowledge, there is only one small (n= 116) study on the overall likelihood of 
spontaneous pregnancy after successful and unsuccessful IVF for all causes of subfertility 
(Cahill et al., 2005). A spontaneous pregnancy rate of 18% up to 3 years after last treatment 
was reported. In none of these studies, however, lifestyle factors were considered, although 
these may influence pregnancy rates. A negative impact on the time to pregnancy for 
non-subfertile couples trying to conceive was found for smoking, caffeine use, and overweight 
of women, and for alcohol intake of men (Hassan and Killick 2004, Bolúmar et al., 2000). These 
factors are likely equally important after IVF treatment.
The aim of this study was to predict the likelihood of a spontaneous conception leading to 
live birth, both after successful and unsuccessful IVF treatment, taking into account female 
age, pregnancy history, duration and cause of subfertility, the number and outcome of the 
preceding IVF treatments, Body Mass Index (BMI), smoking, and caffeine and alcohol use. 
Methods
Design
Data were obtained from a large nationwide historical cohort study set up in 1996, including 
19,840 subfertile women who had at least one IVF treatment in one of the 12 IVF centres in the 
Netherlands in the period 1983-1995 (The OMEGA–project, Klip et al., 2001, Lintsen et al., 2005), 
see Figure 1. From 1996-2000, 19,242 women were sent a 23-page questionnaire about their 
history of subfertility treatment, spontaneous conceptions, months of breastfeeding following 
each delivery, and lifestyle factors. The response rate to the questionnaire was 71%. 
From 1996 to 1999, data were extracted from the medical records in the IVF centres. Due to 
limited funding, the records of 3227 women who had returned the questionnaire, could not 
be abstracted. Bias is unlikely, however, as there was no selection on the patient level. ICSI 
treatments carried out from 1992 and during the first years only in small numbers, were 
excluded from analyses. Also special IVF related treatments (GIFT, ZIFT), and cycles with 
gamete or embryo donation were excluded.
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Participants
The IVF treatment data from the medical records were combined with information from the 
questionnaires for 9047 women, outlined in the grey area of Figure 1. Women with absolutely 
no chance of a spontaneous pregnancy were excluded: women with a history of sterilisation 
without refertilisation, double-sided tubectomy, bilateral ovariectomy, or hysterectomy after 
 
19,840 IVF treated women (OMEGA-project)  
19,242 IVF treated women received questionnaire  
 
13,698  women returned questionnaires (respons rate 71%) 
9942 IVF treated women with available questionnaire and medical record data 
5076 non-responders or did not want to participate (n=468) 
Gave no or incomplete permission to abstract medical files (n=529)  
M edical records not obtained (due to limited project funding) (n=3227)
9047 women  
Excluded: ICSI, GIFT, ZIFT, gamete- and embryo donated cycles 
(n=895)  
Excluded for having no spontaneous conception chance after IVF: 
sterili sation, double sided tubectomy, ovariectomy, and 
hysterectomy (n=378) 
8669 eligible women 
1349 women had a spontaneous pregnancy after IVF (1983 -1996)  
1065 women had a spontaneous pregnancy resulting in live birth after last IVF  
613 spontaneous conceptions leading to live births within 12 months after last IVF 
or within 12 months after a pregnancy or live birth as a result of last IVF   
Not approached (n=598): Deceased, incomplete addresses, emigration, 
or privacy reasons  
284 women had a spontaneous pregnancy not resulting in a live   
birth after last IVF 
7320 women had no spontaneous conception after last IVF  
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Figure 1       Flow chart of IVF patients in the OMEGA-study and of participants of the 
study on spontaneous pregnancies after IVF (grey area). Analyses were 
carried out with the data presented in the bold marked blocks
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IVF (n=378). Women were included in the analyses only once, meaning that only the first 
spontaneous pregnancy after IVF was studied. 
Follow-up
The maximum follow-up duration from last IVF treatment until the questionnaire was 13 
years, the median interval was 5 years and the interquartile range 3-6 years. With a long 
follow-up, the chance of an alteration in the fertility situation increases, e.g. through a divorce, 
remarriage, and conception with another partner. Therefore, we only included spontaneous 
pregnancies within an interval of 12 months after last IVF. In case the last IVF had resulted in 
a pregnancy and a live birth, the follow-up of 12 months  started after delivery taking into 
account months of exclusive breast feeding. In case an IVF pregnancy ended in a miscarriage, 
the follow-up started 3 months  after IVF, the average period of having a miscarriage followed 
by low fertility because of cycle recovery.
Prognostic factors
Prognostic factors were: the age of the patient at last IVF and was extracted from the medical 
files, the most important causes of subfertility of the couple (including tubal pathology, male 
related subfertility, unexplained subfertility, and other causes of subfertility, such as hormonal 
disturbances, cervical hostility, uterine pathology, and endometriosis), primary or secondary 
subfertility (primary: no pregnancy before the IVF referral), and duration of subfertility, defined 
as the time from child wish before the first contact with the general practitioner or gynaecologist 
until last IVF treatment (cut of point at 6 years). Height, weight, and lifestyle-related factors were 
extracted from the questionnaires. Based on the literature and the distribution of these variables 
in our data, caffeine and alcohol use were dichotomized with cutoff values of 4 or more units of 
coffee or tea per day and 3 or more units of alcohol per week. Women who smoked more than 
one cigarette per day for at least one year during the follow-up period were defined as smokers. 
Because the number of obese women was small (n=696, 8% of all eligible women), we did not 
classify the BMI according to the WHO criteria (< 25 normal weight, 25-30 overweight, and 
obese > 30 kg/m2), but used the same classification as in a former paper (Lintsen et al., 2005): 
underweight, BMI < 20 kg/m2 normal weight, BMI 20-27 kg/m2 and overweight, BMI ≥ 27 kg/m2. 
Unknown variables were included as missings. 
Statistical analyses
The statistical analyses were performed using the statistical package SPSS 17.0. The association 
between each prognostic factor and the chance of a spontaneously conceived live birth 
after IVF was studied by means of logistic regression analysis, resulting in crude odds ratios 
(ORs) with 95 percent confidence intervals (95% CIs). After univariable analyses, we performed 
a multivariable regression analysis. The impact on the outcome: spontaneous pregnancy 
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after IVF, was assessed considering multiple independent variables. Backward selection was 
used with a significance level of p < 0.15 for keeping a factor in the model. The results of the 
multivariable regression analysis were converted into a ready-to-use chart for clinicians, to 
calculate the chance of a spontaneously conceived live birth within 12 months after last IVF 
treatment for a certain couple. To provide the internal validity of the resulting prediction 
model the bootstrap method (taking samples with replacement from the original data 
mimicking the situation that the study had been repeated multiple times) was used with 100 
replications. From this procedure, the amount of over-fitting of the model was assessed and 
a ‘shrinkage’ factor was derived; for optimal prediction in future patients, the odds ratios of 
the model should be adjusted with this shrinkage factor (van Houwelingen and Le Cessie, 
1990). The discriminative ability of the model was assessed by the c-statistic, and a correction 
for optimism was applied. The c-statistic equivalent to the AUC (Area Under an Receiver 
Operating Characteristic Curve), measures how well the model would be able to make a 
distinction between couples who may have a spontaneously conceived live birth after IVF 
and couples who may not conceive spontaneously after IVF (Harrell et al., 1996). 
Results
Of the 8669 subfertile women who received one or more IVF treatments between 1983 and 
1995, 1349 women, with a median follow-up period of 5 years, had at least one spontaneous 
pregnancy after last IVF. For 1065 women (79%), this spontaneous pregnancy resulted in a 
live birth of whom 613 women conceived spontaneously within 12 months after last IVF 
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Table I     Characteristics of women in the OMEGA-cohort with no spontaneous 
pregnancy after IVF, compared to women who had a spontaneous 
conception leading to live birth within 12 months after last unsuccessful IVF 
or within 12 months after IVF pregnancy or delivery
No spontaneous 
conception after IVF
Spontaneous 
conception resulting in 
live birth after IVF
No. of women 7,320 (100%) 613 (100%)
Age at last IVF (years),  average (SD)
≤ 29
30-34
35-39
≥ 40
Missing
   34.1 (4.0)
    925 (12.6)
 2,860 (39.1)
 2,740 (37.4)
    591  (8.1)
    204  (2.8)
 32.7 (3.7)
 126 (20.6)
 298 (48.5)
 166 (27.1)
  23   (3.8)
-
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Subfertility history (%)
Primary 
Secondary
Unknown
3,997 (54.6)
1,865 (25.5)
1,458 (19.9)
384 (62.8)
154 (25.1)
  75 (12.2)
Duration of subfertility (years), mean (SD)
< 6
≥ 6
Missing
6.6 (3.4)
3,070 (41.9 )
2,148 (43.0)
1,102 (15.1)
5.5 (2.6)
321 (52.4)
198 (32.3)
  94 (15.3)
Diagnostic category
Tubal pathology
Male subfertility
Unexplained subfertility
Other known causes #
Unknown
2,663 (36.4)
2,008 (27.4)
1,803 (24.6)
   789 (10.8)
     57   (0.8)
125 (20.4)
189 (30.8)
208 (34.0)
  84 (13.7)
    7   (1.1)
Number of IVF attempts, mean (SD)
1
2-3
≥ 4
Missing
3.2 (2.2)
1,638 (22.4)
3,177 (43.4)
2,484 (33.9)
      21  (0.3)
2.6 (1.7)
184 (30.0)
288 (47.0)
139 (22.7)
    2   (0.3)
Pregnancy with last IVF
No
Yes, miscarriage 
Yes, live birth
Missing
4,759 (65.0)
   217   (3.0)
2,150 (29.4)
   194   (2.6)
386 (63.0)
  18   (2.9)
209 (34.1)
-
BMI, mean (SD)
< 20 
20-27 
 > 27
Missing
23.9 (4.0)
    861 (11.8)
5,044  (68.9)
1,307 (17.9)
    108  (1.5)
23.7 (3.6)
65 (10.6)
446 (72.8)
    95 (15.5)
    7   (1.1)
Smoking 
No 
Yes
Unknown
4,076 (55.7)
3,168 (43.3)
     76   (1.0)
403 (65.8)
208 (33.9)
    2   (0.3)
Caffeine intake per day, mean (SD)
< 4 
≥ 4
Missing
4.3 (1.6)
2,524 (34.5)
4,497 (61.4)
   299   (4.1)
4.2 (1.5)
251 (40.9)
352 (57.5)
   10   (1.6)
Alcohol intake per week, mean (SD)
< 3 
≥ 3
Missing
0.5 (0.8)
4,443 (60.7)
2,210 (30.2)
   667   (9.1)
0.4 (0.6)
437 (71.3)
154 (25.1)
  22   (3.6)
# Including: endometriosis and uterine, cervical, ovary and mixed reasons
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treatment, or within 12 months after IVF pregnancy or delivery (see Figure 1). The overall 
probability of a spontaneously conceived live birth was 7% (613/8669), within 12 months after 
last IVF, or within 12 months after the IVF delivery. 
After univariable analyses we found that on average, women with a spontaneous conception 
leading to live birth after IVF were younger, had a shorter mean duration of subfertility, less 
often had tubal pathology, had a lower number of IVF attempts, and more often had a live 
birth as a result of last IVF, compared to women with no spontaneous pregnancy after IVF. 
Furthermore, these women less often had a high BMI, were less often smokers, and drank less 
coffee or tea and fewer alcoholic drinks (Table I). 
We developed  two multivariable logistic regression models, one for women with no IVF 
pregnancy, and one for women who did conceive after last IVF using all relevant variables of the 
univariable analyses. Complete data were available for 4493 women. The impact of the prognostic 
factors on the probability of a spontaneously conceived live birth within 12 months after an 
unsuccessful last IVF, or 12 months after an IVF pregnancy, or IVF live birth are shown in Table II. 
The chance of a spontaneously conceived live birth for women with unsuccessful last IVF 
decreased with  increasing maternal age (OR 0.94, 95% CI 0.91 to 0.98), Compared to tubal 
pathology, the chances of a spontaneously conceived live birth were increased for male-related 
subfertility, unexplained subfertility, and other known causes of subfertility (including 
endometriosis and cervical, uterine, and hormonal causes) with ORs of 1.48 (1.02 to 2.15), 2.00 
(1.27 to 3.17), and 1.94 (1.34 to 2.80), respectively. Overweight (BMI ≥ 27 kg/m2 ), smoking, 
drinking ≥ 4 cups of caffeine containing drinks daily, and drinking ≥ 3 units of alcohol per week 
reduced the chances of a spontaneously conceived live birth with ORs of 0.47 (0.31 to 0.71), 0.72 
(0.54 to 0.94), 0.72 (0.55 to 0.93), 0.57 (0.42 to 0.78), respectively. For women with an IVF-live birth, 
lifestyle factors were no predictors in the multivariable analysis.
For the resulting prediction model, the c-statistic measuring the discriminative ability of the 
model was 0.68, and 0.66 when corrected for optimism. This indicates that the model would be 
able to separate women with a high chance of a spontaneous pregnancy from women with a 
low chance in 66% of the cases. The shrinkage factor determined by the internal validation 
procedure was 0.92, showing only slight overfitting. The reliability of the prediction of a 
spontaneous pregnancy leading to a live birth is evaluated by the calibration of the model, the 
degree to which the calculated probabilities agree with the observed spontaneous pregnancies 
(Coppus et al., 2009). The calibration of the prediction model was added in Figure 2. 
A score chart and a corresponding model is presented that can be used for an individual 
couple to calculate the chance of a spontaneous pregnancy resulting in a live birth within 12 
months after last unsuccessful IVF (see Figure 3). The points given indicate the impact of the 
different factors. For example, a women of 37 years of age (-6 points), with more than 6 years 
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Table II      Analyses of factors predicting a spontaneously conceived live birth  
after IVF within 12 months after unsuccessful IVF treatment or 12 months 
after IVF pregnancy or delivery  
Univariable 
OR (95% CI)
Multivariable
Adjusted
No pregnancy 
with last IVF
N=3,201
OR (95% CI)
Multivariable
Adjusted*
Live birth with 
last IVF
n=1,792
OR (95% CI)
Age at last IVF (continuous) 0.92 (0.90-0.94) 0.94 (0.91-0.98) 0.94 (0.90-0.99)
Subfertility history (%)
Primary
Secondary
  
1.00 (ref )
0.86 (0.71-1.04)
1.00 (ref )
1.27 (0.95-1.70)
1.00 (ref )
0.74 (0.50-1.08)
Duration of subfertility (years)
  < 6
  ≥ 6
1.00 (ref )
0.60 (0.50-0.72)
1.00 (ref )
0.80 (0.61-1.06)
-
Cause of subfertility 
  Tubal 
  Male
  Other
  Unexplained 
1.00 (ref )
2.01 (1.59-2.53)
2.27 (1.70-3.02)
2.46 (1.95-3.09)
1.00 (ref )
1.48 (1.02-2.15)
1.94 (1.34-2.80)
2.00 (1.27-3.17)
1.00 (ref )
1.68 (1.07-2.63)
1.90 (1.23-2.93)
1.70 (1.00-2.92)
Number of IVF attempts
  1
  2-3
  ≥ 4 
1.00 (ref )
0.81 (0.66-0.98)
0.50 (0.40-0.63)
1.00 (ref )
0.96 (0.69-1.33)
0.71 (0.49-1.05)
1.00 (ref )
0.75 (0.52-1.07)
0.60 (0.38-0.94)
BMI (kg/m2)
  20-27
  < 20
  ≥ 27
1.00 (ref )
0.85 (0.65-1.12)
0.82 (0.65-1.03)
1.00 (ref )
0.92 (0.62-1.36)
0.47 (0.31-0.71)
-
Smoking
  No
  Yes 
1.00 (ref )
0.66 (0.56-0.79)
1.00 (ref )
0.72 (0.54-0.94)
-
Caffeine (cups per day)
  < 4
  ≥ 4 
1.00 (ref )
0.79 (0.67-0.93)
1.00 (ref )
0.72 (0.55-0.93)
-
Alcohol (units per week)
  < 3
  ≥ 3 
1.00 (ref )
0.71 (0.59-0.86)
1.00 (ref )
0.57 (0.42-0.78)
-
*The probability for keeping variables in the model was p < 0.15. 
For women with a live birth with IVF, duration of subfertility, BMI, smoking, caffeine and alcohol use are no 
predictors in the multivariable data analyses. The lifestyle variables, BMI, smoking, caffeine and alcohol use 
entered in the analysis are the values recorded after a the whole interval of follow-up (median 5 years).
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(-2 points) of unexplained subfertility (0 points), after 3 IVF attempts (0 points), with overweight 
(-6 points), smoking (-3 points), drinking more than 4 cups of caffeine holding units (-3 points) 
and more than 3 glasses of alcohol per week (-5 points), has a sum score of -25 points and 
thus around 5% chance of a spontaneously conceived live birth. A women with the same age, 
cause, pregnancy history, and duration of subfertility, but with normal weight, non-smoking 
and drinking less than 4 cups of coffee or tea a day, and less than 3 units of alcohol per week 
has a sum score of -8 points and a 18% chance of conceiving spontaneously within a year 
after last IVF. 
Predicted pregnancy rate 
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Figure 2       Calibration plot with calculated probability and observed (actual) 
probability of a sponaneous conception leading to a live birth after 
discontinuation of IVF treatment. The plot shows that the model  
tends to overstimate the probablilities
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Biological factors 
Age 
(year)  
Points Duration  
Subfertility  
(year)  
Points Cause of subfertility  Points Number IVF  
attempts 
Points 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
0 
0 
-1 
-1 
-2 
-2 
-3 
-3 
-4 
-4 
-5 
-5 
-6 
-6 
-7 
-7 
-8 
-8 
-9 
-10  
-10 
< 6  
 6  
0 
-2 
 
Tubal pathology 
Male subfertility  
Unexplained 
Other known causes 
 
-6 
-3 
0 
0 
 
 
1 
2-3 
 4 
0 
0 
-3 
Life -style factors 
BMI  Points Smoking Points  Caffeine intake  
(cups a day)  
Points Alcohol intake  
(glasses a week)  
Points 
< 20 
20-27 
27 
-1 
0 
-6 
No 
yes 
0 
-3 
 
 
< 4 
 4 
0 
-3 
< 3 
 3 
0 
-5 
 
6
spontaneous pregnancy after ivf
Figure 3       score chart with corresponding curve toe calculate the chance of a 
spontaneous conception leading to a live birth within 12 months after a 
unsuccessful IVF
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Discussion 
We conducted a study on subfertility related factors and the chances of a spontaneous 
pregnancy after IVF on a large data base. We also studied the impact of lifestyle factors on 
the spontaneous pregnancy chance after termination of IVF. 
After IVF, within a year of last treatment, or within a year after an IVF pregnancy, or IVF delivery, 
7% of all women had a spontaneous pregnancy leading to a live birth, taking into account 
extra time for a miscarriage, delivery, and breastfeeding. We built a model to predict an 
individual couple’s chance of a spontaneous conception leading to live birth after unsuccessful 
IVF. The probability of a spontaneously conceived live birth after IVF decreased with increasing 
female age, with a long duration of subfertility, after multiple IVF attempts, with overweight, 
smoking, and high caffeine and alcohol intake. The cause of subfertility also influences the 
chance of conceiving spontaneously after IVF, with negative effects of tubal pathology. 
Comparable to a previous report (Cahill et al., 2005), we observed a 16% chance of a 
spontaneous pregnancy after a long follow-up interval (1349/8669). We also confirmed that 
the highest chance of a spontaneous pregnancy occurs within the first year after last IVF 
(Cahill et al., 2005, Roh et al., 1987).  In a study among fertile couples trying to conceive without 
fertility treatment, adverse effects on the interval leading to pregnancy were observed for 
heavy smoking of both women and men, caffeine use and overweight of women, and heavy 
alcohol intake of men (Hassan and Killick, 2004). We found comparable unfavorable effects 
on the chances of a spontaneous pregnancy after unsuccessful IVF, but already at lower 
cutoff values for these variables. Conceivably, the detrimental impact of unhealthy lifestyle 
habits is stronger for subfertile couples. On the other hand, a pregnancy with IVF treatment, 
overruled the variables for lifestyle in the model. 
The chance of a spontaneous pregnancy resulting in a live birth within the first year after IVF 
was 7%. In a previous study, we found a one year cumulative chance of 9% for an ongoing 
spontaneous pregnancy before IVF or ICSI treatment whilst on the waiting list (Eijkemans et 
al., 2008).  These spontaneous pregnancy chances before and after IVF seem comparable, 
although the difference between the populations included in both studies has to be 
mentioned. In this study of spontaneous pregnancies after IVF, we excluded women who had 
definitely no chance of a spontaneous pregnancy (e.g. double sided tubectomy) and ICSI 
treatments. In the study of spontaneous pregnancies before IVF/ICSI, on the other hand, all 
forms of tubal pathology were included and the male subfertile group included both mild 
(IVF) and severe (ICSI) semen pathology. 
The results of our analyses are based on data from IVF treatments between 1983-1995, this 
may affect the extrapolation to current practice. E.g. IVF treatment results have increased 
since, which might lead to lower chances of spontaneous pregnancy. Although, we could not 
confirm this hypothesis with the following analysis: the pregnancy rates before and after 
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1990, the start of standard use of LHRH analogues, did lead to overall higher IVF pregnancy 
rates, but the spontaneous pregnancy rate before and after 1990 did not change.
The data on lifestyle factors used in the analyses are those reported in the self-administered 
questionnaires. For instance, the body weight reported at the moment the questionnaire 
was filled out, was used in the analyses. We acknowledge that this could have been different 
at the time the spontaneous pregnancy occurred, and also recall bias could have influenced 
the results. Further, for the classification of BMI we did not use the WHO classification. 
The number of women with high BMI were too low, but even at the lower cutoff level that we 
used, the effect of overweight on the chance of a spontaneous pregnancy was found. 
In general, the use of unfavorable lifestyle factors may be underreported. As a result, the 
associations that we observed with spontaneous pregnancy chances may in fact reflect 
higher average levels of use. 
For important life events, such as pregnancies, however, it is highly likely that the data on the 
questionnaires are reliably recorded. Furthermore, couples treated for fertility problems are 
known to be a well-motivated population and they appear to have a high sensitivity and 
specificity for self-report as well (Olsen et al.,1997, de Boer et al., 2005). 
In 2006, preparatory for the study on spontaneous pregnancy chances after IVF, we carried 
out an additional pilot study among almost 500 women from this OMEGA dataset, who had 
at least one spontaneously conceived live birth after IVF. These women were sent a 
questionnaire on lifestyle, use of contraceptives, change of partner and child wish after IVF 
treatment. Strikingly, the use of caffeine and alcohol did hardly change over the years 
(comparing the answers on use of caffeine and alcohol in the OMEGA-data and the pilot). 
These lifestyle factors can be rightly named habits and did not change much over a longer 
time period. Furthermore, only 5% of the couples used contraceptives after IVF treatment, 
including the couples that did not have a child wish anymore. This illustrates the disbelief 
couples experience when a spontaneous pregnancy occurs after a long period of infertility 
and going through intensive fertility treatment. 
Unfortunately, in the current dataset we were not informed about relationships that ended 
after IVF. Therefore, we decided to report on the spontaneous pregnancies after IVF within 12 
months after treatment or 12 months after an IVF pregnancy, or IVF delivery, to reduce the 
chance of an alteration in fecundity, by change of partner, or not having a partner at all. 
Of course, even within 12 months after IVF, the ending of a relationships is possible, in 
particular after treatment failure. This could have biased our results in particular for those 
women without an IVF pregnancy. However, a comparison of the spontaneous pregnancy 
chance within 12 months after last IVF to the spontaneous pregnancy chance after complete 
follow-up for women with a male related cause of subfertility, a subgroup with the highest 
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chance of fecundity change, did not show a statistically significant difference (data not 
shown). 
We may have underestimated the chance of a spontaneous pregnancy after IVF because only 
the first spontaneous pregnancy after IVF was included in the analyses. Furthermore, even 
without exclusive breastfeeding, fertility may not have returned in the first few months after 
delivery or women may not have resumed intercourse right away, leading to a shorter 
follow-up interval. Similar arguments may apply to women having had a miscarriage from an 
IVF pregnancy. In addition, some women may have started using contraceptives during 
follow-up.
The strengths of this study include the large cohort of women after successful and 
unsuccessful IVF treatment; the availability of near complete lifestyle data; and the reduction 
of the impact of male partner change by restriction of the analyses to a limited period after 
IVF. We feel that our results about spontaneous pregnancy chances after IVF are relevant for 
general practitioners and gynaecologists. However, validation of the model with new data is 
of course still necessary. 
In conclusion, within 12 months after last IVF, or 12 months after an IVF pregnancy, or IVF-live 
birth, the chance of a spontaneous conception leading to a live birth was 7%. The impact of 
subfertility-related factors, such as the woman’s age, the duration of subfertility, and the 
number of IVF attempts, on the pregnancy chances with IVF treatment (Templeton et al., 
1996, Lintsen et al., 2007) also applied to the spontaneous pregnancy chance after IVF. The 
detrimental effects of overweight, smoking, and caffeine and alcohol use on the spontaneous 
pregnancy chance are demonstrated in subfertile couples after termination of  IVF. With a 
prediction model including both lifestyle and reproductive factors, the chance to conceive 
spontaneously after IVF can be quantified. 
Even after termination of an unsuccessful IVF treatment, couples should be aware that there 
is still a chance of a spontaneous pregnancy, and contraceptive use should be advised when 
a pregnancy is not wished for anymore. On the other hand, women should also be counseled 
about the possible effect of lifestyle changes that can influence their fecundity even after 
discontinuation of fertility treatment.
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Anxiety and depression have  
no influence on the cancellation  
and pregnancy rates of a first IVF  
or ICSI treatment
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Abstract
Background: After many years of research, the impact of psychological distress on the IVF 
treatment outcome is still unclear. This study aimed to determine the influences of anxiety 
and depression before and during IVF or ICSI treatment on the cancellation and pregnancy 
rates of inductees. 
Methods: In a multicentre prospective cohort study, we assessed anxiety and depression at 
baseline and the procedural anxiety level one day before oocyte retrieval, with the short 
versions of the State Anxiety Inventory (STAI) and the Beck Depression Inventory-Primary 
Care (BDI-PC). The effect of baseline anxiety and depression on the cancellation and 
pregnancy rates of 783 women in their first IVF or ICSI treatment was evaluated. We also 
determined if a change in anxiety from the start of treatment until just before oocyte retrieval 
affects the pregnancy rate. The predictive value of distress was assessed while controlling for 
several factors in subfertility treatment. 
Results: Neither baseline nor procedural anxiety, nor depression affected the ongoing 
pregnancy rates, with odds ratio’s (ORs) of 1.04 (95% CI: 0.82-1.33), 0.96 (95% CI: 0.77-1.20), and 
0.85 (95% CI: 0.65-1.10), respectively. Neither did the anxiety gain score affect the pregnancy 
rate, OR 1.08 (95% CI: 0.83-1.41). A cancellation of treatment could not be predicted by anxiety 
or depression, OR 1.16 (95% CI: 0.83-1.63) and 0.85 (95% CI: 0.59-1.22), respectively. 
Conclusions: Inductees in IVF treatment can be reassured that anxiety and depression levels 
before and during treatment have no influence on the cancellation and pregnancy rates.
chapter 7
111
Introduction
Subfertility and stress are inextricably linked together. Women experience the period of long 
unfulfilled child wish, and the treatments that may arise from this need, as very stressful. The 
perception that stress has an adverse effect on the pregnancy chance has become widely 
accepted, but in spite of many years of research on psychological factors and IVF outcome, 
the results are still contradictory. Reviews have suggested a negative correlation between 
distress and IVF outcome (Eugster and Vingerhoets, 1999; Klonoff-Cohen, 2005; 
Campagne, 2006). However, most studies have shown methodological shortcomings, i.e. 
small samples, non-standardized psychological tests, different stages of sampling, and/or no 
discrimination between inductees and veterans. Additionally, except for women’s age, other 
known confounding factors such as duration and cause of subfertility and pregnancy history 
were often not controlled for. 
Stress before and during the IVF treatment is multidimensional. There is the chronic source of 
stress caused by the threat of the permanency of the infertility and loss of hope. Another 
source of stress is the prospect of the treatment itself. These sources of distress can be 
measured before treatment, by baseline anxiety and depression. In addition, the third source 
of stress is the actual participation in the treatment, which can be measured by the level of 
anxiety as a result of the threat of the treatment itself, the so-called procedural or situational 
distress at a certain point in time. It can be the fear for the daily hormone injections or a 
painfully oocyte retrieval, or the strain of the emotional moment at the embryo transfer. 
 
Several prospective studies (with a range of women studied: between 40 and 291 inductees), 
have differentiated with standardized psychological tests, the influence of baseline anxiety 
or depression and/or procedural distress on IVF pregnancy chance: a high baseline distress 
level has negatively influenced the pregnancy rate in the study of Demyttenaere et al. (1992), 
Thiering et al. (1993), Klonoff-Cohen et al. (2001), Smeenk et al. (2001), Verhaak et al. (2001), 
Eugster et al. (2004) and in a large study of Boivin and Schmidt (2005) (818 couples, 75% were 
inductees). Conversely, baseline distress did not affect the pregnancy chance in the study of 
Merari et al. (1992), Boivin and Takefman (1995), Emery et al. (2003), Anderheim et al. (2005), 
and de Klerk et al. (2008). Indications of adverse effects of procedural stress, as measured by 
psychological or biological tests (e.g. hormone level), on the chance of IVF pregnancy were 
established by Boivin and Takefman (1995), Facchinetti et al. (1997), Gallinelli et al. ( 2001) and 
Smeenk et al. (2005). On the other hand, this influence was not found by Klonoff-Cohen et al. 
(2001), Lovely et al. (2003 and de Klerk et al. (2008). Contrary to all expectations, Merari et al. 
(1992) observed a significant higher state of anxiety level before oocyte retrieval for women 
who became pregnant. According to the study of Boivin and Takefman (1995), the period of 
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the highest stress level during an IVF treatment is measured between hCG administration 
and oocyte retrieval. Also the association of a lower adrenaline level at oocyte retrieval with 
an increased pregnancy chance observed by Smeenk et al. (2005) implicates that high anxiety 
levels shortly before oocyte retrieval might influence the implantation phase. To gain more 
insight into the interaction of stress and IVF treatment, we also studied if a change in anxiety, 
measured before treatment and just before oocyte retrieval, has a independent effect on the 
pregnancy rate. Furthermore, pre-treatment depression and anxiety scores have been related 
to the passive drop-out rate, concerning patients who voluntarily discontinue after first or 
subsequent treatment (Smeenk et al., 2004).  In this study, we assessed if basal psychological 
distress also has an association with unfinished, so-called cancelled  treatments. By discrimi-
nating the influence of distress on the cancelled versus the non-cancelled cycles, we tried to 
distinguished the influence of distress on the stimulation phase versus the implantation 
phase. 
In summary, so far studies on distress and IVF pregnancy are still inconclusive. The objective of 
this large prospective multicentre study with women having their first IVF or ICSI treatment is 
to determine the influence of distress at different points during treatment and with different 
end-points, while controlling for potential confounding factors in fertility treatment. 
Materials and Methods 
Design and subjects
We performed a prospective study in seven IVF clinics in the Netherlands: one university 
hospital and two general hospitals with licensed IVF laboratories, one satellite and three 
transport IVF-clinics. In the latter two types of clinics, the stimulation phase is started and the 
patients are referred to the licensed IVF centre for oocyte retrieval and/or embryo transfer. 
All new couples with an indication for IVF or ICSI treatment according to the IVF guideline 
formulated by the Dutch Society for Obstetrics and Gynaecology (NVOG, IVF guideline no 9, 
1998, www.nvog.nl), could be asked by nurses and doctors involved in the research team if 
they wished to participate. In order to examine the influence of distress on the spontaneous 
pregnancy chance on the waiting list for treatment (a subject that goes beyond this paper), 
women were asked to participate in the study by completing three questionnaires on three 
different occasions. The first one was directly after IVF reference, when joining the waiting list 
before treatment (T0); the second questionnaire was one or two months before treatment, 
after pre-treatment information and instruction on self injection of the medication (T1), and 
the third questionnaire was one day before oocyte retrieval (T2). The time women had to 
wait on the waiting list differed between the clinics from 1 to 9 months. If there was no 
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waiting period, women skipped the questionnaire on T1, and the questionnaire on T0 was 
used. For the aim of this study, correlating psychological factors and the IVF cancellation and 
pregnancy rate, we used the second (time point T1 in IVF treatment) and the third (T2) ques-
tionnaires. Exclusion criteria were inadequate apprehension of the Dutch language and use 
of donor gametes. 
This study was part of the national cohort study, on prediction of pregnancy chances with 
IVF and ICSI treatment, that was performed between 2002 and 2004 and published recently 
(IVF dataset: Lintsen et al., 2007). The IVF outcome data and the fertility specific background 
variables such  as pregnancy history, duration and cause of subfertility of all inductees 
participating to this study, as well as all other inductees, were registered in the national 
cohort study. The psychological dataset was matched with the IVF dataset of the seven 
participating hospitals.
The ethical committees of the participating clinics gave approval for the study. 
IVF treatment
The treatment protocols were hospital specific, but all women were treated with conventional 
ovarian stimulation with gonadotrophins combined with a preceding pituitary down-regula-
tion through a GnRH-agonist co-treatment. The oocyte retrieval was timed 34-36 h after ad-
ministration of 5000 or 10 000 I U hCG. Fertilization was performed by standard IVF or ICSI 
technique. A maximum of two embryos were transferred. Luteal support was given by 
progesterone vaginally. Additional good quality embryos were cryopreserved and transferred 
in a later cycle if the treatment had been unsuccessful. 
Distress measures
The baseline emotional status was defined in terms of state anxiety and depression. Anxiety 
was measured by means of the abridged Dutch version of the State Anxiety Inventory (STAI: 
Dutch translation: Spielberger, 1983; van der Ploeg et al., 2000), by 10 items, out of 20, each 
ranging in score from 1 to 4. Each item has a four-point evaluation with a maximum sum 
score of 40, which indicates highest anxiety. Depression was measured using the short Dutch 
version of the Beck Depression Index for primary care (BDI-PC) (Beck et al., 1997). The BDI-PC 
consists of 7, out of a total of 21 items ranging from 0 to 3, to indicate the severity of the 
symptoms. The maximum score could be 21. The questionnaires used have shown reliability 
and validity  (Huiskes et al., 1990a, b; Verhaak et al., 2001, 2005, 2006). The questionnaire on T1, 
one or two months before the start of treatment, measured the baseline anxiety and 
depression status by asking how the participant has felt “the last week”. The questionnaire on 
T2, one day before oocyte retrieval, measured the procedural state anxiety by means of the 
same abridged Dutch version of the STAI. The stress response to treatment was assessed by 
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comparing baseline anxiety at T1 with procedural anxiety at T2 and calculating the residual 
gain score indicating a change in anxiety by controlling for baseline anxiety. The different 
scales showed excellent reliability: anxiety alpha = 0.88; depression alpha = 0.82.
Definitions
Primary subfertility indicates that the woman had no pregnancy before referral to IVF. 
Duration of subfertility is defined as the time between the date of active child wish, or the 
date of last miscarriage, and the date of first IVF. The cause of subfertility contributing to the 
primary indication for IVF was divided into tubal, hormonal, unexplained, endometriosis, 
mild male-related subfertility, treated with IVF, and severe male subfertility, treated with ICSI. 
The first outcome measure was ongoing pregnancy after first IVF or ICSI treatment, confirmed 
by ultrasound of at least one fetus with positive heartbeat at 8 weeks gestation. A second 
outcome measure was cancellation of treatment, defined as having started stimulation 
without reaching oocyte retrieval. 
Data analyses 
Univariate frequencies and means of biological patient characteristics were calculated and 
compared between participants versus non-participants. Univariate frequencies of 
psychological scores at baseline were calculated for women with a cancelled cycle versus 
women who completed the first cycle, and psychological scores were compared between 
pregnant versus non-pregnant women. Multivariate logistic regression analyses were used to 
estimate the predictive effect of psychological scores on the probability of cancellation and 
of an ongoing pregnancy in non-cancelled cycles. The psychological scores were the baseline 
state anxiety and depression level at T1, the procedural state anxiety level at T2 and the 
residual gain score from T1 to T2. We adjusted for the following established variables: women’s 
age, pregnancy history, cause and duration of subfertility (Stolwijk et al., 1996; Templeton et 
al., 1996; Lintsen et al., 2007). All analyses were performed using SPSS 14.0. Statistical testing 
on all outcome measures was done at a 0.05 two-sided level of significance.
Results
Of 1124 eligible women 783 women filled in the first questionnaire before the treatment start 
(70% participation). Figure 1 provides a flowchart of the inclusion. For 78 women the 
treatment was cancelled before oocyte retrieval. 284 women did not complete, or forgot to 
bring along, the second questionnaire that had to be filled in one day before oocyte retrieval. 
We had complete follow-up of the first IVF or ICSI treatment for 421 women who filled in a 
questionnaire at T1 and at T2. 
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Table I presents baseline characteristics and main treatment outcomes of women at T1, of 
women who also contributed at T2, and of all other inductees in the period of study treated 
in one of the hospitals involved (non-participants to this study). Frequencies and means are 
equivalent for the three groups. The mean duration of subfertility was longer in the non-
participating group. 
Table II shows that there were no differences in the mean anxiety and depression levels at 
baseline and no differences in frequencies and means for biological variables for women 
who completed a first cycle and for women who did not reach the oocyte retrieval because 
of cancellation. Women with a cancelled cycle did have a longer mean duration of subfertility 
compared to women who completed the first cycle (3.9 years versus 3.3 years, p=0.02). 
In Table III, the levels for anxiety and depression before and during IVF treatment and the 
anxiety gain score from pre-treatment to oocyte retrieval are shown to be not different for 
783 women lled in 
a questionnaire on T1 
Cancellation of cycle after the start of 
stimulation and before oocyte retrieval 
for 78 women  
 
 
705 women reached 
oocyte retrieval pick-up
284 women did not ll in 
a questionnaire on T2  
1124 women started a rst IVF or ICSI in 7 clinics in 2002-2003  
421 women with a questionnaire on T1 and T2 and oocyte retrieval  
341 women were not asked or did not 
want to participate to the study  
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Figure 1       Flow chart of women starting their first IVF or ICSI treatment in one of 
seven IVF clinics between 2002-2003. The numbers in the shaded areas  
are used in the analyses
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Table II      Univariate analyses of psychological and biological factors predicting  
cycle cancellation at T1
Not cancelled 
(n=705)
Cancelled 
(n=78)
P-value
T1 Basal State anxiety 17.7 (SD=4.9) 18.0 (SD=5.1) 0.68
T1 Depression   1.4 (SD=2.2)   1.3 (SD=2.0) 0.76
Age (mean) 33.2 (SD = 3.6) 33.0 (SD = 4.5) 0.70
Duration (mean)   3.3 (SD = 1.9)   3.9 (SD = 2.5) 0.02
Primary, % (n) a 69.3 (483) 73.3 (55) 0.47
Cause of subfertility a
1.00
      Tubal, % (n) 15.2 (101) 15.9 (11)
      Endometrioses, % (n)   5.4 (36)   5.8 (4)
      Hormonal, % (n)   5.6 (37)   5.8 (4)
      Mild male (IVF), % (n) 17.0 (113) 15.9 (11)
      Severe male (ICSI), % (n) 37.2 (248) 36.2 (25)
      Unexplained, % (n) 17.0 (113) 17.4 (12)
a Percentages do not correspond to the numbers divided by the totals due to missing values.
Table III     Univariate analyses of psychological and biological factors predicting the  
IVF and ICSI ongoing pregnancy rate in patients having an oocyte retrieval
Pregnant, 
Mean (SD)
Non-pregnant, 
Mean (SD)
P-value
T1 Basal State Anxiety a 17.6 (4.7) (n=196) 17.7 (5.0) (n=494) 0.74
T1 Depression   1.2 (1.8)   1.4 (2.4) 0.17
T2 Procedural State Anxiety b 18.4 (5.8) (n=122) 18.5 (5.8) (n=291) 0.82
T1 l T2 Anxiety gain score   0.9 (3.9)   0.8 (4.1) 0.73
Age (mean) 32.9 (3.1) 33.4 (3.8) 0.09
Duration (mean)   3.3 (1.7)   3.4 (1.9) 0.56
Primary subfertility,% (n) c 71.0 (137) 69.0 (338) 0.61
Cause of subfertility c
0.66
      Tubal, % (n) 15.6 (29) 14.6 (68)
      Endometrioses, % (n)   3.2 (6)   6.2 (29)
      Hormonal, % (n)   6.5 (12)   5.4 (25)
      Mild male (IVF), % (n) 19.4 (36) 16.1 (75) 
      Severe male (ICSI), % (n) 36.6 (68) 37.6 (175) 
      Unexplained, % (n) 15.1 (28) 17.8 (83)
aOn T1 for 690 women data on IVF and psychological outcomes were complete. There were 15 missings in 
ongoing pregnancy; bOn T2 for 413 women data were complete, there were 8 missings on ongoing pregnancy; 
cPercentages do not correspond to the numbers divided by the totals due to missing values.
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pregnant compared to non-pregnant women. Pregnant women were younger than 
non-pregnant women, but the level did not reach significance. 
We constructed a multivariate logistic regression model for the prediction of cancellation 
and the ongoing pregnancy rate with the basal anxiety and depression scores at T1 (Table IV). 
We also build a model for the prediction of the ongoing pregnancy chance with procedural 
anxiety at T2 and with the anxiety gain score from T1 to T2 (the latter two models not shown). 
In all models we adjusted for potential biological confounders: female age, pregnancy history, 
duration and cause of subfertility. Overall, as could be expected from the univariate results, 
neither baseline anxiety, nor depression showed influence on the cancellation rate, with ORs 
1.16 (95% CI: 0.83-1.63), and 0.85 (95% CI: 0.59-1.22), respectively. The chance of cancellation 
could be predicted by a longer duration of subfertility, OR 1.14 (95% CI: 1.01-1.27). There was 
no influence of baseline, or procedural anxiety, nor of the anxiety gain score on the ongoing 
pregnancy rate, ORs 1.04 (95% CI: 0.82-1.33), 0.96 (95% CI: 0.77-1.20), 1.08 (95% CI: 0.83-1.41), 
respectively. Depression could not predict the pregnancy rate either, OR 0.85 (95% CI: 
0.65-1.10). Pregnancy history, duration and cause of subfertility also had no influence on the 
pregnancy rate. With higher female age there was a trend towards a decreased chance of 
pregnancy, OR 0.95 (95% CI: 0.90-1.00), (p=0.07). The results didn’t change if we used the 
composite score for anxiety and depression.
Discussion
In this large prospective multicenter study we examined the relation of anxiety and depression 
on the rates of cancellation and pregnancy of women having their first IVF treatment. Both in 
univariate and in multivariate analyses, psychological distress before and during treatment 
did not affect the chance of pregnancy.
In accordance with other studies on anxiety before and during first IVF treatment, we did not 
find an impact of baseline psychological factors or procedural anxiety on the pregnancy 
chance (Thierring et al., 1993; Boivin and Takefman, 1995; Klonoff-cohen et al., 2001; Emery et 
al., 2003; Anderheim et al., 2005; Smeenk et al., 2005; de Klerk et al., 2008). Influence of 
procedural stress in inductees before oocyte retrieval has been found only in small sample 
studies (Boivin Takefman, 1995; Facchinetti et al., 1997; Galinelli et al., 2001).
Former results from our own research group, showed that high baseline state anxiety and 
depression levels had a negative impact on the pregnancy chance of inductees (Smeenk et 
al., 2001; Verhaak et al., 2001), but this could not be confirmed later on (Smeenk et al., 2005). In 
the latter study, the relation between anxiety and the pregnancy outcome was suggested 
with a lower baseline adrenaline and lower (nor)-adrenaline level at embryo transfer observed 
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in women who succeeded with a pregnancy. In the current study, this relation could not be 
confirmed with the procedural anxiety level measured before oocyte retrieval.
Surprisingly, higher women’s age showed only a trend towards a lower pregnancy chance. 
All other biological factors studied (pregnancy history, cause and duration of subfertility), did 
not have an impact on the pregnancy rate. These factors have been shown to be of 
importance in large prospective studies (Templeton et al., 1996; Lintsen et al., 2007). Despite 
participation of a fairly large number of women in this study, the number was probably not 
high enough to reach significance in the prediction of pregnancy. 
We showed that psychological factors were not associated with the cancellation rate. In daily 
practice, the most important reason for cancellation will be medical: imminent ovarian hyper 
stimulation, or in contrast, poor ovarian response. However, this was not reflected in a 
difference of biological characteristics between cancelled and non-cancelled women. 
The only factor predicting cancellation was a longer duration of subfertility.
We compared the baseline state anxiety and depression levels of women that completed a 
questionnaire pretreatment with the anxiety and depression scores of the Dutch Community 
norms and found the levels of our participants within the normal range. This is in accordance 
with the systematic review of Verhaak et al. (2007) in which the investigation of the emotional 
adjustment before the start of IVF treatment over the last 25 years is reviewed: the depression 
level of IVF patients was similar compared to the norm groups, but the pretreatment state 
anxiety scores differed considerably for patient groups as well as for norm groups. This 
difference in norm is partly explicable by cultural differences, but the difference in patient 
approach might be of even greater influence of the patient’s emotional response. 
We had access to the complete database of all eligible new patients and 70% participated, 
but selection bias of participants cannot be fully ruled out. Perhaps nervous women were 
not asked, or maybe women with high distress levels refused to participate. As far as biological 
patient characteristics are concerned, there were no differences between participants and 
non-participants, except  for a longer duration of subfertility for inductees in the non-partic-
ipating group, which we cannot explain. 
We regret that lifestyle factors as smoking, overweight, caffeine and alcohol intake were not 
studied. Although of unarguable influence in IVF treatment and in fertility in general (Sharpe 
and Franks, 2002; Klonoff-Cohen, 2005; Lintsen et al., 2005), the complexity of research, where 
lifestyle factors are understood as mediators in the relationship between distress and fertility, 
requires a different intention of study (Verhaak and Hammer Burns, 2006). 
The emotional impact of an IVF treatment should not be underestimated, but we agree with 
Boivin et al. (1995) and Verhaak et al. (2007), that high expectations of the first treatment after 
adaptation to the subfertility problem after several years, will positively influence the 
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emotional disposition. On the other hand, after unsuccessful IVF treatment, 20% of women, 
showed subclinical forms of anxiety and/or depression (Verhaak et al., 2005). We therefore do 
recommend research in the field of prediction (Verhaak et al., 2006), and of counselling and 
therapy of women who are susceptible to, or have developed, emotional problems after 
unsuccessful IVF treatment.
In summary, in our large prospective study on psychological distress and IVF, we did not find 
an influence of anxiety and depression on the IVF cancellation rates or pregnancy rates. The 
small confidential intervals in the multivariate analyses implicate accurate findings. The 
coherence between psychological factors and IVF outcome is probably more complex and 
cannot be solved without the research of mediating factors as lifestyle and sexual behaviour. 
Large prospective studies on psychological and contributory factors are necessary to reveal 
more information about the interrelationship between emotions and fertility.
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Abstract
Background: Fertility problems are accompanied by a lot of emotional distress, resulting in 
a considerable part of female patients showing severe maladjustment after artificial 
reproductive treatment. This interferes with their daily life, in addition, emotional distress has 
shown to be related to dropout of treatment and deterioration of health behavior. Early iden-
tification of women at risk enables the provision of timely psychosocial support and gives the 
opportunity of focusing psychosocial resources on those who need it most. This study 
investigated the psychometric characteristics of a screening tool SCREENIVF to identify 
women at risk for emotional problems in an early stage in the treatment.
Methods: Risk factors for emotional maladjustment were identified in a previous study and 
incorporated in SCREENIVF which consists of 32 items on general and infertility specific 
psychological factors. Two hundred and seventy nine women in their first IVF treatment cycle 
finished SCREENIVF at pretreatment and three to four weeks after the pregnancy test. 
Regression analyses were performed to investigate the predictive value of SCREENIVF, 
sensitivity and specificity as well as likelihood ratio’s were described .
Results: SCREENIVF successfully identified 75% of the patients as at risk or not at risk. 
The negative predictive value was high: 89%. The positive predictive value was low (48% 
in the total sample and 56% after unsuccessful treatment). Sensitivity was 69%, Specificity 
was 77%.
Conclusions: For its use as a first screening for emotional problems, SCREENIVF is an 
acceptable instrument to identify women at risk. These women could be offered  more 
detailed diagnostics e.g. in a diagnostic interview to further investigate to what extent they 
could benefit from psychological treatment. In addition, physicians can anticipate on this risk 
profile when communicating with these patients. 
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Introduction
The importance of paying attention to emotional outcomes of infertility and its treatment is 
increasingly recognized. This is partly stimulated by the increasing incidence of fertility treatment, 
in combination with a considerable part of the women who still does not succeed in achieving a 
pregnancy. The emotional burden of IVF is well documented (for reviews see Stanton & Dunkel-
Schetter 1991; Greil 1997; Verhaak et al. 2007). It is a stressful emotional experience that could 
interfere with its outcome. Most couples adjust emotionally well to unsuccessful treatment. They 
experience emotional distress in terms of normal feelings of vulnerability, fear and grief. However, 
a considerable part shows disabling emotional problems such as anxiety and depression. Women 
seem more vulnerable than men to develop emotional problems as the result of IVF, in addition, 
unsuccessful treatment is an important risk factor for emotional maladjustment. 
The emotional maladjustment could negatively contribute to the outcome of IVF. There is much 
debate about the direct relationship between  psychological factors and the outcome of IVF. 
Some studies show a direct relationship between emotional stress and the outcome of IVF 
(Demyttenaere et al., 1992, Thiering et al., 1993, Klonoff-Cohen et al., 2001, Smeenk et al., 2001, 
Verhaak et al., 2001, Eugster et al., 2004, Boivin and Schmidt 2005). Others, however, found no 
relationship (Lintsen et al. 2009). Consequently, as yet there is not enough empirical evidence 
to justify psychological treatment for patients to improve their chance to get pregnant. More 
recently, the indirect impact of psychological factors on the outcome is more recognized by its 
role as  mediator in the relationship between biological parameters and outcome of fertility 
treatment. Psychological factors have shown to be related to prematurely drop out of treatment 
by patients indicating emotional strains as important reason to prematurely stop treatment 
(Smeenk et al., 2004, Olivius et al., 2004, Verberg et al., 2008). Psychological factors also contribute 
to health behavior such as eating habits and smoking (Rollnick 1999). In addition, psychological 
factors in terms of prenatal maternal stress are negatively related to the outcome of pregnancy 
and subsequent health of children. This is well documented in spontaneous pregnancies (e.g. 
Bellinger et al., 2008, Lazinsksi et al., 2008; Beydoun et al., 2008; Marcus 2009; Wisner et al., 2009). 
From clinical point of view, it would be important to be able to identify women with an 
vulnerability for emotional problems in time, before starting treatment, enabling clinicians to 
offer them psychosocial care if needed, and to anticipate on this emotional vulnerability in their 
consultations. This could  facilitate patients emotional adjustment to the treatment and its 
outcome, and probably contribute to more favorable health behavior and less drop out of 
treatment . Most physicians judge patients vulnerability for emotional problems on gut feelings. 
Studies in other patients samples indicate health care professionals difficulties in identifying 
those patients vulnerable for emotional problems. They correctly identified only 25% of the 
patients (Glazebrook et al., 2003). 
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An adequate judgment of the need for psychological treatment is also important from  patients 
point of view. Individual patients have difficulties in matching their own levels of distress, their 
perceptions of the merits of psychosocial support and its availability (Boivin et al., 1999).
Studies into the effect of psychosocial interventions on distress levels of patients with fertility 
problems revealed contradictory results (For review see Boivin 2003; Connolly et al., 1993; 
De Klerk et al., 2008; Emery et al., 2003). This is partly attributed to the heterogeneity of the 
patient groups (Wischmann 2008). One important issue is that the majority of patients with 
fertility problems suffer from their inability to get pregnant, but cope effectively with this 
emotional burden indicated by their satisfactory emotional adjustment (Verhaak et al., 2005a; 
Verhaak et al., 2005b). Patients who are already able to adjust well to the stressor of infertility 
are not likely to benefit much from additional psychosocial support. Moreover, it should be 
questioned if scarce availability of psychosocial professionals has to be offered to patients 
who are already well adjusted. It seems more reasonable to focus psychosocial treatment 
possibilities on those who need it most. This is in line with recommendations in several 
psychological intervention studies in infertility (Connolly et al., 1992; De Klerk et al., 2008). 
The challenge is not to improve emotional adjustment in all patients with fertility problems, 
but to identify those with (the risk of) serious adjustment problems in time, and to provide 
them psychosocial treatment, tailored to their individual vulnerabilities. 
In the field of behavioral medicine, several studies have been carried out into risk factors for 
emotional maladjustment to  various medical conditions. These studies are based on stress 
vulnerability models identifying existing distress levels, personality characteristics, coping,  and 
social support as risk factors (Lazarus & Folkman 1984; Cohen & Wills, 1985; Clark et al., 1994; 
Holahan et al., 1996; Beck & Clark, 1997; Alloy et al., 1999). The few prospective studies on risk 
factors for  emotional problems in patients with fertility problems have found support for the 
importance of these factors (Terry & Hynes 1998; Schmidt et al., 2005; Verhaak et al., 2005a; 
Verhaak et al., 2007; Cousineau & Domar, 2007). In our centre, a longitudinal prospective study 
identified pre treatment distress in terms of anxiety and depression, as well as strong focus on 
the child wish, less acceptance of the fertility problems and lack of perceived social support as 
risk factors for emotional problems after unsuccessful IVF in women. The study also indicated 
women as most severely emotionally affected by threatening infertility (Verhaak et al., 2001). 
Accordingly, the identification of these risk factors resulted in the development of a short 
screening tool SCREENIVF which is aimed to identify  women at risk for emotional maladjustment 
before the start of their IVF treatment. In this study, we investigated the validity of SCREENIVF in 
women. We investigated to what extend SCREENIVF, administered before the start of the first 
treatment cycle  showed a predictive value for the emotional adjustment of women after this 
cycle in a large sample recruited from different fertility centers. 
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Materials and Methods
Design and subjects
Seven IVF clinics in the Netherlands participated into the study which was part of a larger 
study into the prediction of pregnancy with IVF or ICSI treatment performed in 2002-2004 
(Lintsen et al., 2007).  Women with an indication for IVF or ICSI treatment according to the IVF 
guideline formulated by the Dutch Society for Obstetrics and Gynaecology (NVOG, IVF 
guideline no 9, 1998, www.nvog.nl), and starting first treatment, were eligible to participate 
in the study. For this study, they were asked to complete two short questionnaire: one was 
administered before the start of the treatment (T1), the other one three weeks after the 
pregnancy test (T2). The inclusion period covered 12 months per clinic. Exclusion criteria 
were inadequate apprehension of the Dutch language and use of donor gametes. The IVF 
outcome data and the fertility specific background variables as pregnancy history, duration 
and cause of sub fertility of all women participating in this study were registered in the 
national cohort study. The psychological dataset was matched with the IVF dataset of the 7 
participating hospitals.
The ethical committees of the participating clinics gave approval for the study. 
Distress measures
SCREENIVF was based on the results of our previous prospective study into the prediction of 
the emotional response to unsuccessful IVF treatment (Verhaak et al., 2005a and Verhaak et al., 
2005b). This study revealed five risk factors: (1) pre treatment anxiety and (2) pre treatment 
depression, cognitive coping in terms  of (3) helplessness and (4) less acceptance regarding 
fertility problems and (5) a lack of social support as risk factors for increased emotional 
problems. A short questionnaire was developed. It consisted of the scales  assessing these 
five risk factors based on the previous study. This resulted in a 31 item questionnaire consisting 
of 10 items assessing state anxiety, 7 items assessing depression, 6 items assessing 
helplessness, 6 items assessing lack of acceptance  and 5 items assessing perceived social 
support. The items assessing anxiety were based on a short version of Spielberger State and 
Trait Anxiety Inventory (Spielberger 1983, Van der Ploeg 2000) used in the IRGL (Invloed van 
Reuma of Gezondheid en Leefwijze; impact of rheumatoid arthritis on health and daily 
activities). The depression items were the 7 items of the short Beck Depression Inventory 
version for patients of general practitioners (Beck et al.,1997). The items on helplessness 
regarding fertility problems and acceptance of fertility were from the Illness Cognition 
Questionnaire for IVF patients (Evers et al., 2001; Verhaak et al., 2005b). Perceived social support 
was assessed by 5 items derived from the Inventory of Social involvement (Van Dam Baggen 
& Kraaimaat 1992). The assessments of anxiety, depression and perceived social support are 
based on generic instruments, the assessment of cognitive coping is based on a fertility 
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specific instrument. The different scales showed excellent reliability: anxiety alpha=.88; 
depression alpha =.82; helplessness alpha=.87; acceptance alpha=.92 and social support 
alpha=.89. The items of the helplessness, acceptance and social support scales of SCREENIVF 
are presented in the appendix, the items of anxiety can be found in Van Dam Baggen and 
Kraaimaat (1992), the depression items could be found following Beck et al. (1997). 
SCREENIVF was handed out after pre-treatment information and instruction on self injection 
of the medication. Patients were asked to administer the follow up assessment three to four 
weeks after the pregnancy test. Emotional adjustment after the first treatment cycle was 
assessed in terms of anxiety and depression after the pregnancy test of the first treatment 
cycle. For the follow up assessment, the anxiety and depression scales of SCREENIVF were 
administered (Beck et al., 1997; Van der Ploeg 2000).  The follow up score consisted in continue 
scores on anxiety and depression. Additionally, the same cut off scores as in pre treatment 
assessment were used to indicate yes or no clinical relevant problems concerning anxiety 
and or depression. This resulted in a dichotomous variable: yes or no clinical problems at post 
treatment. Clinical problems at post treatment was defined as showing scores above the cut 
off for anxiety and/ or depression. The moments of assessment are presented in Table I.
Patients were defined as at risk when their scores on one of the five risk factors showed 
clinical relevant problems. The cut off of the depression scale was 4 or higher. This is in line 
with the cut off presented in other studies (Beck et al., 1997). The cut off for the short version 
of the STAI was based on scores of one standard deviation above the mean in a Dutch norm 
group consisting of women: score 24 and above. For the scores of helplessness, acceptance 
and social support, no norm scores were available. The cut off scores were based on one 
standard deviation above the mean scores of IVF-patients in a previous study (Verhaak et al. 
2005a) resulting in a cut off of 14 and above for helplessness, 11 and less for acceptance and 
15 and less for social support.  Accordingly, SCREENIVF resulted in a dichotomous scores on 
each of the five risk factors: score 0 if the patient scored below the cut off, and score 1 when 
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Table I    Assessments at different moments of measurement
Risk factors Questionnaires
T1 pre treatment 
(SCREENIVF)
T2 post treatment
Anxiety STAI short version: 10 items X X
Depression BDI short version 7 items X X
Helplessness Scale ICQ 6 items X
Acceptance Scale ICQ 6 items X
Social support 5 items X
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scoring above or equal as the cut off score. The score range on SCREENIVF was 0 to 5: 0 
indicating no risk factors and 5 indicating 5 risk factors.  
Data analyses 
In order to assess to what extend the five scales of SCREENIVF, administered at  T1 could 
predict anxiety and depression after one treatment cycle, two multiple regression analyses 
were performed with anxiety and depression post treatment (T2) as dependent variable. In 
the first step, baseline levels of the dependent variable (anxiety or depression) were entered, 
in the second step the other predictors (baseline anxiety or depression; helplessness, 
acceptance, social support) were entered.  
In addition, the predictive value of the screening tool was assessed by investigating to what 
extend SCREENIVF could predict yes or no clinical emotional problems at post treatment. 
This was assessed using likelihood ratios assessing the probability that a patient with clinical 
problems at T2 is indeed identified as at risk at T1, divided by the probability that a patient 
without clinical problems was identified as at risk at T1. Clinical emotional problems at post 
treatment (T2) were defined as a dichotomous variable indicating showing yes or no clinical 
relevant anxiety and or depression at post treatment (T2). Likelihood ratios of 1-2 indicate a 
minimal increase in likelihood of the disease by using the test, 2-5 is a small increase, 5-10 a 
moderate increase and more than 10 a large increase (Ebell, 1999). 
In addition, sensitivity (the probability of having a positive screening result among patients 
with clinical emotional problems), specificity (the probability of having a negative screening 
result among patients  without clinical emotional problems), positive predictive value (the 
probability of having clinical emotional problems among patients with a positive screening 
result), and negative predictive value (the probability of having no clinical emotional 
problems among patients with a negative screening result) were computed. 
Results
555 Women in seven centers agreed to participate, 279 (50%) completed both T1 and T2 
questionnaires. Pregnancy rate as well as baseline anxiety, depression, cognitions regarding 
infertility and social support did not differ between women who completed both question-
naires and those who did not. Thirty three percent of the treatment cycles resulted in an 
ongoing pregnancy confirmed by an ultrasound in week seven. 
Table II shows that 34% of the patients showed clinical relevant problems at T1. In the table, 
the mean scores on anxiety, depression, helplessness, acceptance and social support at T1 as 
well as the percentage of patients showing clinical relevant problems on these risk factors is 
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also indicated. In addition, it shows the percentage of patients showing clinical emotional 
problems. At post treatment (T2), 24% of the women showed clinical relevant emotional 
problems.
Predictive value of the screening tool
Two regression analyses were performed to assess the predictive value of the screening tool 
administered at T1 for  respectively anxiety and depression at T2. In Table III, R2 and R2 change 
are indicated for the various regression analyses. The findings show that SCREENIVF 
significantly predicted post treatment anxiety and depression. In all analyses, the cognitions 
regarding fertility problems and social support, next to baseline anxiety or depression, added 
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Table II     Different risk factors at T1: mean scores and percentage of women scoring  
at risk  
Mean score (SD)
T1
% women above cut off
T1 At risk 34%
T1 Anxiety 17.3 (4.8) 10
T1 Depression 1.3 (2.4) 11
T1 Helplessness 10.9 (3.7) 16
T1 Acceptance 15.8 (4.2) 16
T1 Social support 18.3 (2.8) 16
Table III     Regression coefficients and R2 change for prediction of anxiety and  
depression by two regression analyses
Total sample R2 R2 change Significance
Regression analysis 1
Anxiety T1 .37 < .000
Cognitions regarding fertility 
problems and 
Social support
.41 .04 .008
Regression analysis 2
Depression T1 .23 <.000
Cognitions regarding fertility 
problems and 
Social support
.33 .10 <.000
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significantly to the explained variance. Baseline anxiety explained 37% of the variance in post 
treatment anxiety, the other risk factors added 4% in explained variance. Baseline depression 
explained 23% of the variance in post treatment depression, the other risk factors added 10% 
in explained variance. 
Sensitivity and specificity
Performance of SCREENIVF in detecting post treatment anxiety and depression is indicated in 
Table IV.
SCREENIVF identified 34% of the women (95 out of 279) as at risk at pre treatment (T1). 
The sensitivity was 69%, the specificity 77%. This means that SCREENIVF identified 69% of the 
patients as at risk, who indeed showed problems at T2 (46 out of 67). In addition, 77% of the 
patients without problems at T2, were indeed not identified as at risk by SCREENIVF at T1 (163 
out of 212). The positive predictive value was 48, the negative predictive value was 89, indicating 
that SCREENIVF better identified patients without clinical problems, than patients with clinical 
problems: relatively less patients who were identified as not at risk (21 out of 184), still developed 
problems post treatment, however, relatively more women who were identified as at risk, 
showed no emotional problems at T2 (49 out of 95). The overall efficiency of SCREENIVF was 
75%: 46 patients were correctly identifies as at risk and 163 were correctly identified as not at 
risk. This means that SCREENIVF was able to identify 209 out of 279 patients correctly. 
Table V shows the differences in proportion of clinical problems after treatment in patients 
who were and those who were not identified as at risk by SCREENIVF. In the bottom row it is 
shown that 48.4 % of patients who were identified as at risk when entering treatment (T1) 
showed clinical emotional problems after treatment (T2) compared to 11.4% in patients not 
identified as at risk (Likelihood ratio 3.0). The top row indicate that patients showing anxiety 
8
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Table IV     Comparison between screened at risk at T1 with clinical problems at T2.  
Numbers in bold indicate numbers of patients correctly identified  
by SCREENIVF.
N=279
Clinical problems 
after IVF (T2)
SCREENIVF = 
at risk (T1)
Yes no Total
 YES 46 49 95
 NO 21 163 184
Total 67 212 279
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at pre treatment had greatest chance showing clinical problems at post treatment: 71.4% of 
the patients with clinical anxiety at pre treatment (T1) showed clinical problems at T2 
compared to 18.6 % of the patients without pre treatment anxiety (likelihood ratio 7.5). 
Figure 1 indicates the predictive value of the risk factors, assessed at T1 for emotional problems 
at T2. It indicated how many patients showed emotional problems at T2 after being screened 
as at risk on one of the indicated factors (correctly identified, middle grey part of the bar), 
it indicates how many patients were screened as not at risk, but who showed clinical problems 
at T2 ( false negative, dark grey part of the bar), and how many patients were screened as at 
risk, but who showed no clinical problems at T2 (false positive, light grey part of the bar).
Discussion
In general, SCREENIVF performed as an acceptable screenings instrument to differentiate 
between women entering IVF treatment with lower and higher risk for emotional problems 
during and after an IVF treatment cycle. Likelihood ratio’s indicated small improvement for 
identification of patients at risk by use of SCREENIVF, when focusing on specific risk factors, 
improvement was moderate for patients showing anxiety or depression at pretreatment. 
chapter 8
Table V     Differences in % post treatment clinical problems by pre treatment  
assessment and likelihood ratios
Risk factor at pre 
treatment (T1)
% clinical problems at post 
treatment (T2) likelihood ratio
Anxious 
Yes
No
71.4
18.6
7.5
Depressed
Yes
no  
63.3
19.0
5.7
Helplessness
Yes
No
61.4
16.9
5.0
Less acceptance
Yes
no 
55.6
17.9
4.1
Less social support
Yes
No 
48.9
19.1
3.0
1 or more risk factors
Yes
No
48.4
11.4
3.0
133
SCREENIVF can be used as a screening tool before the start of the treatment, but also after 
the first treatment cycle, going to a second one. 
The performance of SCREENIVF should be interpreted against the purpose for which it is 
used. In clinical practice, SCREENIVF can be used as a screening tool to identify women with 
a risk profile for emotional problems. Physicians  and nurses could anticipate on this risk 
profile to pay special attention to the emotional aspects of the treatment in patients at risk. 
For instance, pay special attention to these patients when giving instructions before 
treatment, ask them for need for an additional appointment when treatment progress is un 
satisfactory. In addition they could offer these patients a reference to a psychosocial 
professional who is able to investigate the possible need for psychosocial support for the 
individual patient. In that case, SCREENIVF is a first step in a triage for judging the need for 
additional psychosocial support for women entering IVF. The second step is the more 
thorough diagnostic investigation which could identify those who need additional 
psychosocial treatment (third step) and those who do not. Using SCREENIVF is an improvement 
from overall clinical practice of offering psychosocial support on face value by physicians or 
nurses, or on initiative of patients themselves. Such a triage is already recommended in other 
patient groups like patients with cancer (Carlson & Bultz, 2003; Thomas et al., 2008), COPD 
(Vercoulen et al., 2008).
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Figure 1       Classifi cation of IVF patients based on SCREENIVF compared to post 
treatment emotional problems
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Studies in other health care patient groups already indicated that identification of patients at 
risk for emotional problems is difficult for health care professionals. On average only 25% is 
identified correctly (Glazebrook et al., 2003). Recently, the study of Volgsten et al., (2008) 
showed that the majority of women who suffered from psychiatric morbidity, did not receive 
the support they needed . Entering these women in a strenuous treatment like IVF is 
accompanied by the risk of further deterioration of emotional wellbeing, especially in case of 
unsuccessful treatment.
This study only focused on women. The emotional impact of fertility problems in men is still 
insufficiently investigated. Many studies do not take men into account (Hynes et al., 1992; Lok 
et al., 2002; Verhaak et al., 2005; Visser et al., 1994). Several other studies showed a lower 
emotional impact of fertility problems in men compared to women (Lund et al., 2009; Newton 
et al., 1990; Slade et al., 1997; Verhaak et al., 2001). It is suggested that men seem to be affected 
differently by the stress of subfertiity than women, differently in a way that does not seem 
easily recognizable by standardized general psychological meassures. Specific assessment 
tools, measuring infertility related distress, will probably better identify the emotional impact 
of fertility problems in men. However, disease specific measures often lack informtaion about 
norms which makes interpretations of scores in relation to general emotional wellbeing 
difficult. This does not mean, however, that men should be left out of screening procedures. 
Men with clinical relevant emotional problems at the start of IVF will be more at risk for 
deterioration of their emotional health than others. However, the state of research into other 
predictors of emotional adjustment problems in men still does not provide sufficient 
information for the selection of the most important risk factors. This paper offers a recom-
mendation for screening patients on emotional health before they start their IVF tratment. 
This recommendation includes both men and women. SCREENIVF provides a validated 
instrument that included only women. The next step is to include men too, in a study to 
investigate the predictive validity of SCREENIVF. SCREENIVF should not reveal a prerequisite 
for psychosocial support. The positive predictive value does not prove this. However, a 
screening tool such as SCREENIVF can provide patients information on their risk profile and 
could give them the feedback  that they could benefit from additional psychosocial support. 
In optimal circumstances, this support could be given by a psychosocial professional within 
the team of reproductive medicine. However, physicians and nurses are able to, based on the 
risk profile of the patient, address the psychosocial issues of the treatment with the patient or 
to anticipate on possible negative effects of the emotional vulnerability of the patient on the 
treatment outcome.
Another reason to avoid a positive screening result as prerequisite for referral for psychosocial 
support is the limited sensitivity. Still nearly one third of the women showing clinical 
emotional problems after IVF was not identified correctly. This gives the risk of deterioration 
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of emotional health in special cases such as threatening psychiatric morbidity or escalation 
of problems in intimate relationships. Sensible care for patients treated with IVF should take 
their emotional well being into account in order to be able to anticipate on possible risk 
factors for deterioration of the emotional condition as well as to integrate issues regarding 
emotional health in decision making regarding treatment.
In sum, patient care in infertility would improve by screening patients on psychosocial health 
when they enter treatment and when they pass different kinds of treatment. It provides 
evidence for the gut feeling of the clinician. In addition it offers both clinicians an patients to 
anticipate on emotional vulnerability of the patient and its possible negative effects on the 
course of the treatment.
Appendix
Items of three scales SCREENIVF: helplessness, acceptance, social support
My infertility frequently makes me feel helpless
My infertility limits me in everything that is important to me
My infertility controls my life
Because of my infertility, I miss the things I like to do most
My infertility prevents me from doing what I would really like to do
My infertility makes me feel useless at times
I have learned to accept my infertility
I have learned to live with my infertility
I can accept my infertility well
I can cope effectively with my infertility
I think I can handle the problems related to my infertility even if they will not be solved
I can handle the problems related to my infertility
If I feel distressed, there is someone to help me
If I enjoy things, there is someone to share with
If I’m in pain, there is someone supporting me
If I’m sad, there is someone to share with
If I need help with a small job I cannot do alone, there is someone helping me
8
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Chapter I 9
Absence from work and emotional 
stress in women undergoing IVF or ICSI.
An analysis of IVF-related absence from work  
in women and the contribution of general and 
emotional factors
140
Abstract
Objective: To assess productivity losses due to absence from work during IVF/ICSI treatment 
and to describe the pattern of IVF-related absence from work. Additionally, the influence of 
general and psychological variables on IVF-related absence from work was analysed. 
Design: Prospective cohort study. 
Setting: Eight IVF hospitals participated in the study.
Sample: Women undergoing their first treatment with IVF/ICSI.   
Methods: The HLQ was used to estimate the costs of IVF-related absence from work (n=384). 
Diaries were used to collect back ground information and reasons for IVF-related absence. 
Psychological data were derived using the STAI, BDI-PC, Inventory Social Relations and the 
Illness Cognition Questionnaire. Regression analyses were performed using two models, one 
without and one model with psychological data, to assess the impact of the different 
variables on IVF-related absence from work. 
Main outcome measure: IVF-related absence from work and the costs of productivity losses 
due to IVF/ICSI per treatment. 
Results: Overall absence from work during IVF/ICSI treatment was on average 33 hours, of 
which 23 hours were attributed to IVF/ICSI. Costs of productivity losses due to IVF/ICSI were 
€ 596 per woman. Significant predictors of IVF-related absence from work were the number 
of hours of paid work, age and self-reported physical and/or emotional problems due to IVF 
treatment. 
Conclusions: Women experiencing emotional complaints and women with physical 
complaints due to IVF/ICSI reported significantly more IVF-related absence from work. 
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Introduction
The introduction of in vitro fertilisation (IVF) was a breakthrough in bypassing barriers to fertilisation 
in couples failing to achieve a spontaneous pregnancy. Intracytoplasmic sperm injection (ICSI), 
a variant of IVF, was added in 1992 for couples suffering from severe male infertility. Nowadays IVF 
and ICSI are frequently adopted interventions. In 2000, about 2% of all newborns in the Netherlands 
were born after IVF or ICSI and this percentage continues to increase (Kremer et al., 2002).
The (direct) medical costs of IVF and ICSI treatment are high (Collins et al., 2002), but little is 
known about the indirect costs. Indirect costs originate from sick leave (hereafter called 
absence from work) due to health-related problems, which may result in productivity losses. 
The international literature reports that the costs of productivity losses related to IVF are 
about 10% or more of the total costs per treatment cycle (Neumann et al., 1994; Stern et al., 
1995; Fiddelers et al., 2006). However, in most of these studies, it was unclear whether costs of 
productivity losses were based on empirical data on absence from work. The most recent 
study was performed in the Netherlands and presented cost estimates based on actual data 
on absence from work in both women and their partners during a four week IVF treatment 
period (two weeks before and two weeks after the embryo transfer) (Fiddelers et al., 2006). 
The average costs of productivity losses related to IVF treatment were approximately € 456 
per treatment cycle per couple. The authors stated that the costs of productivity losses were 
mainly due to absence from work of the women whereas their partners were more likely to 
take days off. However, an IVF/ICSI treatment cycle generally covers a longer period than 4 
weeks. In a national Dutch costing study, the period from pituitary down regulation, the 
so-called “long protocol”, followed by ovarian hyper stimulation up to the embryo transfer 
alone, was found to average already some four weeks (Bouwman et al., 2008). Consequently, 
productivity losses due to IVF/ICSI treatment cycle may appear over a longer period. 
Besides the number and costs of absence from work in IVF/ICSI treated women, information 
on the predictors of absence from work in this group is limited. Both physical and emotional 
complaints due to the treatment may contribute to absence from work. Emotional distress in 
particular may lead to an increase of absence from work, as the emotional impact of fertility 
treatment is commonly considered to be even more strenuous than the physical impact of 
the treatment (Kopitzke et al., 1991). Studies have indicated that, next to pre treatment anxiety 
and depression, lack of social support and appraisals of helplessness with fertility problems 
are risk factors for emotional problems (Verhaak et al., 2005). 
This study aimed to describe the number and the pattern of absence from work during an 
average IVF/ICSI treatment cycle and to estimate the costs of productivity losses in women 
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with paid work. Additionally, we analysed the extent to which general and emotional factors 
had contributed to absence from work. 
Materials and Methods
Data and methods
From January 2002 through March 2005 a national cohort study was performed in the 
Netherlands to assess the cost-effectiveness of IVF/ICSI in women undergoing IVF/ICSI 
(n=9016). Alongside this study, data on absence from work were collected in 8 IVF centres 
and transport clinics (from a total of 31 centres and clinics), thus presenting a representative 
sub sample of the women who participated in the national study. A total of 660 women were 
asked to fill in daily diaries during their first treatment cycle starting at the first day of 
 gonadotrophin-releasing agonist injections (defined as the start of treatment) until 10 weeks 
thereafter. 
The 10-week follow-up period generally covered an average treatment period including the 
post treatment evaluation (e.g. 4 weeks preceding the embryo transfer and 6 weeks after the 
embryo transfer). For the measurement of absence from work, the Health and Labour 
Questionnaire (HLQ) was used, which is a validated questionnaire that differentiates between 
different causes for health-related absences from work (Hakkaart-van Roijen et al., 1999). For 
this study, we asked the respondents to distinguish between absence from work related to 
IVF/ICSI (hereafter called IVF-related absence) and absence due to other health-related 
problems. In addition, we collected data on general characteristics of the respondents, e.g. 
age, educational level and work status. Information about work status comprised questions 
about the number of paid work per week (e.g. number of days per week and number of hours 
per day of paid work). Furthermore, the women were asked to report the main reason for 
IVF-related absence from work during this period: 1) physical problems, 2) emotional 
problems, 3) both or 4) hospital visits.
Additionally, data on psychological factors were derived. For the measurement of pre 
treatment anxiety and depression, the translated short version of the Spielberger State and 
Trait Anxiety Inventory (STAI) (van der Ploeg et al., 2000; Spielberger 1983), and  the short 
version of the Beck Depression Inventory for Primary Care (BDI-PC) ( Beck et al., 1997) were 
used. Both questionnaires are validated instruments and provide an indication of the 
presence of general emotional distress in the patient. Factors that may contribute to 
emotional distress, e.g. perceived social support and appraisals regarding fertility problems, 
were assessed by the Inventory Social Relations (van Dam- Baggen et al., 1992) and the Illness 
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Cognition Questionnaire, which were adjusted to the infertile population (Verhaak et al., 
2005; Evers et al., 2001). Appraisals were defined as the evaluation of fertility problems in 
terms of acceptance of possible infertility and helplessness towards infertility and the degree 
of feelings of benefit from IVF/ICSI treatment. 
Data analyses
Data of women with paid work were used for the analyses. Descriptive analyses were performed 
on raw data and imputed data were used for inferential analyses. In order to account for missing 
data and the additional uncertainty this introduces, we used multiple imputation on data 
related to absence from work. This is a technique in which each missing value is replaced by 
simulated values (Rubin and Schenker 1991; Rubin 1987; Lavori et al., 1995). Data on the number 
of days of absence from work of 26 % of the respondents were incomplete. As is often the case, 
the number of missing values increased with the duration of the follow-up period. For the 
fractions of missing data (7%) in this study 10 simulations were found to be sufficient to stabilise 
the outcomes in terms of the SE for all analyses. The resulting imputed versions of the complete 
data were analysed separately by standard complete-data methods. These results were then 
combined to produce a single result that includes uncertainty due to missing data (Rubin 1996; 
Schafer 1997). We used SAS Proc MI for the imputations, with the Monte Carlo Markov Chain 
(MCMC) approach. Student’s t-tests were used to analyse differences in absence from work 
between subgroups. Cross-sectional relations were explored using the Pearson correlation 
coefficient or Spearman’s rho (in case of categoral variables). 
In order to assess the impact of general and emotional factors on IVF-related absence from 
work, two models were constructed, one of which included general variables (hours of paid 
work, age and educational level) combined with the self-reported main reason for absence 
from work. This was called the general model. In the second model, general variables were 
combined with emotional factors. This model was called the emotional model. Anxiety and 
depression were summarized to a composite score called ‘general distress’ by using 
standardised Z-scores. 
On the basis of regression analyses the prognostic value on IVF-related absence from work of 
each model was assessed. Statistical significance was defined at p=0.05.
Calculation of productivity losses 
The costs of productivity losses due to absence from work were calculated in accordance 
with the  Dutch guideline for economic evaluations in health care (Oostenbrink et al., 2004). 
Hourly costs of productivity losses, based on national figures, differentiated to age of the 
women were taken from the guideline and adjusted to 2006 prices using national labour 
index figures ( Statistics Netherlands CBS, http://statline.cbs.nl). Previous research has shown 
that a reduction of labour time due to absence from work causes a less than proportional 
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decrease of work activity (Koopmanschap et al., 1995). Therefore the guideline recommends 
applying an elasticity of labour time and productivity of 0.8 for the calculation of the cost of 
productivity losses. Thus costs estimates were calculated on the basis of the hourly costs of 
productivity losses multiplied by 0.8 times the number of hours of absence from work. All 
costs are presented in 2006 euros.
Results
A total of 411 (62%) women returned the diaries, of whom 384 (93%) reported having a paid 
job. The characteristics of the respondents with a paid job and the results of the IVF/ICSI 
treatment cycles are presented in Table I. 
Of all the women with paid work, 62% reported IVF-related absence from work. Overall, 
IVF-related absence from work averaged 23 hours (SD 37.3). 
In Table II, the results on absence from work are presented of the women, grouped by the 
self-reported main reason of IVF-related absence from work. Over 50% of the women 
reporting IVF-related absence from work attributed the absence mainly to visiting the IVF 
centre. The volume of IVF-related absence from work in these women was relatively low 
compared to the women with physical and/or emotional problems. Over a quarter of the 
women reported that IVF-related absence was mainly caused by physical complaints and 
about 23% of the women reported that emotional problems (alone or combined with 
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Table I     Characteristics of the women with paid work and resultsª of IVF/ICSI  
treatment (n=384)
Mean (SD) N (%)
Age (years) 32.4 (3.5)
Paid work per week (hours) 28.3 (8.6)
IVF/ICSI treatment results
Oocyte retrieval
Embryo transfer
Pregnancy rate
371 (96.6) 
346 (90.1)
129 (31.3)
Educational level
Low
Secondary
High
50 (13.7)
199 (52.5)
132 (33.8)
ª Results on the basis of one IVF/ICSI treatment per women during 10-week follow-up
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physical problems) were the main reason for IVF-related absence from work. The hours of 
IVF-related absence from work in women with physical and emotional problems (or both) 
were comparable. 
The pattern of IVF-related absence represented the treatment course (see Figure 1). 
The number of hours of IVF-related absence steeply increased from 0.3 hour on average at 
the start of treatment to 7.2 hours in week 5 of the follow-up period, which generally 
coincided with the period in which the oocyte retrieval and the embryo transfer were 
performed. Next, IVF-related absence from work decreased rapidly from 4.7 hours in week 6 
to 0.9 hours in week 10.
IVF-related absence from work at the end of the follow-up period was relatively higher in 
women who became pregnant compared to the women who did not get pregnant after the 
IVF/ICSI treatment. The difference was, on average, two hours in week 8, week 9 and in week 
10, but this was not significant. 
Absence from work due to other health related problems was reported by 19% of the women 
and amounted to 9.5 hours (SD 40.0) on average. Notably, both IVF-related absence from work 
and absence related to other health problems were highest among women who reported 
physical and emotional problems as the main reason for IVF-related absence. Overall, the 
average costs of productivity losses due to absence from work during the 10-week follow-up 
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Figure 1       The pattern of IVF-related absence from work during 10 weeks following 
the start of treatment with gonadotrophin-releasing hormone injections 
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period were € 845 (see Table II). About 68% of these costs were attributed to IVF/ICSI treatment, 
resulting in, on average, € 596 in costs of productivity losses per IVF/ICSI cycle started. By 
comparison, the average costs of productivity losses due to IVF-related absence from work in 
all women reporting physical or emotional problems or both as the main reason for IVF-related 
absence from work almost doubled to on average € 1063 per cycle. 
T-tests revealed that the number of hours of IVF-related absence from work between women 
with different educational levels were not significantly different. A significant difference was 
found between women reporting IVF-related absence from work and those with no 
IVF-related absence concerning the hours of paid work. Women with no IVF-related absence 
worked on average 2.8 hours less per week (95% CI: 0.85 to 4.82). The average weekly hours 
of paid work were significantly higher among high-educated women (mean difference 4 
hours; 95% CI: 2.5 to 5.9). Age of the women and IVF-related absence from work correlated 
significantly: the number of hours of absence decreased with increasing age of the women 
(rho = - 0.15; 95% CI: -0.25 to -0.04). Additionally, age and educational level correlated 
significantly (rho = 0.11; 95% CI: 0.01 to 0.21). 
No correlation was found between the number of IVF-related absence and absence from 
work due to other health-related problems. Additionally, absence due to other health-related 
problems was not significantly correlated with the hours of paid work of the women or age 
of the women.
Regression analyses using the general model showed that the number of hours of paid work 
per week appeared a significant predictor of IVF-related absence from work (Table III). 
Additionally, women with a secondary education level reported significantly more IVF-related 
absence from work in comparison to more highly educated women. Finally, the self-reported 
reason for IVF related absence from work had a significant predictive value. 
Women experiencing physical and/or emotional problems had, on average, 32 hours more 
IVF-related absence from work compared to the women who attributed absence from work 
primary to the hospital visits. The regression analyses resulted in a predictive value of 19.1 % 
(adjusted R square), meaning that the general model was able to explain approximately 19 % 
of the variances in IVF-related absence from work.  
Pre treatment anxiety, helplessness, acceptance and to a lesser extent perceived social support 
correlated significantly, though moderately, with IVF-related absence from work. However, 
further analyses showed that all these factors correlated significantly with each other.
In the emotional model, as in the general model, the number of hours of paid work was a 
significant predictor of IVF-related absence from work. The predictive values of the emotional 
factors on IVF-related absence from work were limited and the only significant contribution 
was shown by acceptance of and feelings of benefit towards the fertility treatment. Regression 
analyses showed that the predictive value of the emotional model was 5.8% (adjusted R 
square).
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Discussion
Overall absence from work during the 10-week follow-up of IVF/ICSI treatment among women 
with a paid job was on average 33 hours, of which 23 hours were attributed to IVF/ICSI treatment. 
Costs of productivity losses due to IVF/ICSI treatment were € 596 on average per cycle.
Overall, IVF-related absence from work was highest during the days around the oocyte 
retrieval and the embryo transfer. Both procedures involve relatively more contact time with 
the IVF-centre in comparison with the other visits. Above all, these procedures may go 
together with more physical and emotional stress.
The number of hours of paid work, the self-reported main reason for IVF related absence, and 
appraisals regarding infertility and infertility treatment were significant predictors of 
IVF-related absence from work. The influence of educational level of the women on IVF-related 
absence from work was less clear. On the basis of the results of the t-test in combination with 
the regression analyses, we assumed a trend of less IVF-related absence from work in more 
highly educated women. Probably, the non-significant difference within this study was due 
to the small sample size of the women with a lower educational attainment. 
As far as we know, this is the first study to combine data on IVF-related absence from work with 
psychological data. Although most emotional data correlated significantly with IVF-related 
absence from work, the regression analyses showed that, especially, acceptance of infertility and 
perceived benefit of fertility treatment, which are both indicators of the ability of coping, had a 
predictive value on IVF-related absence from work. 
Additionally, the regression analyses showed that the model that included data on emotional 
variables was less suitable in interpreting the variation in IVF-related absence from work among 
the women. Based on the general model it can be concluded that emotional problems and 
physical problems contribute equally to an increase of IVF-related absence from work. 
Moreover, these two factors appear in approximately 50% of the women who reported 
IVF-related absence from work (e.g. 30% of all women).
IVF-related absence from work was higher in women who got pregnant, although the 
difference was not significant, compared to the hours of absence from work in women who 
did not become pregnant after the IVF/IVSI treatment. This difference may have been caused 
by pregnancy complications (e.g. bleeding, ectopic pregnancy or miscarriage). 
Additionally, other medical parameters may have contributed to the variance in IVF-related 
absence from work during these periods. It would be interesting to assess the influence of 
these factors in future studies.
IVF-related absence from work and absence due to other health-related problems were not 
correlated. Despite this, both IVF-related absence and absence related to other problems 
seemed higher in women viewing physical and/or emotional problems as the main reason 
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for their IVF-related absence from work. Possibly, the distinction between IVF and non-IVF 
related absence from work is less clear for women with these problems. 
Thirty-eight percent of the women reported no IVF-related absence from work. Additionally, 
the number of hours of IVF-related absence from work was relatively low in the women who 
reported visits to the IVF centre as the main reason for absence from work in comparison with 
the average number of hospital visits (6) during a complete IVF/ICVSI cycle.
No correlation was found between the number of hours of paid work and absence from work 
due to non-IVF related health problems. Nor were age of the women and absence due to 
other health related problems correlated, contrary to the correlations found between these 
factors and IVF-related absence from work. 
The response rate of the diaries was 62%, which seems comparable with response rates in 
other studies (Slade et al., 1997; Newton et al., 1990; Hammarberg et al., 2001) The response 
rate is relatively satisfactory, taking into account the effort women had to spend in completing 
the daily assessments during a period of 10 weeks. Additionally, as this was a multicentre 
study, the response rates may have been lower than those from single studies. 
Results of the national study showed that during the first IVF/ICSI cycle 90% of the women 
starting IVF/ICSI with gonadotrophin analogues injections proceeded to the oocyte retrieval. 
In approximately 73.5% of the women an embryo transfer was performed (Bouwmans et al., 
2008). However, the pregnancy rates were comparable. Given the relatively high percentages 
of oocyte retrievals and embryo transfers in the women who participated in our study, 
non-response was probably partial caused by women with incomplete treatment cycles. It is 
not clear how this may have biased our results. 
Seven percent of the responders were women without paid work. In the study of Fiddelers et 
al, it was reported that 11% of the women were unemployed. Probably, women without paid 
work were less likely to return the diary.  
Given the course of IVF-related absence from work, we assume that the 10-week follow up 
period was representative of absence from work related to IVF/ICSI treatment. Our findings 
were in line with the results presented by Fiddelers et al. (2006). However, a detailed 
comparison was not possible, since data on absence from work were not presented and the 
follow-up period differed. 
Our study used data collected in women during their first IVF/ICSI cycle. Emotional distress, 
and therefore absence from work, may be higher in women undergoing their second or third 
treatment cycle. More research is necessary to assess the impact of the number of treatment 
cycles on IVF-related absence from work. This study was performed in a large group of 
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women; hence the results on absence from work and costs of productivity losses are 
 representative for Dutch women with paid work undergoing IVF/ICSI. 
In summary, both women who experienced emotional and women with physical complaints 
due to IVF/ICSI reported significantly more IVF-related absence from work. The absence 
especially concentrated around the period of the oocyte retrieval and the embryo transfer. 
Future research should be aimed at possible ways of reducing the physical and emotional 
impact on women of IVF/ICSI during the treatment.
Financial support: 
Supported by a research grant (number 945-12-013) from the Dutch Organisation for Health 
Research and Development ZonMW).
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A detailed cost analysis of  
in vitro fertilization and intracytoplasmic 
sperm injection treatment
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Abstract 
Objective: To provide detailed information about costs of in vitro fertilization (IVF) and 
 intracytoplasmic sperm injection (ICSI) treatment stages and to estimate the costs per IVF 
and ICSI cycle and ongoing pregnancy.
Design: Descriptive micro-costing study.
Setting: Four Dutch IVF centers. 
Patient(s): Women undergoing their first treatment cycle with IVF or ICSI.
Intervention(s): IVF or ICSI.
Main outcome measure(s): Costs per treatment stage, costs per cycle started, and for ongoing 
pregnancy.
Results: Average costs of IVF and ICSI hormonal stimulation were € 1630 and € 1585; 
the costs of oocyte retrieval were 5500 and  725, respectively. The cost of embryo transfer 
was € 185. Costs per IVF and ICSI cycle started were € 2381 and € 2578, respectively. Costs per 
ongoing pregnancy were € 10,482 and €10,036, respectively. 
Conclusions: Hormonal stimulation covered the main part of the total costs per cycle (on 
average 68% and 61% for IVF and ICSI, respectively) due to the relatively high costs of 
medication. The costs of medication increased with increasing age of the women, irrespective 
of the type of treatment (IVF or ICSI). Fertilization costs (IVF laboratory) constituted 12% and 
20% of the total costs of IVF and ICSI. The total cost per ICSI cycle was 8.3% higher than IVF.
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Introduction 
The introduction of In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) has 
led to a significant increase in couples seeking treatment for infertility. In 1996, one out of 77 
newborns in the Netherlands was conceived via IVF or ICSI. By 2000, the frequency had 
increased to one in every 55 newborns (Kremer et al., 2002). In the Netherlands, both IVF and 
ICSI are strictly regulated, which has resulted in a total of 13 IVF centers with licensed 
fertilization laboratories. Fertility teams, consisting of gynecologists, specially trained fertility 
physicians, fertility nurses, clinical embryologists, laboratory technicians and administrative 
personnel form the staff of each of these centers. There are also so-called transport clinics 
where hormonal stimulations and oocyte retrievals are performed, with the actual fertilization 
(laboratory) and embryo transfer taking place in the affiliated IVF center. 
Because IVF and ICSI are expensive procedures, their increased use has been associated with 
significant economic costs. However, detailed information about the actual costs of IVF and 
ICSI is scarce. Recently, Collins et al., 2002, presented a literature overview of health economic 
aspects of IVF and ICSI, focusing on the utilization, cost, and cost-effectiveness of IVF/ICSI. 
Cost estimates of an IVF treatment cycle for the United States were compared with figures 
from 25 other countries. The average cost per IVF cycle ranged from $ 1272 to $ 9547 (prices: 
2002). Only two studies reported estimates based on actual expenditures of which, one was 
an older Dutch study (Collins et al., 2002, Goverde et al., 2000).
The costs of ICSI were not included in these studies. Recent cost-estimates differentiating 
between IVF and ICSI and the different treatment settings for the Netherlands are lacking. 
Our study provides detailed cost estimates for the different stages of both IVF and ICSI 
treatment. In addition, these results were used to calculate the costs of IVF and ICSI per 
treatment cycle and pregnancy in the Netherlands.
Materials and methods
Detailed costs data were collected during a national study that was performed from January 
2002 through December 2004. All 13 Dutch IVF centers and transport clinics (n=23) were 
invited to participate. Within this study, detailed cost data were collected, which made the 
present costing study possible.
This micro-costing study is based on the 2002 data of resource use and unit prices that were 
collected at four IVF centers: two academic and two non-academic IVF centers that were 
assumed to be representative of all Dutch IVF centers; 38% of all the IVF/ICSI cycles that were 
started in the Netherlands in 2002 were performed in these centers. Additionally, resource 
use and cost estimates were assessed in one transport clinic. 
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Within this study we focused on the direct medical costs during treatment. The following 
cost components were distinguished: costs of the fertility department, costs of medication, 
costs of the IVF laboratory, and costs of complications due to IVF/ICSI through the first 8 
weeks of pregnancy. Based on the availability of eligible sources, either a top-down or a 
bottom-up approach was used (Table I) (Oostenbrink et al., 2004).
In the top-down approach, cost data obtained from the hospital financial department served 
as the primary source. These were subsequently allocated to all services of the department 
on the basis of a predefined formula. For the bottom-up approach, the volume of personnel, 
equipment and materials for each service was assessed and cost calculations were performed 
based on purchase prices of materials and equipment and cost standards for personnel. 
Housing and overhead costs were accounted for by an augmentation of personnel and 
material costs by 45% (Oostenbrink et al., 2004). 
Cost of the fertility departement
The data from the hospital financial departments were insufficiently specific for allocating 
the information to all the different treatment activities. Expenditures consisted of costs of 
personnel, diagnostic procedures (including ultrasounds) and materials. 
A gynecologist from each center was interviewed for the identification of the resources used 
during the consecutive treatment stages. In addition, we asked for an estimate of the 
percentage of patient contacts carried out by a gynecologist and a fertility physician. 
The time spent on face-to-face contact in each treatment stage was based on the average 
length of time planned for these consultations. 
A 30% charge was added to account for the indirect time spent on matters such as 
 administration, consultation, and preparation (Oostenbrink et al., 2004) Fertility nurses were 
interviewed to assess material use during follicle aspiration and embryo transfer and the 
nurse time spent per patient outside the consultation time. The average number of visits per 
treatment cycle was derived from patients’ diaries. 
Personnel costs were calculated on the basis of the average functional salary scales. For the 
costs of the diagnostic procedures the rates assessed by the National Health Tariffs Authority 
(CTG/ZAio) were used, since these were considered a reasonable reflection of real cost 
(Oostenbrink et al., 2004). The costs of materials were based on the hospital purchase prices.
Cost of medication 
Cost of medication consisted of medication used during the hormonal pituitary down- 
regulation and ovarian hyper stimulation, including gonadotrophin-releasing hormone 
(GnRH) agonist, recombinant follicle stimulating hormone (FSH) and human chorionic 
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gonadotrophin (hCG). The hCG was fixed at 10,000 IU per stimulation, which was the standard 
procedure in the Netherlands at the time of this study. The actual use of the amount of units 
of recFSH was taken from the centers’ IVF registries. Generally, a long- stimulation protocol 
was applied. On average, GnRH agonist was used for 25 days per stimulation. For the cost 
estimates, the costs of 28 days of GnRH agonist were used, which is in line with the actual 
number delivered per prescription. Cost calculations were based on Dutch wholesale prices 
(Farmacotherapeutisch Kompas, 2003). 
Cost of an IVF laboratory
A top down approach was applied to calculate the costs of an IVF laboratory. Production data 
of the laboratories were obtained from the annual reports over 2002. A list of personnel was 
obtained from the managing embryologist of the IVF laboratories. Total personnel costs 
were calculated using the number of full-time equivalent (FTE) personnel and the reported 
salary scales. 
Equipment was valued based on the centers’ actual purchase price inflated to 2002 prices using 
Dutch price index figures (Oostenbrink et al., 2004). Based on information from two different 
suppliers of ICSI devices, an equal sum was assumed for each IVF laboratory for the purchase of 
a complete ICSI device. Costs of equipment per year were calculated according to the annuity 
method (Oostenbrink et al., 2004). As adequate information on equipment maintenance costs 
was not available  these costs were assumed to be 5% of the equipment purchase prices. 
Total materials costs were derived from the financial records of the centers. Expenditures per 
product were allocated by assessing the used amount of equipment, materials and personnel 
time per laboratory product with the aid of a questionnaire. 
Cost of complications 
Costs of complications were limited to the costs of inpatient hospital days, as these were 
expected to account for the bulk of the costs of complications. Clinical complications related 
to IVF treatment included ovarian hyper stimulation syndrome and complications resulting 
from the follicle puncture (Berg and Lundkvist 1992). Data on hospital admissions during 
2002 and 2003 were obtained from the annual reports of three academic IVF centers. 
Nation-wide figures of the number of cycles that were performed in 2002 were used to 
calculate the extra cost per treatment cycle due to complications. We used reference prices 
for the costs of a hospital day in an academic and non-academic center (Oostenbrink et al., 
2004) Costs of complications were attributed to their occurrence in general. 
The stage of oocyte retrieval 
Costs of IVF and ICSI are presented per treatment stage, which were defined as follows: 1) 
hormonal stimulation, 2) oocyte retrieval, including fertilization (laboratory), 3) embryo 
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transfer and 4) evaluation, consisting of follow-up visits. The costs of the different stages are 
presented per type of center (academic, non-academic and transport clinic). Additionally, the 
weighted average costs are presented on the basis of the number of academic and 
non-academic IVF centers and the number of transport clinics in the Netherlands.
Now that cryopreservation of residual embryos and cryo embryo transfers has become 
common practice, cost estimates for these procedures were calculated separately. Total costs of 
IVF and ICSI treatment for the Netherlands in 2004 were calculated on the basis of figures from 
the national infertility registration (LIR) (www.lirinfo.nl), and the weighted cost estimates that 
were inflated to 2004 prices through application of the Dutch general consumer price indices 
of 2.1% and 1.2% for 2003 and 2004, respectively (http://statline.cbs.nl).  These results were used 
to calculate the 2004 costs per treatment cycle started and per ongoing pregnancy.
Results
Stage 1
The costs of hormonal stimulation consisted of the costs of the fertility department and costs 
of medication. The mean number of visits to the IVF center during the hormonal stimulation 
stage was three. Among the fertility departments, the costs varied from € 179 to € 220. 
The average amount of recFSH per IVF/ICSI cycle was 2370 IU (SD 1095) per stimulation.
Overall, mean total costs of medication (GnRH agonists, rec FSH, hCG) per stimulation cycle 
were € 1425. The costs of medication showed statistically difference among women in 
different age groups (p<0.005) and increased with increasing age of the women from € 1193 
(age 20-24), € 1270 (age 25-29), € 1351 (30-34 year), and € 1547 (age 35-39) to € 1729 
(age 40-44). 
Stage 2 
The costs of oocyte retrieval were composed of department costs, laboratory costs and costs 
of complications. Department costs included costs of medication during the luteal phase 
(progesteron daily), and ranged from € 178 to € 237. Costs differences were merely due to 
differences per center in the number of fertility physicians and gynecologists performing the 
retrievals. Other differences concerned the planned length of a consultation, which varied 
from 30 to 45 minutes per oocyte retrieval. 
The IVF and ICSI laboratory costs ranged from € 228 to € 347 and from € 436 to € 612 respectively. 
Laboratory costs of ICSI were higher both because of the relatively high cost of specific 
equipment and because ICSI fertilization is a  more labour-intensive procedure than IVF.
Complication rates related to OHSS were based on information from the annual reports of 
three academic IVF centers. In the period from 2001 to 2003, a total of 4355 IVF/ICSI cycles 
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were started in these centers. During this period, 10 patients were hospitalized due to 
complications of hormonal stimulation, resulting in an incidence of 0.23 per 100 stimulations 
started. Patients spent on average 9.7 days in the hospital. Based on these figures, the 
OHSS-related costs were calculated at € 10.40 and € 7.35 per cycle for academic and 
non-academic centers, respectively. 
Data on complications resulting from follicle aspiration were derived from the annual reports 
of two academic centers. In the period from 2001 to 2003, 11 hospitalizations related to the 
follicle aspiration were recorded. The incidence was 0.4 per 100 oocyte retrievals. The mean 
hospital stay was 6.7 days per admission. The costs of complications due to follicle aspiration 
were  € 12.45 and € 8.80 per cycle for academic and non-academic centers, respectively.
Stage 3 
The costs of embryo transfer were made up of costs incurred by the fertility department and 
laboratory costs. Fertility department costs ranged from € 59 to € 79; laboratory costs from 
€ 99 to € 132. The average total cost of an IVF/ICSI embryo transfer was € 185. 
Stage 4 
During the evaluation, the treatment results are discussed with the couple. The evaluation of 
patients with a positive pregnancy test after ET varied in length from one to two visits, 
depending on the procedure followed by the relevant center regarding the point at which 
patients were referred to their own (local) gynecologist or to a midwife. The mean costs of 
evaluation of a patient with a positive pregnancy test were € 99. 
Resource use for patients with a negative pregnancy test differed: in some centers, the 
outcome was discussed with the couple during an extra visit, while in other centers, the next 
contact usually coincided with the start of a new treatment cycle. The mean costs of 
evaluation for patients with a negative pregnancy test were € 45. 
Cryopreservation and cryo-preserved-embryo transfer 
Freezing residual embryos is an alternative for repeated stimulation cycles, although the live 
birth rates resulting from thawed cycles are lower. The annual reports of the IVF laboratories 
indicated that, on average, 18.9% of all oocyte retrievals resulted in cryopreservation of 
residual embryos. Costs of cryopreservation after a retrieval resulting in residual embryos 
were € 141 and € 173 for academic and non-academic IVF laboratories, respectively. Based on 
these figures, we estimated that the additional cost of cryopreservation per oocyte retrieval 
was € 29.
Costs of a cryo embryo transfer consisted of laboratory costs (thawing) and department costs 
(transfer). Total costs ranged from € 302 to € 473 due to different methods followed by the 
centers. For example, in some clinics cryo-preserved embryo transfers were performed in the 
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natural cycle. This can be timed by urine luteinizing hormone tests, or by ultrasound, the 
latter resulting in higher costs. At other centers, cryo embryo transfers take place within an 
artificially stimulated cycle. 
The weighted average costs of a cryo embryo transfer were € 387 (see Table II). Additionally, 
the evaluation costs after a cryo embryo transfer resulting in a positive pregnancy result were 
€ 111. Cost differences between the evaluation of a cryo cycle and a regular IVF/ICSI cycle 
were due to the application of prolonged admission of progesteron in artificially regulated 
cryo cycles.
Cost per treatment cycle and cost per ongoing pregnancy
A total of 15,297 treatment cycles (9178 IVF and 6119 ICSI) were started in 2004. A total of 
14,497 embryo transfers were performed, of which 2023 were cryopreserved embryos. 
An ongoing pregnancy resulted from 21.1% of all IVF cycles that were started and 24% of all 
ICSI cycles;16.2% of the cryo-preserved transfers resulted in an ongoing pregnancy. Based on 
these figures, the average cost per ongoing pregnancy was estimated at € 10,290. Costs per 
treatment cycle started were € 2381 and € 2578 for IVF and ICSI respectively. Costs per 
ongoing pregnancy resulting from IVF and ICSI were € 10,482 and € 10,036. 
Discussion
The 2004 average costs per started IVF and ICSI treatment cycle were € 2381 and € 2578 
respectively, and costs per ongoing pregnancy were € 10,482 and € 10,036. Examining the 
different cost components per treatment cycle, it is evident that the hormonal stimulation 
stage is the most expensive part of IVF and ICSI, followed by the stage of oocyte retrieval 
(Figure 1). 
Costs of medication constituted more than half of the total costs for both IVF and ICSI (61 and 
55% respectively). Approximately 12% of the total costs of an IVF cycle and 20 % of an ICSI 
cycle were related to the fertilization (laboratory). On the basis of costs per started cycle, ICSI 
was 8.3% more costly than IVF, which was mainly due to the higher laboratory costs of ICSI. 
However, costs per ongoing pregnancy of ICSI were lower compared to IVF due to fewer 
incomplete treatment cycles and higher success rates per cycle. 
Older women undergoing IVF/ICSI incurred higher costs per cycle than younger women 
because of the higher mean dosages of recombinant FSH needed during the hormonal 
stimulation. Additionally, the pregnancy chances decrease with age, resulting in increasing 
costs per ongoing pregnancy in women aged 34 years and older. Treatment costs varied in 
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the different settings. Generally, costs in academic centers were lower compared to 
non-academic centers. 
The costs of an embryo transfer after cryopreservation were higher than the costs of a fresh 
embryo transfer (€ 387 versus € 185) due to higher laboratory costs. Extra costs were related 
to the thawing of cryo-preserved embryos (personnel time and materials) and the adminis-
trative procedures for preservation of residual embryos. 
To our knowledge, this is the first study in which the opportunity costs (i.e. actual costs) of IVF and 
ICSI are presented in detail on the basis of data from a representative number of IVF centers. 
Our findings were in line with the cost estimates reported earlier by Goverde et al., 2000. The costs 
of medication reported in that study were relatively low, probably due to the standard use of 
human menopausal gonadotrophin, which is less expensive than the current IVF stimulation 
protocol that uses recombinant FSH. The costs of ICSI were not reported in their study. 
In the international literature, the cost estimates of IVF vary widely (Collins et al., 2002. 
However, most estimates are based on charges, which limit the comparability with the 
findings from our study. For reasons of comparison, we conducted a supplementary literature 
search for cost data following the period searched by Collins. English language publications 
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Figure 1       Price portions of the treatment stages of IVF/ICSI
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were identified through MEDLINE using the keywords IVF, ICSI, cost(s) and cost-effectiveness 
over the period 2001 to May 2006, which resulted in 14 publications that described the costs 
of treatment with IVF and/or ICSI (Table III). 
Four studies originated from northern European countries (Sweden, Norway and Finland), 
two from the United Kingdom, one from Belgium, one from Hungary, four from the 
Netherlands and three from the United States. Original estimates in pounds sterling and US 
dollars were converted to Euros. Additionally, all prices were inflated to 2004 costs using 
Dutch consumer price index rates. The highest cost estimates were those of Kansel-Kalra et 
al., 2005, although how these estimates were calculated remained unclear, as detailed 
information was lacking. The lowest estimates were presented by Kovacs et al., 2004. 
Only two studies (Lloyd et al., 2003; Fiddelers et al., 2006), presented cost estimates that were 
based on actual expenditure. The study of Fiddelers was performed in the Netherlands. The 
estimates were derived from one, relatively small Dutch IVF center and no  distinction was 
made between the costs of IVF and ICSI. Most cost estimates in this study were relatively high 
compared to the ‘harmonized Dutch cost estimates’ calculated for an integrative study in the 
Netherlands on the basis of information from six IVF-related studies financed by the Dutch 
Organisation for Health Research and Development (ZonMW). It was assumed that the 
variation in costs was due to differences in the size of this IVF center and the adopted method 
of cost calculation.
In four studies, the costs of IVF and ICSI were reported separately (Kjelberg et al., 2006; Kovacs 
et al., 2004; Silverberg et al., 2002; Strandell et al., 2005). Costs of an ICSI cycle averaged 11% 
more than the costs of IVF, with the exception of the estimates presented by Kovacs et al, 
who reported ICSI costs that were more than 30% higher than IVF costs (Kovacs et al., 2004). 
In general, the intercountry comparability of the cost of IVF and ICSI was low, due to 
differences in the definition of a treatment cycle, differences in study questions and 
differences in health-care setting.
According to the figures in the ESHRE report of 2006, the IVF centers in most European 
countries are relatively small compared to the Dutch centers (ESHRE, EIM, 2006). Overall, 14% 
of the European centers in the ESHRE registry performed more than 1000 cycles in 2002 and 
almost 16% of the centers performed fewer than 100 cycles. Of the 13 Dutch IVF centers, 
eight reported performing at least 1000 treatment cycles (range 1171-2027) in 2004, and in 4 
centers the number of cycles performed ranged from 610 to 952. Differences in the 
international cost estimates may partly result from differences in the size of the centers. 
Generally, the financial departments of hospitals are not tailored to register resource use on 
the level of patient groups, which inhibited a uniform methodology for calculating costs. 
The bottom-up approach that was used for most cost components results in a more precise 
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allocation of costs to a service although the actual expenditures may have been underesti-
mated, as this method does not consider ‘wasting’ costs. Furthermore, our estimates were 
based on patients who actually started with hormonal stimulation. A small number of 
patients may have quit treatment during the stimulation phase before the start of medication. 
In this study, we focused on the direct medical costs. We assumed that indirect costs, such as 
costs of productivity losses were relatively small. 
Diagnostic work-up costs were not included in this study. Although, strictly speaking, these 
costs are not within the province of IVF/ICSI treatment, these costs must be taken into 
consideration in the broader context of the IVF/ICSI program. During the diagnostic work-up, 
couples are extensively counseled about the treatment. In couples with severe male infertility 
diagnostic tests are performed to inform the couples about the possibility of transferring 
genetic abnormalities into offspring. We calculated the average costs of the diagnostic 
work-up preceding IVF at € 286 (data not shown). The extra costs of genetic diagnostics 
preceding ICSI varied considerably, and ranged from €31 to € 1836. Given these findings, 
further research is needed to study the cost-effectiveness of these diagnostic procedures.
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Table III   Overview of IVF/ICSI cost estimates from international studies 
Study Country Focus of the study
Original 
currency
Original price
(year)
Bases of estimates
Costs per cycle 
2004 (€)
IVF + medication
ICSI + 
medication
Cryo ET
Main conclusions of the study
Eijkemans et al., 2005 Netherlands
Patient-tailored treatment 
algorithm for anovulatory 
infertility.
Euro 2002
Hospital costs + medication: 
inflated figures from the study of 
Goverde et al 
IVF 1,883
-
-
A treatment strategy of CC+FSH+IVF was 
efficient for women aged < 30 years with 
normal androgen levels. For women > 30 
years with elevated androgen levels, FSH 
may be skipped 
Lukassen et al., 2005 Netherlands SET vs DET Euro 2003
Hospital costs + medication: 
reimbursement 
IVF 2585
-
-
Two cycles with SET were equally effective 
as one cycle with DET, and the medical 
costs were the same
Fiddelers et al., 2006 Netherlands SET vs DET Euro 2003
Hospital costs; unit costs from the 
financial department. Including 
medication costs. Laboratory 
costs based on cost price 
calculation.
IVF/ICSI 3491
The extra costs of DET per additional 
pregnancy compared with elective SET 
were € 19,096. These costs were due to 
the higher costs of pregnancy after DET
Gerris et al.,2004 Belgium Euro 2003
Average reimbursement of IVF/
ICSI, including cost of medication
IVF/ICSI 2477
-
Granberg et al., 2003 Sweden
Laparascopic surgery vs IVF 
in patients with tubal factor 
infertility 
U.S. dollar 2001
Hospital: standardized hospital 
charges (partly based on DRG’s); 
Medication: mean costs of 
standardized stimulation protocol
IVF 3378
-
Cryo ET 1057
Only small differences were found 
between the average costs per delivery 
after tubal surgery and treatment with 
three IVF cycles 
Kjellberg et al., 2005 Sweden SET vs DET Euro 2004
Hospital costs: DRG Medication: 
sales prices Costs of complication 
not included
IVF 4174
ICSI 4627
Cryo ET 994
SET was superior to DET (lower average 
total costs)
Strandell et al., 2005 Sweden/
Danmark
Immediate IVF vs 
salpingectopmy before IVF.
Euro 2004
Hospital costs: Standardized 
Hospital charges (partly based on 
DRG); Medication: sales prices 
IVF 4275
ICSI 4748
Cryo ET 1038
The incremental cost-effectiveness ratio 
of salpingectomy prior to IVF was € 9306 
compared to immediate IVF
Koivurora et al., 2004 Finland
Prenatal and neonatal costs 
after IVF vs spontaneous 
conception
Euro 2003
Hospital: hospital data (not 
specified). Medication: social 
insurance institution Finland
IVF 3247
-
-
Total health care costs for singleton 
and IVF twins were € 5780 and € 5580 
respectively
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Table III   (continued) 
Study Country Focus of the study
Original 
currency
Original price
(year)
Bases of estimates
Costs per cycle 
2004 (€)
IVF + medication
ICSI + 
medication
Cryo ET
Main conclusions of the study
Sykes et al., 2001 (20) U.K.
Modelled evaluation of 
three alternative hormonal 
stimulations: rec FSH, urinary 
FSH and HMG
U.K. 
pound 
1999
Hospital: average prices from 20 
IVF; average dose of medication 
per IVF attempt: based on expert 
panel; hospital costs and duration 
due to OHSS: expert panel
IVF 2456-3001
-
Cryo ET 539
RecFSH was a cost-effective stimulation 
strategy
Lloyd et al, 2003 U.K.
Evaluation of ovarian 
stimulation with highly 
purified hMG versus rec FSH
U.K. 
pound
Hospital treatment: Hospital 
financial department;
Medication: sales prices
IVF/ICSI 
3754-4253
Highly purified hMG and rec FHS were 
equally effective, but hMG was less 
expensive per cycle
Kovacs et al., 2004 Hungary
Hormonal stimulation using 
CC + hMG vs GnRH + hMG
U.S. dollar Not stated
Hospital costs: not stated
Medication: patient charts
IVF 1206-1300a
ICSI 1637-1731a
Costs per cycle were higher with GnRHa+ 
gonadotropin, however, the cumulative 
costs were reduced by the time a clinical 
pregnancy was achieved
Silverberg et al., 2002 U.S.
Modelled evaluation of rec 
FSH vs urinary FSH
U.S. dollar Not stated
Hospital costs + medication: 
70% of billed charges 
(=reimbursement level of 
managed care)
IVF 10,164-10,486a
ICSI 11,417-
12,810a
Cryo-ET 1566a
Rec FSH was more cost-effective (more 
effective at lower costs) than urinary FSH
Kansal-Kalra et al., 
2005 
U.S.
Modeled evaluation of a 
strategy of immediate IVF 
vs gonadotropin therapy for 
unexplained infertility
U.S .dollar 2003
Hospital costs + medication: 
inflated figures from the study of 
Goverde et al
IVF 12,646
-
-
Considering the risk of high order 
multiple pregnancy, immediate IVF was 
more costly than gonadotropins prior 
to IVF.
Hatoum et al, 2005 U.S.
Modeled evaluation of urinary 
FSH vs recFSH
U.S. dollar 2003
Hospital costs: figures from the 
study of Silverberg et al
Medication: wholesale acquisition 
costs 
IVF 10,263
-
-
Costs of IVF treatment with urinary FSH 
were lower in comparison to treatment 
with recFSH.
Note: CC, clomiphene citrate; cryo-ET, cryo-preserved-embryo transfer, DET, double embryo transfer;  
DRG, diagnosis related group; FSH, follicle-stimulating hormone; GnRH-a, gonadotropin-releasing agonist;  
hMG, human menopausal gonadotropin; OHSS, ovarian hyperstimulation syndrome; recFSH, recombinant FSH; 
SET, single embryo transfer. 
a Proxies were used if the price year was not reported: UK £ = € 1.43882, U.S. $ = € 0.825785
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Cost-effectiveness of IVF/ICSI  
for sub groups of subfertile patients:  
a Prospective Cohort - Waiting List Study
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Abstract
Background: A few countries have guidelines for In Vitro Fertilisation (IVF), using the 
diagnostic category, age of the woman and duration of subfertility. The cost-effectiveness of 
these guidelines is unknown, and the evidence-base exists only for bilateral tubal occlusion, 
not for the other diagnostic categories. We aimed to establish the cost-effectiveness of 
starting IVF compared to waiting for one more year, depending on prognostic patient char-
acteristics.
Methods: A prospective cohort study included 5962 couples eligible for IVF or ICSI treatment 
according to the Dutch IVF/ICSI guideline, registered in a national waiting list in The 
Netherlands. Chances of treatment-independent ongoing pregnancy were estimated from 
the waiting list observations and chances with IVF from follow-up data of couples that did 
start treatment. Prognostic factors considered were female age, duration of subfertility, 
primary or secondary subfertility and diagnostic category. Costs of IVF were determined on a 
representative sample of patients. A cost-effectiveness comparison was made between two 
scenario’s: I) wait one more year and then undergo IVF for one year and II) direct IVF during 
one year, with treatment-independent pregnancy chances after that year. Comparisons were 
made for strata determined by the predictive factors and the outcome was live birth.
Results: The gain in pregnancy chances of the direct IVF scenario versus postponed IVF 
increased with age, but was independent from diagnostic category or duration of subfertility. 
Contrary, the corresponding increase in costs primarily depended on diagnostic category 
and duration of subfertility. The cost-effectiveness ratio for endometriosis was just below € 
10,000 per live birth from age 34 onwards at 2 years duration. For unexplained subfertility at 
three years duration, the ratio was below € 30,000 per live birth from age 32 onwards. It 
reached € 20,000 per live birth only with 4 years duration at age 34 and older. The cost-effec-
tiveness ratio was in between for the other diagnostic categories.
Conclusions: Postponing IVF saves money against a small loss in overall live birth rate. The 
duration at which starting IVF becomes cost-effective depends on diagnostic category, 
female age and society’s willingness to pay for an extra live birth.
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Introduction
A few countries have guidelines for In Vitro Fertilisation (IVF) (Dutch Society for Obstetrics 
and Gynaecology, guideline no. 09, 1998; NICE. Clinical guideline 11, 2004). The guidelines 
recommend, for given combinations of diagnostic category and age of the woman, at which 
duration of subfertility IVF should be started. The cost-effectiveness of these guidelines has 
never been assessed.
The indications for IVF have been widened considerably since its introduction in 1978. 
Whereas in earlier days bilateral tubal occlusion was seen as the only reason to perform IVF, 
nowadays IVF is used for virtually any diagnostic category of subfertility. Yet, it is only for the 
tubal indication group that evidence from a randomised controlled trial is available (Soliman 
et al., 1993). The evidence base for other categories is considered to be weak or lacking 
(Hughes et al., 2004; Pandian et al., 2005).
The alternative treatment options for the other categories are not many: for tubal pathology, 
endometriosis, and for severe male infertility the choice is between waiting for a spontaneous 
conception or start IVF. For idiopathic, mild male or cervical subfertility, Intra Uterine 
Insemination (IUI) is the only treatment option prior to IVF. The usefulness of IUI is however 
being debated (Pashayan et al., 2006) and further, it is not self-evident that a couple should 
start IVF directly after failed IUI; a waiting time could be indicated to profit from a remaining 
spontaneous pregnancy chance before IVF treatment is commenced, given the high cost 
and burden of IVF. Therefore, an evidence-based comparison of expectant management 
versus IVF is needed for all diagnostic categories. Within current practice, a randomised 
comparison would not be feasible. Instead, the waiting period before the actual start of IVF 
could be used to estimate the treatment–independent pregnancy chances of couples that 
are going to start IVF. 
Though it is well recognised that pregnancy chances with IVF depend on age of the woman 
and on duration of subfertility, IVF appears to be equally effective for the various diagnostic 
categories for subfertility (Templeton et al., 1996; Lintsen et al., 2007). Similarly, age and 
duration are predictive of treatment-independent pregnancy chances, but in this case 
diagnostic categories differ substantially. Because the same factors are predictive for both 
treatment-independent and treatment-related pregnancy, we might infer that the relative 
efficacy of IVF over waiting longer would depend only slightly or not at all on patient charac-
teristics. In a modelling exercise, Mol et al., 2000, showed that the cost-effectiveness strongly 
depends on the age of the female partner. However, this remains to be assessed on 
prospective data and for other predictive factors. 11
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The aim of the current study is to determine the cost-effectiveness of IVF compared with 
waiting for a longer period, according to prognostic factors female age, duration of subfertility, 
type of subfertility (primary or secondary) and diagnostic category.
Materials and Methods
Subjects 
Between 1-1-2002 and 31-12-2003, a national cohort study was executed in the Netherlands 
that prospectively registered all patients in IVF clinics on a waiting list, at the moment of 
indication for IVF or ICSI by their gynaecologist. During 2004, the registered data were 
cross-checked with the IVF treatment registries of the clinics, to see whether the patients had 
actually started IVF or not. Patients that could not be identified in the IVF registries were 
traced by hand searching the patient files: detailed patient data were collected, and the 
reason for not starting IVF was registered, including the occurrence of a pregnancy without 
treatment. From the data collected, prediction models were developed for the chance of 
treatment-independent pregnancy, as observed during the period on the waiting list 
(Eijkemans et al., 2008) and for the chance to become pregnant with IVF/ICSI (Lintsen et al., 
2007). The costs of IVF/ICSI were determined on a representative sample of patients 
undergoing treatment in 5 participating clinics (Bouwmans et al., 2008a). The current study 
integrates these findings.
Cost-effectiveness analysis
The aim of the study was to assess the cost-effectiveness of IVF/ICSI compared to waiting 
longer, for subgroups of patients. The methodology followed is similar to the one used in a 
previous study in anovulatory patients (Eijkemans et al., 2005): comparisons between 
treatment scenarios were made for subgroups of patients defined by the prognostic factors 
female age, duration of subfertility, type of subfertility and diagnostic category. Two treatment 
scenarios were compared: I) wait one year, then one year of IVF and II) direct IVF during one 
year, then one year no treatment. The time horizon of the analysis was therefore two years, 
and is the same for both scenarios. We do not have direct observations of outcomes for both 
scenarios, because no randomized data are available. However, the relevant chances of the 
periods with and without treatment in both scenarios may be obtained from our predictions 
models on IVF chances (Lintsen et al., 2007) and on chances on the waiting list (Eijkemans 
et al., 2008). 
The effectiveness measure of the study was a live birth following ongoing pregnancy. 
Ongoing pregnancy was defined as foetal heart beat activity on ultrasound after at least 8 
weeks gestation. Our data contained ongoing pregnancy and not live birth. Therefore 
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ongoing pregnancy was converted to live birth using published data of Arce et al., 2005: 92% 
(95% confidence interval: 88-96%) of ongoing pregnancies will result in a live birth.
The prediction models for treatment-independent pregnancy (‘treatment-independent’ 
model) (Eijkemans et al., 2008) and for pregnancy following IVF (IVF model) (Lintsen et al., 
2007) were converted to live birth and subsequently used to compare the live birth chances 
of the two treatment strategies for various patient profiles:
Scenario Model calculations
I: Postpone IVF for 1 year
‘treatment independent’ chances within 12 months leading  
to live-birth
PLUS
IVF pregnancy chances within 12 months leading to live-birth,  
with 1 year added to the age and duration of subfertility of the 
patient and weighted by the chance of not being pregnant  
after waiting for 1 year.
II: Direct IVF for 1 year
IVF pregnancy chances within 12 months leading  
to live-birth
PLUS
‘treatment independent’ pregnancy chances within 12 months 
leading to live birth, with 1 year added to the age and duration of 
infertility of the patient and weighted by the chance of not being 
pregnant within 1 year after the start of IVF
Figure 1 shows the principle. Scenario I starts with one year of rather low treatment- 
independent chances, and stays far behind scenario II (direct IVF). However, in the second 
year, scenario I almost catches up with II.
Comparisons were made for patient strata determined by the factors in the prediction 
models. To illustrate the calculations in detail, reference case analyses were performed using 
four “example” patient profiles: unexplained subfertility and endometriosis both at female 
ages 30 or 38 years and all with primary subfertility of 3 years duration. 
The health economic perspective was that of society. We therefore included direct and 
indirect medical and non-medical costs. The costs of the treatment-independent pregnancy 
attempts were assumed to be zero. The direct medical costs of IVF/ICSI were determined 
from the per-cycle cost estimates from Bouwmans et al., 2008a. To this we added an estimate 
of 596 euro per cycle as direct non-medical costs due to absence from work (Bouwmans et 
al., 2008b). The resulting total cost per cycle were applied to the data from all patients starting 11
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IVF/ICSI treatment used in Lintsen et al., 2007 and for each patient, the costs over a 1-year 
period of treatment were aggregated. On these data, a prediction model for the costs of IVF 
over a 1-year period was developed using the same four factors as used in the prediction 
models for pregnancy chances, using linear regression analysis. The resulting model equations 
are available from the authors on request. 
In case of an ongoing pregnancy leading to live birth, the costs of subsequent delivery and 
neonatal care were added to the costs of treatment. We used the estimates from (Lukassen 
et al., 2004) for IVF conceived pregnancies:  € 2549 for a singleton and € 13,469 for a twin 
pregnancy. In a sensitivity analysis, we used recent cost estimates for delivery and neonatal 
care following IVF and naturally conceived pregnancies from Chambers et al., 2007. 
The age-standardised estimates for singletons were € 4624 and € 4098 (difference: € 526) 
with IVF and naturally conceptions respectively. For twin pregnancies, the estimates were 
€ 14,114 and € 13,350 (difference: € 764) respectively. The cost differences between IVF and 
chapter 11
Figure 1       Cumulative chances of ongoing pregnancy leading to live birth, against 
time with the two scenarios for IVF
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treatment-independent pregnancies found by Chambers et al., 2007 were also applied in the 
standard analysis with costs of IVF pregnancies from Lukassen et al., 2004. We further assumed 
that 21.5% of IVF pregnancies were twins, as registered for the Netherlands in 2003 (Kremer, 
National IVF figures, 2007), and 1% of treatment-independent pregnancies.
The cost-effectiveness comparison was made between scenarios (II) (direct IVF) and (I) (first 
wait for 1 year). The difference in live birth rate (effectiveness) between the scenarios was 
calculated as well as the difference in costs. The cost-effectiveness ratio, the cost difference 
divided by the effectiveness difference, indicates the extra costs per extra live birth of (II) 
versus (I). In order to translate the cost-effectiveness ratio to a policy recommendation, for 
each age the duration of subfertility was determined at which a pre specified threshold for 
the cost-effectiveness ratios is attained. Following standard methodology in economic 
appraisals, costs and effects were discounted to present values. A discount rate of 3.5% was 
used for both costs and effects, as recommended by NICE, 2008. 
The statistical uncertainty in the results was assessed by a bootstrapping method with 5000 
replications. We used samples from the original waiting list cohort data, including the 
subsequent IVF treatment data, and re-estimated the prediction models for treatment-inde-
pendent pregnancy chances and for pregnancy chances and costs of IVF on each sample. 
The resulting model-predictions for the four base-case patient profiles were used to assess 
the difference in costs and effects of the two scenarios. From these resampled differences in 
costs and effects, a cost-effectiveness acceptability curve was derived that shows, for the 
four patient profiles, the proportion of samples in which direct IVF is cost-effective, given a 
threshold value for the cost-effectiveness ratio.
Results
Characteristics of the study inclusion have been published before (Lintsen et al., 2007; 
Eijkemans et al., 2008). Briefly, there were 6221 patients rightfully included on the waiting list. 
Of 5962 patients, the follow-up could be established, and they formed the basis of analysis. 
The estimated proportion of treatment-independent ongoing pregnancies after 12 months 
was 9% ( Eijkemans et al., 2008). Further, 4928 couples started IVF, resulting in an ongoing 
pregnancy rate of 45% within 12 months ( Lintsen et al., 2007).
Table I shows, for the four reference case patient profiles, the treatment-independent live 
birth rates in the first and second year, the IVF live birth rates in the first and second year and 
the comparison between the two scenarios. The treatment-independent pregnancy chances 11
cost-effectiveness of ivf
178
chapter 11
Ta
bl
e 
I  
    C
ha
nc
es
 o
f p
re
gn
an
cy
 le
ad
in
g 
to
 li
ve
 b
ir
th
 o
f t
he
 t
w
o 
st
ra
te
gi
es
, f
or
 fo
ur
 s
el
ec
te
d 
p
at
ie
nt
 p
ro
fil
es
pa
tie
nt
 p
ro
fil
es
 w
ith
 p
ri
m
ar
y 
su
bf
er
til
it
y 
of
 3
 y
ea
rs
 a
nd
:
D
ia
gn
os
tic
 c
at
eg
or
y
A
ge
U
ne
xp
la
in
ed
30
U
ne
xp
la
in
ed
38
En
do
m
et
ri
os
is
30
En
do
m
et
ri
os
is
38
Tr
ea
tm
en
t-
in
de
pe
nd
en
t c
ha
nc
e 
in
 y
ea
r 1
Tr
ea
tm
en
t-
in
de
pe
nd
en
t c
ha
nc
e 
in
 y
ea
r 2
IV
F 
ch
an
ce
 in
 y
ea
r 1
IV
F 
ch
an
ce
 in
 y
ea
r 2
C
ha
nc
e 
w
ith
 S
ce
na
rio
 I,
 p
os
tp
on
in
g 
IV
F 
fo
r 1
 y
ea
r*
C
ha
nc
e 
w
ith
 S
ce
na
rio
 II
, d
ire
ct
 IV
F*
C
ha
nc
e 
di
ffe
re
nc
e 
II 
– 
I (
D
el
ta
 P
)
0.
12
7
0.
11
1
0.
49
5
0.
48
4
0.
55
0
0.
55
1
0.
00
1
0.
08
9
0.
07
9
0.
32
3
0.
27
3
0.
33
8
0.
37
6
0.
03
8
0.
03
7
0.
03
2
0.
42
3
0.
41
3
0.
43
5
0.
44
2
0.
00
7
0.
02
6
0.
02
3
0.
26
8
0.
22
6
0.
24
6
0.
28
5
0.
03
9
* 
Pr
eg
na
nc
y 
ch
an
ce
s 
le
ad
in
g 
to
 li
ve
 b
irt
h 
pe
r s
ce
na
rio
 a
re
 c
al
cu
la
te
d 
fr
om
 th
e 
re
le
va
nt
 y
ea
r-
sp
ec
ifi
c 
ch
an
ce
s 
ap
pl
ie
d 
to
 th
os
e 
co
up
le
s 
th
at
 d
id
n’
t b
ec
om
e 
pr
eg
na
nt
 in
 th
e 
pr
ev
io
us
 y
ea
r. 
E.
g.
 P
re
gn
an
cy
 c
ha
nc
e 
w
ith
 S
ce
na
rio
 II
, d
ire
ct
 IV
F 
=
 0
.4
95
 +
 (1
-0
.4
95
)*
0.
11
1 
=
 0
.5
51
.
179
differ between diagnostic categories and are lower for older age. IVF chances also decline 
with age, but they show less dependence on diagnostic category. All chances are lower in 
the second year than in the first year, but the differences vary over patient profiles. 
The chances with the direct IVF scenario (II) are slightly higher than with the postpone IVF 
scenario (I) and the difference depends more strongly on age than on the diagnostic category. 
The difference varies from 0.001 for unexplained subfertility at 30 years to 0.039 for 
endometriosis at 38 years. 
Table II shows the costs and the cost effectiveness comparison for the four reference case 
patient profiles. With older age, IVF becomes more costly, because more treatment cycles are 
needed to compensate for the decreased chances per cycle, and because the cost of 
medication per cycle increases (Bouwmans et al., 2008a). For each patient profile, the costs of 
IVF as well as the costs of delivery and neonatal period are higher in scenario II, direct IVF, 
than in scenario I, postponing IVF. Therefore, in total, direct IVF is more costly than postponing 
IVF. The undiscounted cost-effectiveness ratio, obtained by dividing the cost difference by 
the live birth rate difference, is very high for unexplained subfertility at age 30: one extra live 
birth gained by direct IVF as compared to postponing IVF costs 574,000 euro. The ratio is 
lowest for endometriosis at age 38: 6300 euro per live birth. Discounting has a profound 
impact, making the very high ratio considerably lower. Using the costs for delivery and 
neonatal care from Chambers et al., 2007 had little impact on the cost-effectiveness ratios. 
The statistical uncertainty of the estimated differences in costs and effects, derived from 
5000 bootstrap samples from the original cohort data, was assessed for the four patient 
profiles. The corresponding uncertainty in cost-effectiveness ratios is represented as cost-
effectiveness acceptability curves in Figure 2. At age 38 we may be more than 95% certain 
that direct IVF is cost-effective at a 15,000 euro threshold level for endometriosis and at a 
27,000 euro per live birth level for unexplained infertility.
Comparisons for all possible combinations of couple characteristics, restricted to female ages 
above 30 and primary subfertility, are depicted in Figures 3a and 3b. Figure 3a shows the 
differences in live birth rates. The difference becomes larger with age, reaching a maximum 
at age 38. The difference at a given age is almost the same for the various diagnostic 
categories or durations of infertility. The difference in costs between the two scenarios (not 
shown), did hardly depend on age, but strongly on diagnostic category and on the duration 
of infertility. The cost difference was lowest for endometriosis, around 400 euros, decreasing 
with duration of infertility by 25 euros per year. The highest cost difference was seen for 
unexplained subfertility, with values around 800 euros, decreasing with duration of infertility 
by 75 euros per year.
11
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In Figure 3b, the cost-effectiveness ratio is depicted. The cost-effectiveness of direct IVF is 
mainly dependent on diagnostic category and age and less on the duration of infertility. 
A steep decline with age is visible, followed by a slight increase from age 36 onwards. 
This pattern is clearly related to the patterns in effect-differences and cost-differences from 
Figures 3a and 3b respectively. For unexplained subfertility at three years duration, the ratio 
is below € 30,000 per live birth from age 32 onwards. It reaches € 20,000 per live birth only 
with 4 years duration at age 34 and older. At a € 10,000 per live birth level, direct IVF is cost-
effective only for endometriosis from age 33 onwards, at 3 years duration. For the other 
indications, the cost-effectiveness ratio stays above € 10,000 per live birth, for all durations 
and ages. For male subfertility, we cannot conclude cost-effectiveness from our results, as 
there was no differentiation on the waiting list between mild and severe male infertility. 11
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Figure 2       Results of a bootstrapping procedure with 5000 replications from the 
original cohort data (n= 5962): Cost-effectiveness acceptability curves, 
representing the chance that direct IVF is cost-effective against Society’s 
willingness to pay for a live birth
182
chapter 11
Figure 3       Difference in live birth chances (3a) and the corresponding cost-
effectiveness ratio (3b) between ‘Direct IVF’ and ‘postponing IVF for one 
year’, in relation to female age. Separate panels for diagnostic categories 
and separate curves for duration of infertility
(a)
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Discussion
We conducted a cost-effectiveness analysis of starting IVF in subfertile couples versus 
postponing IVF for one year, stratifying on diagnostic category, age, duration and type of 
subfertility. Observations from a large prospective study on IVF pregnancy chances and costs 
in the Netherlands, including estimates of treatment-independent pregnancy chances while 
on the waiting list for IVF, formed the empirical basis of the study. Results showed that the 
cost-effectiveness of IVF is most plausible for endometriosis, irrespective of the duration of 
subfertility or age. For unexplained subfertility, IVF may be postponed for women under 32 11
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until the duration of subfertility reaches more than 3 years, mainly because treatment- 
independent chances are still considerable while IVF chances after one year will hardly have 
decreased.
The eventual loss in chance of a live birth due to postponing IVF for one year is less than 6% 
for all cases and mainly depends on age (Figure 3a and Table I).  The couples that would 
otherwise have a live birth with IVF in the first year, will either have a live birth after treat-
ment-independent pregnancy during that first year, or from a pregnancy with IVF in the 
following year. The main effect of direct IVF compared to postponing IVF is therefore that 
treatment-independent pregnancies are replaced by IVF pregnancies, against considerable 
extra costs. In a recent simulation study, Habbema et al., 2009 showed a similar finding. 
From the present results, we can evaluate the current guideline for IVF in the Netherlands 
(Dutch Society for Obstetrics and Gynaecology, guideline no. 09, 1998). According to this 
guideline, the time when to start IVF or ICSI treatment depends on the cause and duration of 
subfertility, the seriousness of the disorder and women’s age. When the problems are caused 
by pathology of the tubal function, such as tubal blockage (1) or severe endometriosis (2), IVF 
should be offered directly. In case of relative tubal pathology, the infertility should be at least 
of 1 or 2 years duration. If there is no reason found (3), IVF is only indicated after a period of 
infertility of at least three years and should be preceded by intra uterine insemination (IUI) 
treatments while waiting for the required duration of subfertility. Minimal endometriosis is 
treated as unexplained subfertility (3). In case of ovulation disorders (mainly caused by 
polycystic ovary syndrome (PCOS) (4), at least twelve cycles of ovulation induction should 
precede IVF. When there is a disturbance in the interaction between semen and mucus 
(cervical hostility or immunological subfertility) (5), and for mild male subfertility (6), if the 
multiplication of the volume, concentration and motility (VCM) of the semen analyses is 
between 1-10 million, IVF is offered after a duration of at least two years and is preceded by 
IUI. For severe male subfertility, (VCM < 1 million), there is a direct indication for ICSI. For all 
diagnostic categories applies: IVF can be offered 1 or 2 years earlier, if women are over 36 
years or 38 years, respectively. There is no absolute age limit, but the guideline advises not to 
treat women over 40 years of age, because of poor treatment outcome. In Figure 4, showing 
an alternative representation of the relationship of the cost-effectiveness of direct IVF with 
diagnostic category, duration of infertility and age, we also depicted the durations at which 
IVF would be indicated according to the Dutch guideline. For ages over 34 years, the duration 
according to the guideline coincides with levels of the cost-effectiveness ratio approximately 
between 15,000 and 25,000 euro per live birth. For ages below 34, the durations according to 
the guideline correspond with higher levels of the cost-effectiveness ratio, reaching 56,000 
euros per live birth for unexplained subfertility at age 30. 
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The costs per extra ongoing pregnancy were above 10,000 euros for most combinations of 
diagnostic category, age and duration. Depending on the threshold level of the CE ratio per 
live birth, direct IVF becomes cost-effective, but this depends on the female age: the cost-
effectiveness ratio decreases with age, reaching a minimum around age 35-37, after which it 
increases again. There is no consensus on the level of costs per extra live birth that is 
acceptable. This is in contrast with the standard in health economics, with the Quality 
Adjusted Life Years (QALY) as effectiveness measure. There, a threshold between 30,000 and 
80,000 euro per QALY is generally considered as the limit of acceptability (NICE, 2008). Up till 
now, no studies have been published that translated a pregnancy leading to birth of a child 
into a gain in QALY for the parents.
Limitations of our study are the following:
We applied estimates of chances with IVF, excluding frozen embryos, for which we had no 
data. However, it is plausible that the same factors influencing IVF pregnancy chances will 
affect the chances with frozen embryos. Further, our cost calculations include a ‘punishment’ 
in costs for twin pregnancies, which mainly result from transferring two embryos after IVF. If 
only single embryo transfer (SET) would be performed, these extra costs would largely 
disappear. However, we may also expect that the pregnancy chances of IVF would diminish 
considerable with SET (van Montfoort et al., 2006).
Our calculations of treatment-independent pregnancy chances were based on data from a 
waiting list for IVF (Eijkemans et al., 2008) that comprised exposure time up to two years. We 
assumed that the treatment-independent chances after unsuccessful IVF are the same as for 
couples who never had IVF. A Danish 5-year cohort study in 818 couples starting assisted 
reproductive treatment (ART) found that 156 (19%) had delivered from a naturally conceived 
pregnancy, mostly after start of treatment (134 couples) (Pinborg et al., 2009). Likewise, Cahill 
et al., 2005, in a three-year follow-up study, found that 18% of couples conceived naturally 
after unsuccessful IVF. 
Just as was found previously by Mol et al., 2000, our results were highly sensitive to the 
application of a discount rate, particularly at ages around 30. IVF pregnancy chances do not, 
or only slightly diminish at that age, which means that there is no loss in pregnancy chances 
when postponing IVF for one year, but that there is a saving in costs of unnecessary IVF 
treatments. Therefore, cost-effectiveness ratio of direct IVF is very high. When discounting 
future live births and costs, we imply that the preference for a child now would be higher 
than that of a child next year. A willingness-to-pay study using the direct choice experiment 
(DCE) method, found evidence of such a preference (Ryan et al., 1999).
Further, it is likely that couples aged over 35 will feel a time pressure, especially when they 
consider having more than one child. 11
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We conclude that the duration at which IVF becomes cost-effectives depends, firstly on the 
level of society’s willingness to pay for one extra live birth, and secondly, given a certain level 
of willingness to pay, on the age of the woman and the diagnostic category. 
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General discussion
This final chapter gives answers to the six research questions. The limitations of the findings 
will be discussed, conclusions will be drawn and recommendations given.
Answers to the research questions:
1.   What is the chance of pregnancy for couples starting IVF or ICSI treatment in the 
Netherlands? 
The chance of an ongoing pregnancy was on average 24% after one cycle of IVF or ICSI and 45% 
after one year since the start of treatment.
A national prospective cohort study was set up to predict the chance of pregnancy for 
subfertile couples with an indication for IVF or ICSI treatment  (chapter 2). There was a loss of 
22% of the initially included couples, because 2 IVF centres and 3 transport clinics could not 
deliver the treatment data. A bias was however unlikely, as the overall yearly treatment results 
of the centres that did not participate did not deviate from the results of the other centres 
(see www.lirinfo.nl). In the IVF databases of the participating centres, 15% of the couples were 
lost due to inexact dates of the start of the first treatment. This loss to follow-up was equally 
spread over all centres. 
The number of embryos transferred per cycle, and the transfers of cryo-preserved embryos 
were in most centres not recorded. We assumed that a maximum of two embryos were 
transferred in all centres and that during the study period, the amount of elective single 
embryo transfers (eSET) were low. The results of cryo-preserved embryos were left out of the 
analyses for all centres for the reason of comparability.
The relationship of women’s age and the pregnancy chance showed a decline after the age of 
30, but also a lesser chance for women under 30. This decline in chance in young women was 
also found in other large datasets (NICE guideline 2004, Templeton et al., 1996). We assumed 
that child wish at young age could be related to social economic class and lifestyle. On the 
other hand the decline in chance for women between 40 and 45 was less steep than expected. 
This could be due to a selection of women with favourable prognostic factors. We recommend 
further research on in particular this older age group, to improve counselling based on evidence 
concerning biological predictors instead of solely cut off points by age limits.
The diagnostic category was not of influence on the pregnancy chance. However, it is 
debatable if unexplained subfertility is a uniform category. It could be a reservoir of couples 
with different (unexplained) reasons and therefore different chances of pregnancy reflected 
by e.g. the ovarian reserve capacity. Research on more diagnostic tools to distinct between 
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good and bad prognosis couples will lead to improvement of the prediction of pregnancy for 
couples in this category. The higher pregnancy chance with ICSI was most probably attributed 
to a selection of couples with only severe male, and in most cases no female subfertility. 
This was demonstrated by the use of ICSI for other than severe male related subfertile couples, 
for whom ICSI did not improve the pregnancy chance (Bhattacharya et al., 2001).
With the study results we developed a model that can be used in counselling couples about 
their pregnancy chances with IVF or ICSI in the Netherlands. It is of importance to validate 
and refine the model with recent data of a complete and more extended national registry. 
Registration of the full fertility history and pregnancy outcome, including prior fertility 
treatments as intra-uterine insemination, will be necessary to optimise the prediction of IVF/
ICSI outcome.
2.   Are there differences in pregnancy chance between IVF centres in the 
Netherlands?   
Differences in pregnancy chance between IVF centres in the Netherlands were present, despite a 
national IVF guideline, and similarity in experience and size. The adjusted one year ongoing 
pregnancy chance ranged from 36% to 55%.
The treatment outcomes of the centres obtained from the Dutch national cohort study on 
pregnancy chance with IVF or ICSI, were compared in chapter 3. Adjustments for patient mix 
and sampling variability narrowed the differences between centres. However, other patient 
related predictors, such as lifestyle, ethnicity, and socioeconomic class, were not available, 
and could be of importance on the IVF/ICSI treatment chance as well. 
The pregnancy chance per frozen-thawed embryo transfer, and the number of multiple 
pregnancies differ between centres. These outcome data could only be obtained for a 
minority of centres and had to be left out of the analysis for all. During the period of study, 
double embryo transfer (DET) took place in the majority of all transfers, which enabled the 
comparison of centres. 
We showed differences in pregnancy results between centres which should be researched 
more extensively after complete registration of all IVF outcome data and registration of more 
prediction factors, such as lifestyle. We also suggest to look beyond clinical variables, e.g. 
differences in laboratory procedures.
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3.   What is the chance of a spontaneous pregnancy when IVF is postponed,  
and the chance of a spontaneously conceived live birth after termination of  
IVF treatment? 
The average chance of a spontaneous pregnancy when IVF/ICSI treatment would be postponed for 
one year was 9%. The first year after termination of IVF, the chance of a spontaneously conceived 
pregnancy was on average 7%.
It is questionable if the waiting list construction was really mimicking postponement of 
treatment by delay of referral for IVF (chapter 4). The prospect of a treatment on a waiting list, 
could influence a couple’s own attempts of pregnancy. Reversibly, a waiting list could also 
lead to stress relieve and positively influence the spontaneous pregnancy chance (Evers et al., 
1998), although our data did not confirm this assumption. 
The average chance of a spontaneous pregnancy on the waiting list was lower compared to 
the spontaneous pregnancy chance in the most similar study (Collins et al., 1995). 
An important explanation for this difference can be found in the compliance of all centres to 
the national guideline for IVF in the Netherlands, which is different from other countries. The 
guideline restrains couples with still a reasonable chance of a spontaneous pregnancy, by 
implementing the duration of subfertility per diagnostic category. Furthermore, couples on 
the waiting list did not succeed with prior, also guideline regulated, conservative treatment 
options and were therefore a selection of couples with a low chance of a spontaneous 
pregnancy. This was in contrast with the study of Collins et al., in which the couples had no 
prior treatment.
The chance of a spontaneously conceived live birth after IVF might have been under estimated 
(chapter 6), because only the first spontaneous pregnancy was included. Besides, contraceptive 
use and a period of very low fertility after delivery, because of low frequency of intercourse 
and cycle recovery, were not reckoned with. 
To limit the chance of confounding factors affecting the estimates of a spontaneous 
pregnancy (e.g. partner change), the follow-up was restricted to 12 months after the last 
treatment. This method has not been used in the literature, maybe therefore higher chances 
of pregnancy after termination of IVF were found by others.   
The models on the spontaneous pregnancy chance before and after termination of IVF/ICSI, 
could only distinct the high chance couple from the low in 65% and 66% respectively, of all 
cases. By adding more prediction factors, e.g. ovarian reserve capacity, pregnancy treatment 
history, and lifestyle, the ability of the models to predict a spontaneous pregnancy will 
increase. Couples and professionals should be made aware of the determinants of influence 
on this chance. It may prevent unnecessary treatment and surprises.
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4.   What is the impact of lifestyle factors on the pregnancy chance with IVF, and after 
termination of IVF? 
Women who smoke, and women with overweight (BMI ≥ 27 kg/m2) reduce the live birth rate with 
IVF treatment by one third. The chance of a spontaneously conceived live birth after termination of 
IVF treatment was decreased by smoking, overweight, caffeine and alcohol use.
Information on lifestyle factors and pregnancy chance of women who received IVF treatment 
in the past, were obtained from a historical cohort, the OMEGA-project (chapter 5 and 6). 
The relatively high response to the questionnaires (71%), was overrepresented by women 
who had an IVF child. A lifestyle associated selection bias is however unlikely. Due to limited 
funding, 24% of all questionnaires were not abstracted. This concerned the medical records 
of couples of the last hospitals yet to be visited. The loss of questionnaires were therefore not 
on a patient level, and will not have biased the results on lifestyle and pregnancy chance.
Unfavourable lifestyle factors may have been underreported and the negative effects on the 
IVF pregnancy rate, or on the spontaneous pregnancy chance after termination of IVF may 
hold true for actually higher levels of use. 
Women and professionals should be conscious of the impact of lifestyle factors on the 
pregnancy chance during and after termination of IVF. By changing habits women can 
improve their fecundity throughout the whole fertile live span. The results of lifestyle and the 
spontaneous pregnancy chance after termination of IVF, suggests that there might also be an 
adverse effect of caffeine and alcohol on the pregnancy chance with IVF treatment. To clarify 
the impact of lifestyle factors during fertility treatment, we recommend to register and 
analyse these patient characteristics in a large scale prospective study.
5. What is the influence of psychological factors on the outcome of IVF? Are 
emotional problems after unsuccessful IVF treatment predictable?  
Anxiety and depression before and during IVF treatment did not lead to a lower pregnancy chance 
or a higher chance of cancellation of treatment. A screening tool could identify 75% of the women 
starting a first IVF treatment as being (not) at risk for emotional problems.
In spite of the large number of women included in our study on psychology and subfertility 
(see chapter 7), lack of power might have been the reason for not finding a relation between 
patient characteristics (women’s age, pregnancy history, cause and duration of subfertility), 
and IVF pregnancy chance. The same reason might have hold true for the relationship 
between distress and the IVF pregnancy chance, but our findings were in line with other 
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prospective studies on baseline and procedural distress and the effect on IVF treatment 
(Boivin and Takefman, 1995, Klonoff-Cohen et al., 2001, Emery et al., 2003, Anderheim et al., 
2005, Smeenk et al., 2005, de Klerk et al., 2008).
Poor prospects of treatment could have been made aware by prior counselling, but this was 
not reflected in a higher pre-treatment distress level for women with cancelled cycles. 
Couples will have their hopes up high and treatment start is often a relieve after “waiting” 
several years for a pregnancy to occur. The method the fertility problem is communicated, is 
known to influence the patients’ emotional response (Verhaak et al., 2007). Both reassons 
explain why the average scores of anxiety and depression at pre-treatment were in the 
normal range of the Dutch Community.
Non-participants had an almost equal subfertility related profile compared to participants. 
Nevertheless, a bias concerning the distress levels between the two groups cannot be ruled 
out. Maybe more nervous women were not asked, or had a tendency not to participate, but 
an opposite reaction on readiness of participation for more distressed women could also 
hold true. 
Lifestyle as smoking, weight, caffeine and alcohol use are known to mediate between fertility 
and distress, but unfortunately these variables were not added to this study. In future studies 
lifestyle factors should be involved to create a full picture of psychological state and fertility 
treatment.
Risk factors for emotional maladjustment were identified by Verhaak et al (2005), and 
incorporated in the questionnaires handed out before and after IVF treatment (chapter 8). 
SCREENIVF should not be used as a prerequisite for psychological support because of the 
low positive predictive value (48%) and the limited sensitivity (69%) which could lead to 
unidentified women with clinical emotional problems. Next to SCREENIVF as a first step in 
triage, anticipation on deterioration of emotional health is still essential for both patients and 
professionals. Subsequently, diagnostic investigation and if needed, psychological support 
can be given to those women who need it the most. 
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6. What are the costs of an IVF and ICSI treatment in the Netherlands? 
The average direct costs of IVF/ICSI treatment were € 10,250 per ongoing pregnancy. The indirect 
costs, caused by absence from work related to the IVF/ICSI treatment was on average € 600 euros 
per treatment. The cost-effectiveness ratios per live birth of direct IVF/ICSI compared to postponing 
treatment with one year were between € 10,000 and € 50,000, depending on women’s age, cause 
and duration of subfertility.
Due to fewer incomplete treatment cycles, lower mean medical costs and higher success 
rates, the average costs per ongoing ICSI pregnancy were € 250 lower compared to IVF, 
despite the higher laboratory costs of ICSI (chapter 9). There is however no evidence that ICSI 
treatments carried out for other causes of subfertility than severe male, will increase 
pregnancy chances and lower the overall costs. 
An embryo transfer with frozen-thawed embryos were double the costs of a fresh embryo 
transfer, but was only 20% of the costs of a complete IVF/ICSI cycle. Research on improvement 
of pregnancy chances after cryo preservation, will lead to a decreased physical burden, and 
higher cost-effectiveness.
The actual costs of a IVF and ICSI treatment may have been underestimated, because wasting 
costs, were not considered. The diagnostic work-up and costs for counselling preceding a 
treatment were left aside because of the wide variance between centres. However, we 
recommend cost-effectiveness research on in particular costs in diagnostic genetics for male 
related subfertility treated with ICSI. 
Differences in health care setting, and heterogeneity of study methods have lead to a low 
comparability between costs expenditures of IVF and ICSI treatment between European 
countries. However, the large sized IVF centres in the Netherlands may be the reason for the 
lower cost estimates compared to the often smaller IVF clinics in other European countries. 
(Nyboe Andersen et al., 2009). 
The response rate to the study on the productivity loss caused by absence from work was 
only 62%, which is however reasonable considering the 10 week period of completing the 
daily dairies (chapter 10). Respondents to the study had an embryo transfer in 90% of the 
cases, which is a high average compared to the national average of 86% reaching embryo 
transfer in 2003  (www.lirinfo). Under reportage of absence from work could have happened 
as women with incomplete treatments with no embryo transfer because of fertilisation 
failure, could have stopped keeping the diary and therefore been overrepresented in the 
non-responders. Further, results on absence from work were assessed on women having a 
first IVF or ICSI treatment, but emotional distress and with this, absence from work could 
increase after more unsuccessful treatments. The higher incidence of twin pregnancies with 
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IVF treatment and consequently more obstetric complications are likely to increase the 
absence from work for IVF pregnancies, compared to spontaneous pregnancies. In this study 
only the first weeks of pregnancy were followed, and absence from work was not significantly 
different for pregnant women compared to non-pregnant women in the first 8 weeks of 
gestation. 
The explained variance with respect to absence from work of the factors studied (age, hours 
of work, education level, main reason for absence, and psychological factors), was limited, 
other, e.g. work-related factors, which we did not study, may have a stronger prediction value 
on absence from work. 
The costs of absence from work for women with physical and/or emotional problems were 
almost double from the average costs of the IVF related absence from work. We therefore 
recommend research on prevention of both general and emotional problems with IVF 
treatment. 
The cost-effectiveness of IVF/ICSI for different subgroups of patients was correlated with the 
spontaneous pregnancy chance and the gain in pregnancy chance with IVF (chapter 11). 
It was most cost-effective for endometriosis, irrespective of the duration of subfertility and 
least for unexplained subfertility, because the chance of a spontaneous pregnancy for 
women in this category was still considerable. It is however questionable if the chance of a 
pregnancy with, or without treatment, is equal for all couples with unexplained subfertility at 
a certain age. More research is needed to find out if there are women within this diagnostic 
category with an extreme low chance of a spontaneous pregnancy, which could be 
considerably higher with IVF. This study was not conclusive on male subfertility because dif-
ferentiation between  the cost-effectiveness for mild male and severe male subfertility could 
not be estimated. It is plausible that severe male subfertility, for its low chance of a spontaneous 
pregnancy and high chance with ICSI,  was at least as cost-effective as endometrioses.
The cost calculations include the extra costs for twin pregnancies. When more single embryo 
transfers are performed, the extra costs will diminish, although the chances of pregnancy 
with IVF/ICSI will reduce also.
By postponing IVF with one year, more spontaneous pregnancies will occur that would in 
case of direct IVF, be replaced by IVF pregnancies against considerable extra costs. However, 
this approach will also ignore the preference of a couple to have a pregnancy now instead of 
next year and restrict a couple in having more children in succession. Further, there is no 
consensus on the society’s willingness to pay for one extra live birth with IVF/ICSI.  
12
general discussion
198
Conclusions 
 1. The pregnancy chance with IVF or ICSI treatment predominantly depends on female 
age, to a less extend on the duration of subfertility and pregnancy history, and not on 
the diagnostic category.
 2. Differences in success rate between IVF centres in the Netherlands can not be explained 
by the presently registered patient characteristics.
 3. The chance of a spontaneous pregnancy before and after termination of IVF, is dependent 
on the woman’s age, her pregnancy history, the cause and duration of subfertility.
 4. Smoking and overweight have a detrimental impact on the pregnancy chance with IVF, 
and on the spontaneous pregnancy chance after termination of IVF, which is also 
harmed by caffeine and alcohol use.
 5. Anxiety and depression before and during a first IVF/ICSI treatment do not influence the 
pregnancy chance with IVF.
 6. The psychological screening tool “SCREENIVF” can be used as a triage to identify women 
at risk for emotional problems after IVF/ICSI treatment.
 7. Absence from work related to IVF is mainly because of physical and emotional problems 
due to treatment. 
 8. The costs of IVF/ ICSI treatment are mainly determined by the costs of medication. 
 9. The cost-effectiveness of IVF/ICSI treatment depends on the combination of women’s 
age, cause and duration of subfertility.
10. The recommendations of the current IVF guideline are valid, except for unexplained 
subfertility.
Recommendations
 1. The prediction model on pregnancy chances with IVF/ICSI should be validated.
 2. Registration of fertility treatment in the Netherlands should be uniform and complete 
and should include lifestyle. 
 3. Differences between IVF centres should be studied including more prognostic factors 
and should not be restricted to clinical variables.
 4. Counselling of couples on their chance of a spontaneous pregnancy should be based on 
prediction models which include lifestyle. 
 5. A large scale prospective study on lifestyle during fertility treatment should be carried 
out.
 6. Lifestyle factors should be included in research on distress and fertility. 
 7. The positive predictive value and the sensitivity of the psychological screening 
instrument “SCREENIVF” should be improved by further research. 
 8. IVF/ICSI treatment should focus on prevention of physical and emotional problems to 
reduce absence from work and involved costs.
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 9. The focus on improvement of the pregnancy chance with IVF/ICSI, should be on progress 
of the pregnancy chance with frozen-thawed embryo’s, to reduce the burden and costs 
per treatment.
 10. More research on the cost-effectiveness of IVF is needed for couples with unexplained 
subfertility, in particular for women under age 32. 
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Summary
In Chapter 1 the background of the thesis and the study design were outlined. After one 
year of unprotected intercourse, 15% of all couples do not conceive spontanously. IVF or ICSI 
treatment can lead to pregnancy and a live birth for some of the involuntary childless 
couples.
In the Netherlands, IVF exists for more than 25 years and fertilisation with ICSI for more than 15 
years. The number of IVF and ICSI treatments has increased every year. At this moment 1 in 
every 39 children in the Netherlands is an IVF or ICSI child. An important explanation for the 
rising number of IVF and ICSI treatments is the high mean age at which Dutch women try to 
conceive their first child. During the optimal fertile period, women give priority to education 
and their carrier instead of motherhood. With rising women’s age the chance of pregnancy 
decreases and women will appeal to medical treatments more often.
On average, the chance of pregnancy is around 25% per IVF or ICSI cycle. The chance per couple 
differs and is dependent on known and still unknown factors. It is desirable to predict the 
chance of success, to save futile treatments, disappointment, risks, and unnecessary costs.
Former research to the factors of influence on the chance of pregnancy have led to the 
development of the recent IVF guideline, formulated by the Dutch Community of Obstetrics 
and Gynaecology (NVOG). 
The guideline describes when, and after which diagnostic procedures, the indication for IVF 
and ICSI is reached. Couples with no, or hardly any chance of a spontaneous pregnancy, or 
after unsuccessful less invasive treatments (e.g. IUI), are referred for IVF. The chance of 
pregnancy with IVF/ICSI should be weighed up against risks and complications through 
treatment. The last version of the guideline was written more than 10 years ago and should 
be updated . Further the evidence for most indications for IVF, according to the guideline 
should be well-founded. 
 
This thesis addresses six research questions:
1. What is the chance of pregnancy for couples starting IVF or ICSI treatment in the 
Netherlands? 
2. Are there differences in pregnancy rate between IVF centres in the Netherlands?   
3. What is the chance of a spontaneous pregnancy when IVF is postponed, and the 
chance of a spontaneously conceived live birth after termination of IVF 
treatment? 
4. What is the impact of lifestyle factors on the pregnancy chance with IVF, and after 
termination of IVF? 
5. What is the influence of psychological factors on the outcome of IVF/ICSI? 
Are emotional problems after IVF treatment predictable?  
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6. What are the costs of an IVF and ICSI treatment in the Netherlands? 
Part I (chapter 2-4) of the thesis was mainly based on a prospective cohort study, in which 
almost all IVF centres in the Netherlands participated. Research question 1, 2 and 3 could be 
answered with data from this study. We made use of the existing waiting period before IVF/
ICSI treatment, which developed because the increasing demand for IVF and ICSI exceeded 
the supply of treatments per centre. The chance of a spontaneous pregnancy during the 
waiting period of subfertile couples eligible for IVF treatment, was compared to the chance 
of pregnancy with treatment for those couples that eventually started IVF/ICSI. Couples were 
followed from the moment they were on the waiting list up until the first ongoing pregnancy. 
This is defined as a pregnancy at minimal 8 weeks gestation, with fetal heartbeat 
demonstrated with sonography. This was applicable for spontaneous, as well as for 
pregnancies after treatment. Couples on the waiting list were followed until a ongoing 
spontaneous pregnancy occurred or, in case a spontaneous pregnancy did not occur, until 
the start of treatment and 12 months there after. The influences of patient characteristics, 
such as female age, pregnancy history (primary or secondary subfertility), cause and duration 
of subfertility on the chance of pregnancy were analysed in a prediction model. A comparable 
prediction model on the chance of a spontaneous pregnancy was developed for couples on 
a waiting list before treatment. Further, we investigated if there were differences in pregnancy 
chance per IVF centre.
In part II  (chapter 5-8), other determinants on the chance of pregnancy for subfertile couples, 
such as lifestyle and psychological factors were studied and gave answers to research 
questions 4 and 5. We used data from the OMEGA-project, a large scale nationwide historical 
cohort study. This study was initiated in 1995, among women who had at least one IVF 
treatment between 1983 tot 1995, in one of the IVF centres in the Netherlands. These women 
were asked to fill in an extensive questionnaire on medical treatments, pregnancies, and 
lifestyle, before during and after their IVF treatment period. These questionnaires were 
combined with the  medical records. The influences of smoking and the body mass index 
(BMI) during IVF treatment, and also the influence of caffeine and alcohol use on the 
spontaneous pregnancy chance after termination of IVF treatment, were assessed. 
During the national prospective cohort study on the chance of pregnancy with IVF and ICSI 
in 7 IVF clinics (3 IVF centres en 4 transport clinics), another research was carried out with 
validated questionnaires on the influence of psychological factors (anxiety and depression) 
on the chance of pregnancy and a premature cancellation of treatment. Furthermore, a 
psychological screening instrument to identify women at risk for psychological damage after 
unsuccessful treatment was tested.  
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In part III (chapter 9-11), indirect and direct medical costs of IVF/ICSI treatment were calculated 
(research question 6). The direct medical costs of an IVF and ICSI treatment were described in 
detail, using data of 4 IVF centres and 1 transport clinic. The indirect costs of IVF related 
productivity loss, were assessed in 8 IVF clinics, by combining a diary on absence from work 
with a psychological questionnaire, to give insight into costs and the factors of influence on 
the absence from work due to IVF treatment. 
Finally, a costs-effectiveness study was carried out by combining the prediction models on 
the spontaneous pregnancy chance and the chance of pregnancy with IVF/ICSI treatment in 
relation to the costs of treatment for couples with different patient profiles. 
In Chapter 2 the prognostic values of different patient characteristics used in the Dutch IVF 
guideline were assessed and evaluated in a model to predict the ongoing pregnancy chance 
within 12 months after the start of treatment. In a national prospective cohort study, 4928 
couples starting IVF or ICSI treatment for the first time between 2002 and 2004, were followed, 
using the IVF databases of 11 IVF centres and including 20 transport clinics. 
The average one-year ongoing pregnancy chance was 45%. Age was identified as the most 
important predictor of pregnancy, with the highest chance at 30 years of age, and a slight 
decline for younger and older women. After the age of 35, the pregnancy chance dropped 
more steep. The chance of pregnancy for women around 40 were half the chance of women 
of 30 years of age. Couples with severe male subfertility treated with ICSI had a 22% higher 
chance of an ongoing pregnancy than couples in the other diagnostic categories treated 
with IVF. The chance of pregnancy for women with a pregnancy history was on average 10 % 
higher compared to women with primary subfertility. The results also showed that with a 
longer duration of subfertility the chance of pregnancy decreased with 3% every year. 
In this study we developed a model for the prediction of  pregnancy with IVF or ICSI. The 
prognostic factors mentioned can be used to counsel individual couples about their chance 
of pregnancy at the start of a first treatment. 
In Chapter 3 we investigated if the differences in the one year ongoing pregnancy chance 
between IVF centres remained after adjustment for patient mix. For this study we used 
prospectively collected IVF and ICSI treatment data, see also chapter 2, and separated the 
outcomes per centre. Adjustment for differences in patient mix per centre was carried out by 
implementing the prognostic index which included the subfertility related factors: age, 
pregnancy history, cause and duration of subfertility, and which was obtained from the 
model in chapter 2. 
The crude one year ongoing pregnancy chance was compared to the mean of all centres and 
differed nearly a factor 3 between centres. Accounting for sampling variation the range 
shrank to a factor 2. After adjustment for patient mix the range narrowed a little further. One 
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year after the start of treatment, the adjusted ongoing pregnancy chance differed between 
36% and 55% in the two utmost centres. 
Only17% of the variation between centres could be explained by the differences in patient 
mix, as registered in the IVF databases. Further research is needed to elucidate the causes of 
the remaining differences.
In Chapter 4 we estimated the chance of a spontaneous pregnancy for IVF and ICSI patients, 
using data on the waiting list before the start of treatment. In a prospective cohort study 
with a duration of two years, we included 5962 couples, registered on a national waiting list 
before IVF or ICSI. The waiting list data were matched with the IVF/ICSI registries of the IVF 
centres that participated to the study (see chapter 2). For the couples that did not match, the 
medical files were searched by hand. The patient characteristics of the couples that had not 
started IVF/ICSI because of the occurrence of a spontaneous pregnancy while on the waiting 
list, were determined and used in the analysis. The prediction of a spontaneous pregnancy 
was assessed while considering female age, the duration of subfertility, pregnancy history, 
and the diagnostic category.
The cumulative probability of a spontaneous ongoing pregnancy on a waiting list before the 
start of IVF or ICSI was 9% at 12 months. For less than 10% of the couples this chance was 
more than 15%. The chance of a spontaneous pregnancy decreased with 5% with every year 
increase of women’s age, with 15% per year increase in the duration of subfertility, and with 
29% for primary, compared to secondary subfertility. All diagnostic categories showed higher 
chances of a spontaneous pregnancy compared to tubal pathology. For couples with 
unexplained subfertility this chance was even 2,6 times higher. 
The chance of an ongoing spontaneous pregnancy while waiting for an IVF treatment was on 
average below 10% but maybe as high as 25% within one year for couples with only favourable 
prognostic factors. 
In Chapter 5 the separate and combined effects of subfertility related factors and the lifestyle 
factors smoking and BMI on the live birth rate with IVF were studied on women who had a first 
IVF treatment in one of the IVF centres in the Netherlands during 1983 and 1995. Information on 
lifestyle and pregnancy outcome was retrospectively obtained from questionnaires filled in by 
8457 women and combined with their medical records (the OMEGA-project). 
In those days, the overall live birth rate per cycle was 15%. With increasing female age the 
overall live birth rate decreased with 2% with every year increase. Multivariate analysis 
revealed that the chance of an IVF live birth decreased with 28% for smokers. Women with 
overweight (BMI ≥ 27 kg/m2 ), had a 33% lower chance of an IVF live birth compared to normal 
weight women (BMI ≥ 20 and < 27 kg/m2). Couples with male subfertility had a 30% lower 
chance of a live birth with IVF treatment compared to the other two diagnostic categories 
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defined (tubal pathology and other subfertility reasons). The duration of subfertility and the 
pregnancy history before the start of the first IVF did not influence the live birth rate. 
This research with historical data on IVF treatment in the Netherlands revealed the average 
chance of a live birth with IVF between 1983-1995, and gained insight into the influences of 
subfertility related factors and lifestyle on that chance. 
In Chapter 6 we predicted the chance of a spontaneous conception leading to a live birth 
after termination of successful and unsuccessful IVF treatments, based on subfertility related 
factors and lifestyle. The historical OMEGA-cohort (see also chapter 5), of 8669 women who 
received at least one IVF treatment were used, the follow-up interval after last IVF treatment 
was on average 5 years.
Within the first year after last IVF, or within a year after the delivery of an IVF live birth, the 
chance of a spontaneous conception which led to a live birth was 7%. The chance decreased 
with 6% with every year increase of women’s age. There was a differerence in effect of the 
variables of influence on the chance of a spontaneous pregnancy for couples with, and 
without an IVF-child after last IVF. For couples with an unsuccessful last IVF the chance of a 
spontaneously conceived live birth decreased with 20% after more than 6 year duration of 
subfertility, and with 29% after more than 4 IVF attempts. Smoking decreased the chance 
with 28%, for women with a BMI higher than 27 kg/m2 the chance decreased with 53%, for 
caffeine use of more than 4 units per day with 28% and with 43% when more than 3 units of 
alcohol per week were used. 
The influence of subfertility related factors and lifestyle on the chance of (spontaneous) 
pregnancy for subfertile couples before and during IVF, also applied for the spontaneous 
conception chance after termination of IVF.
In Chapter 7 we performed a multicentre prospective cohort study in 783 women starting a 
first IVF or ICSI treatment, to assess the influences of anxiety and depression on the pregnancy 
rates. Additionally, we studied the effect of anxiety and depression on the chance of premature 
cancelation of an IVF treatment. We also determined if a change in anxiety level from 
pre-treatment to just before oocyte retrieval, affects the pregnancy rate. Anxiety and depression 
levels were assessed by a validated questionnaire containing the short versions of the State 
Anxiety Inventory (STAI) and Beck Depression Index-Primary Care (BDI-PC). Results from the 
questionnaires were combined with the treatment outcomes from the IVF registries obtained 
from the national cohort study (see chapter 2). The predictive values of distress were assessed 
while controlling for women’s age, pregnancy history, duration and cause of subfertility.
Neither anxiety, depression, nor a rise in anxiety during treatment, had an effect on the 
pregnancy rate. The cancellation rate was also not affected by the pre-treatment anxiety and 
depression levels. 
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Inductees in IVF/ICSI  treatment can be reassured about the influence of distress on the 
chance of pregnancy.
In Chapter 8 we investigated the psychometric characteristics of a screening tool to identify 
women, before treatment, who are at risk to develop emotional problems caused by IVF/ICSI. Risk 
factors for emotional maladjustment were determined in a previous study and incorporated in a 
questionnaire. “SCREENIVF” was handed out at pre-treatment (see also chapter 7), and 6 weeks 
after oocyte retrieval, and was studied in 279 women. 
SCREENIVF successfully identified 75% of the women at risk, or not at risk for emotional 
maladjustment. The sensitivity of the test was 69%, meaning that 69% of the women with 
emotional problems after the first treatment indeed were identified by the test. negative 
predictive value was high (89%), but the positive predictive value of SCEENIVF was low: only 
48% of the women testing positive on risk factors indeed had clinical signs of emotional 
problems. 
SCREENIVF can be used as a triage instrument and a tool to anticipate on the risk profile of women 
starting IVF. Subsequently, detailed diagnostic interviews, possibly followed by psychological 
treatment could prevent drop-out of treatment or deterioration of psychological wellbeing.
In Chapter 9 the productivity loss and the pattern of absence from work due to a first IVF/
ICSI treatment was assessed. Additionally, the influences of general and psychological 
variables on the absence from work were analysed. In a prospective multicentre cohort study 
the costs of IVF related absence from work was derived from a diary kept by 384 women, 
from the start of treatment up until 10 weeks thereafter. Women filled in a psychological 
questionnaire at pre-treatment (see also chapter 7) and at closure of the diary. The treatment 
results of these women were obtained from the national cohort study on the prediction of 
IVF /ICSI treatment (chapter 2).
On average, women had 33 hours of absence from work during the 10 weeks registered. The 
overall absence from work due to IVF/ICSI treatment was 23 hours per first cycle, which was 
a productivity loss due to the treatment of almost € 600. The main reason for absence from 
work was for half of all women physical and/or emotional problems. The average productivity 
loss for women with complaints were 4 times higher than for the other women who registered 
hospital visits as the main reason for absence from work, which was on average 10 hours. 
Absence from work was positively correlated with the hours of paid work and with physical 
or emotional complaints. Women with a high education level had a lower average of absence 
from work compared to a secondary education level. To reduce the costs due to absence 
from work we should focus on prevention of physical and emotional problems. 
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In chapter 10 the costs of a first IVF and ICSI treatment up until an ongoing pregnancy were 
described per stage of treatment and per treatment with frozen-thawed embryos. Detailed 
information about the costs of a first IVF and ICSI treatment were obtained in 4 IVF centres 
and 1 transport clinic. The treatment results were derived from the IVF registrations from the 
national cohort study (see chapter 2), from the annual reports of three IVF centres, and from 
the national infertility registration (LIR). 
The costs of a first IVF or ICSI cycle were on average almost € 2500. The costs of an ICSI treatment 
were on average 8% higher compared to an IVF cycle, due to the higher specific equipment 
costs and labour-intensive procedures. Per ongoing pregnancy the costs with ICSI were on 
average lower compared to IVF, because of a higher chance of success with ICSI. The cost for 
medication covered the major part of the treatment costs. From 34 years onward, the total 
costs per ongoing pregnancy increased because of a higher mean dosage of follicular 
stimulating hormone used and a lower mean chance of pregnancy. The costs of preservation, 
thawing and transfer of cryo-preserved embryos were on average € 550 per treatment. 
Based on the number of treatments from the LIR data in 2004 and the average ongoing 
pregnancy rates after IVF, ICSI, and cryo-transfers, the costs per ongoing pregnancy resulted 
from IVF or ICSI were around € 10,250. 
In Chapter 11 we aimed to establish the cost-effectiveness comparison between starting 
IVF/ICSI according to the IVF guideline as used in the Netherlands (“direct-IVF”), and waiting 
one more year before the start of treatment. The prediction model on the pregnancy chance 
one year after the start of IVF/ICSI (see chapter 2), and the prediction model on the 
spontaneous pregnancy chance on a national waiting list before treatment (see chapter 4), 
were used for comparison of effectiveness. Costs of treatment were determined from couples 
starting IVF/ICSI (see chapter 10). The total costs of the treatment per live birth were added to 
the costs of subsequent delivery and neonatal care. The costs and the percentage of multiple 
births with IVF/ICSI were reckoned with. Analyses were carried out for women with different 
diagnostic categories, age and duration of subfertility. 
The cost-effectiveness ratio is the difference in costs per live birth with direct IVF compared 
to the costs of postponing IVF with one year, divided by the difference in chance of a live 
birth between the two scenario’s. The cost-effectiveness ratios were between € 10,000 and 
€ 50,000 per live birth. For women with endometriosis the cost-effectiveness ratio was just 
below € 10,000 from 34 years onward. For all other diagnostic categories, regardless off age, 
the cost-effectiveness ratio is higher. For women with unexplained subfertility the ratio was 
€ 30,000 from age 32 onward and 3 year duration of subfertility. 
In conclusion, postponement of IVF will save costs against a small loss in overall live birth rate. 
The cost-effectiveness of IVF is dependent on the diagnostic category, on woman’s age, and 
the duration of subfertility, but also on the society’s willingness to pay for an extra live birth. 
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In chapter 12 the answers to the research questions, the main conclusions and recommen-
dations are given:
1. In the Netherlands, the chance of an ongoing pregnancy was on average 24% after one 
cycle of IVF or ICSI and 45% after one year since the start of treatment. The pregnancy chance 
with IVF or ICSI treatment is mainly dependent on the female age, partly on the duration of 
subfertility and pregnancy history, and not at all on the cause for IVF. The prediction model 
on pregnancy chance with IVF/ICSI should be validated with a national uniform registration 
of fertility treatment and include lifestyle. 
2. The adjusted one year ongoing pregnancy chance between IVF centres in the Netherlands 
ranged from 36% to 55%. Patient mix explains these differences for only a small part. To 
elucidate the differences between centres, more clinical and non-clinical variables should be 
registered and included in research.
3. The average chance of a spontaneous pregnancy when IVF/ICSI treatment would be 
postponed for one year was 9%. The first year after termination of IVF, the chance of a 
spontaneous pregnancy was on average 7%. Both before and after termination of IVF, the 
chance of a spontaneous  pregnancy, is dependent on the woman’s age, her pregnancy 
history, the cause and duration of subfertility. Counselling of couples on their chance of a 
spontanous pregnancy should be based on prediction models including lifestyle.
4. Women who smoke, and women with overweight (BMI ≥ 27 kg/m2) reduce the live birth 
rate with IVF treatment by one third. The chance of a spontanously conceived live birth after 
termination of IVF treatment was decreased by smoking, overweight, caffeine and alcohol 
use. Lifestyle factors during fertility treatment should be prospectively studied on a large 
scale.
5. Anxiety and depression before and during IVF treatment did not lead to a lower pregnancy 
chance or a higher chance of cancellation of treatment. “SCREENIVF” could identify 75% of 
the women starting a first IVF treatment as being (not) at risk for emotional problems after 
treatment.
The sensitivity of the psychological screening instrument should be improved. Further 
research on distress and fertility should include lifestyle factors. 
6. The average direct costs of IVF/ICSI treatment were € 10.250  per ongoing pregnancy.
The indirect costs, caused by absence from work related to the IVF/ICSI treatment was on 
average € 600 euros per first cycle. By prevention of physical and emotional problems during 
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IVF/ICSI treatment, the costs of absence from work due to IVF treatment can be importantly 
lowered.
For women over 32 years of age of all diagnostic categories, the cost-effectiveness ratios of 
direct IVF compared to postponement was between € 10,000 and € 25,000 per live birth. 
Except for women with unexplained subfertility. Unless they would wait at least one other 
year on top of the recommended three years of the current guideline IVF.
summary
12

223
Samenvatting 
Hoofdstuk 1
Achtergrond, doelen en de onderzoekspopulaties 
Zwanger worden via de natuurlijke weg is voor ongeveer 15% van alle paren een probleem. 
Een IVF of ICSI behandeling kan voor sommige ongewenst kinderloze paren een oplossing 
bieden. Bevruchting via IVF bestaat in Nederland inmiddels ruim 25 jaar, middels ICSI al meer 
dan 15 jaar. Het aantal IVF en ICSI behandelingen dat per jaar wordt uitgevoerd neemt nog 
steeds toe. Op dit moment is 1 op de 39 kinderen in Nederland een IVF of ICSI kind. Een 
verklaring voor de stijgende behoefte aan IVF en ICSI heeft te maken met het uitstellen van 
de kinderwens. Tijdens de optimaal vruchtbare periode geven veel vrouwen de voorkeur aan 
het volgen van een opleiding en de ontwikkeling van een carrière om sociaal/maatschap-
pelijke en economische redenen. Naarmate een vrouw ouder wordt, dalen echter haar kansen 
op een zwangerschap en zal zij vaker een beroep doen op de medische mogelijkheden om 
deze kans te vergroten. 
Met de ontwikkelingen in de voortplantingsgeneeskunde is de kans van slagen per 
behandeling in de loop der jaren toegenomen. Voor alle vormen van kunstmatige bevruchting 
ligt de gemiddelde kans op zwangerschap rond de 25% per behandeling. De kansen per paar 
zijn verschillend en afhankelijk van een aantal bekende, maar ook nog steeds onbekende 
factoren. Het is wenselijk om een zo goed mogelijke voorspelling van de slaagkans te kunnen 
doen, om vergeefse behandelingen, teleurstelling en risico’s te voorkomen en onnodige 
kosten te besparen. 
Eerder onderzoek naar de factoren van invloed op de kans op zwangerschap hebben geleid 
tot de ontwikkeling van de huidige richtlijn IVF geformuleerd door de Nederlandse Vereniging 
voor Obstetrie en Gynaecologie (NVOG). De richtlijn beschrijft op welk moment en na welke 
diagnostische procedures, er een indicatie bestaat voor een behandeling IVF en ICSI, met  als 
doel de paren die via de natuurlijke weg, of na minder invasieve methodes van behandeling 
(bijvoorbeeld intra uterine inseminatie, IUI) geen, of weinig kans maken op een zwangerschap, 
te verwijzen voor behandeling. De kans op een zwangerschap door IVF/ICSI dient daarbij ook 
afgewogen te worden tegen de kansen op een complicatie door behandeling. De laatste 
versie van de richtlijn bestaat inmiddels ruim 10 jaar en is toe aan herziening. Daarbij zou de 
richtlijn voor de meeste indicaties wetenschappelijk beter onderbouwd kunnen worden. 
Dit proefschrift behandelt zes onderzoeksvragen:
1. Wat is de kans op zwangerschap voor paren die een IVF of ICSI behandeling 
ondergaan in Nederland?
2. Zijn er verschillen in kans op zwangerschap tussen de IVF centra in Nederland?   
3. Wat is de kans op een spontane zwangerschap indien IVF één jaar langer zou 
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worden uitgesteld en de kans op een spontane zwangerschap nadat IVF is 
afgesloten?
4. Wat is de invloed van levensstijl factoren op de kans op zwangerschap met IVF en 
de kans op een spontane zwangerschap nadat IVF is afgesloten? 
5. Wat is de invloed van psychologische factoren op de uitkomst van IVF/ICSI? Zijn 
emotionele problemen die kunnen ontstaan na IVF te voorspellen? 
6. Wat zijn de kosten van IVF en ICSI in Nederland? 
Opbouw proefschrift: 
In deel I van dit proefschrift (hoofdstuk 2-4), werd de kans op een zwangerschap voor paren 
die volgens de richtlijn IVF in aanmerking kwamen voor een behandeling IVF of ICSI berekend. 
De invloed van verschillende patiënt karakteristieken: de leeftijd van de vrouw, de aard van 
de subfertiliteit (primaire of secundair), de oorzaak (diagnostische categorie) en duur van de 
fertiliteitstoornis werden meegewogen in een kansmodel. Deze paren stonden vóór 
behandeling op een wachtlijst. Voor de kans op een spontane zwangerschap in de wachttijd 
voor IVF werd eveneens een predictie model gemaakt. 
Paren verschillen in kans op zwangerschap, of er ook verschillen bestaan in de kans op 
zwangerschap per IVF centrum is eveneens onderzocht.
In deel II (hoofdstuk 5-8), werden andere factoren die de kans op een zwangerschap kunnen 
beïnvloeden onderzocht. De invloed van psychologische (“stress”), en levensstijlfactoren 
zoals roken, overgewicht, cafeïne- en alcohol gebruik op de kans op zwangerschap voor, 
tijdens en na IVF/ICSI werden bestudeerd. Tevens hebben we onderzocht of voortijdige 
herkenning van vrouwen die mogelijk psychische schade ondervinden van een behandeling 
mogelijk was.
In deel III van het proefschrift (hoofdstuk 9-11), werden de kosten van een IVF/ICSI behandeling 
en de doelmatigheid, oftewel de kosten-effectiviteit van een behandeling bepaald. De direct 
medische kosten werden berekend en de indirect medisch kosten ten gevolge van produc-
tiviteitsverlies door werkverzuim werden onderzocht. De kosteneffectiviteit analyse werd 
uitgevoerd voor paren in verschillende diagnostische categorieën, waarbij de duur van de 
vruchtbaarheidsstoornis en leeftijd van de vrouw werden meegewogen. 
Een prospectief cohort onderzoek, waaraan vrijwel alle IVF centra in Nederland hebben 
deelgenomen, vormt de basis voor dit proefschrift. Alle paren in dit onderzoek hadden een 
verwijzing voor behandeling IVF of ICSI. Ten tijde van het onderzoek bestond door de 
toenemende vraag naar behandelingen en een beperking in het aantal behandelingen per 
IVF centrum, bij vrijwel alle klinieken een wachttijd vóór behandeling. Om de effectiviteit van 
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IVF te beoordelen, werd de kans op een spontane zwangerschap in de wachtperiode voor 
IVF vergeleken met de kans op zwangerschap met IVF/ICSI, voor die paren die uiteindelijk 
gingen starten met een behandeling. Paren werden gevolgd vanaf het moment dat ze op de 
wachtlijst werden geplaatst tot aan de eerste “doorgaande” zwangerschap. Dat betekent een 
zwangerschap van 8 weken na de laatste menstruatie, waarbij echografisch hartactie is 
geconstateerd. Dit gold zowel voor de spontane zwangerschap als voor de zwangerschap 
ontstaan na behandeling. 
Voor de invloed van levensstijlfactoren op de kans op zwangerschap tijdens en ná IVF is 
gebruik gemaakt van het OMEGA-gegevensbestand. Het OMEGA-project is gestart in 1995: 
vrouwen die vanaf 1983 tot 1995 IVF ondergingen in Nederland, konden een uitgebreide 
vragenlijst invullen over medische behandelingen, zwangerschappen en levensstijl factoren 
vóór, tijdens en na de IVF periode. De vragenlijst gegevens werden gecombineerd met de 
gegevens uit de medische dossiers. 
Gedurende het nationale prospectief cohort onderzoek naar de kans op zwangerschap met 
IVF en ICSI werd er in 7 IVF klinieken (3 IVF centra en 4 transportklinieken), tevens een 
prospectief onderzoek gestart met gevalideerde vragenlijsten naar de invloed van psycholo-
gische factoren (angst en depressie) op de kans op zwangerschap en het voortijdig afbreken 
van een behandeling. Bovendien is het onderscheidend vermogen van een nieuw 
ontwikkelde psychologische vragenlijst getest. De vraag was of vrouwen met een hoog risico 
op psychische schade na een behandeling, voorafgaand aan de behandeling geïdentificeerd 
kunnen worden met de test. Tenslotte diende de vragenlijst inzicht te geven in de invloed 
van fysieke en emotionele problemen op het ziekteverzuim.
De kosten van een IVF en ICSI behandeling zijn gedetailleerd in kaart gebracht. Met deze 
gegevens en met de gegevens van het predictie model betreffende de kans op spontane 
zwangerschap en het model over de kans op zwangerschap met IVF of ICSI, is een kosten-
effectiviteits analyse van een behandeling IVF/ICSI verricht per diagnostische categorie. Op 
grond van de leeftijd van de vrouw en de duur van het vruchtbaarheidsprobleem zouden 
met deze gegevens een nieuwe richtlijn IVF ontwikkeld kunnen worden. 
Hoofdstuk 2
Kans op zwangerschap met IVF of ICSI 
In dit hoofdstuk werd de voorspelling van de kans op een doorgaande zwangerschap binnen 
één jaar vanaf de start van een eerste behandeling IVF of ICSI onderzocht. De voorspellende 
waarde van verschillende patiënt karakteristieken werd berekend met behulp van een 
predictie model. De gegevens voor dit onderzoek zijn verkregen tijdens een nationale 
prospectieve cohort studie uitgevoerd tussen 2002 en 2004. Van 11 van de 13 IVF centra en 
20 van de 23 transportklinieken in Nederland zijn de behandelgegevens van in totaal 4928 
paren gebruikt 
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Binnen 1 jaar na start van de behandeling IVF of ICSI was de kans op een doorgaande 
zwangerschap gemiddeld 45%. De volgende determinanten zijn gebruikt in het model: de 
leeftijd van de vrouw, de diagnostische categorie, of te wel de indicatie voor behandeling, de 
duur en de aard van de subfertiliteit (primair of secundair). De leeftijd van de vrouw was de 
belangrijkste voorspeller van de kans op zwangerschap. Met het stijgen van de leeftijd van 
de vrouw nam de kans op zwangerschap af. De hoogste kans lag rond de 30 jaar en er was 
een lichte afname in kans voor zowel jongere als voor oudere vrouwen tot 35 jaar, daarna 
daalde de kans op zwangerschap sterker. Voor vrouwen rond de 40 bleek de kans op 
zwangerschap slechts de helft van de kans ten opzichte van vrouwen rond de 30 jaar. De 
grootste kans van slagen lag bij paren die behandeld werden met ICSI vanwege ernstig 
verminderde zaadkwaliteit. Zij hadden 22% meer kans van slagen binnen 1 jaar na de start 
van behandeling in vergelijking tot paren die behandeld werden met IVF. Dit was onafhankelijk 
van de indicatie voor IVF. Vrouwen die al eerder zwanger waren geweest hadden 10% meer 
kans op een doorgaande zwangerschap met IVF/ICSI dan vrouwen met een primaire subfer-
tiliteit. Hoe langer de duur van de subfertiliteit, des te kleiner de kans op zwangerschap, per 
jaar nam de kans met 3% af. 
Met bovenstaande gegevens is een model ontwikkeld, waarmee de individuele kans van 
slagen met behulp van de verschillende patiëntkarakteristieken voor een paar berekend kan 
worden. 
Hoofdstuk 3 
Verschillen tussen IVF klinieken in Nederland 
In dit hoofdstuk was onderzocht of er verschillen bestaan in de kans op een doorgaande 
zwangerschap met IVF of ICSI tussen de verschillende IVF centra in Nederland nadat 
gecorrigeerd was voor de verschillen tussen de patiënten per centrum. De prospectief 
verzamelde gegevens van 11 centra, zie hoofdstuk 2, zijn hiervoor gebruikt. De prognostische 
index factor (een maat voor de invloed per voorspellende factor op de zwangerschapskans), 
verkregen vanuit het model in hoofdstuk 2, was gebruikt om voor de verschillen tussen de 
patiënten per kliniek te corrigeren. Tevens is rekening gehouden met de variatie in steekproef. 
Per IVF centrum was het absolute verschil in doorgaande zwangerschapskans, één jaar na 
start van de behandeling, vergeleken met de gemiddelde kans van alle centra.
De ruwe zwangerschapskansen verschilden een factor 3 tussen de centra. Na aanpassing aan 
de variatie in steekproef per centrum nam het verschil in zwangerschapkans tussen de twee 
uiterste centra af tot een factor 2. Bij een derde vergelijking is gecorrigeerd voor de 
indexfactor, waarbij er rekening werd gehouden met de leeftijd van de vrouw, of ze ooit 
eerder zwangerschap was geweest (primaire dan wel secundaire subfertiliteit), de duur van 
de fertiliteitstoornis en de diagnostische categorie. Hierdoor werd het verschil tussen de 
centra nog wat kleiner. Een jaar na de start van de behandeling, bedroeg de aangepaste en 
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gecorrigeerde kans op een doorgaande zwangerschap voor de twee uiterste centra 36% en 
respectievelijk 55%.
Slechts 17% van het verschil in zwangerschapskans tussen de centra kon worden verklaard 
door de verschillen in de geregistreerde patiënten karakteristieken. De overige redenen die 
de verschillen zouden kunnen verklaren dienen verder onderzocht te worden. 
Hoofdstuk 4
Zwangerschapskans op de wachtlijst vóór IVF of ICSI
In dit hoofdstuk werd een model weergegeven dat de kans op een spontane zwangerschap 
in de wachttijd vóór IVF of ICSI voorspelt. Alle paren die voor IVF of ICSI in aanmerking 
kwamen in één van de deelnemende IVF centra werden gedurende twee jaar prospectief 
gevolgd vanaf het moment dat ze op wachtlijst stonden. Hierna vond een koppeling plaats 
tussen de paren op de wachtlijst met de paren van de IVF registraties van de verschillende 
klinieken. Van de paren die niet in de IVF registraties gevonden werden, maar die wel op de 
wachtlijst stonden, werd vanuit de medische dossiers onderzocht wat de reden van het 
uitblijven van een behandeling was. De invloed van de factoren: leeftijd van de vrouw, de 
oorzaak, de duur en de primaire dan wel secundaire subfertiliteit op de kans op een spontane 
zwangerschap gedurende de wachttijd vóór IVF, werden in een predictie-model weer-
gegeven. 
De cumulatieve kans op een doorgaande spontane zwangerschap in de wachttijd voor IVF, 
indien de behandeling IVF of ICSI 1 jaar zou worden uitgesteld was gemiddeld 9%. Minder dan 
10% van alle paren op de wachtlijst had een kans die groter was dan 15%. Per jaar leeftijdsstij-
ging nam de kans op een spontane zwangerschap bij uitstel van de behandeling met 5% af. 
Met ieder jaar dat de fertiliteitstoornis langer duurde, nam de kans met 15% af. Ook de 
diagnostisch categorie was van invloed. Voor paren met een onbegrepen fertiliteitstoornis was 
de kans 2,6 maal groter dan voor paren verwezen vanwege tubapathologie. Vrouwen die niet 
eerder zwanger waren, hadden bijna 30% minder kans om alsnog spontaan zwanger te worden 
in de wachttijd vóór een behandeling in vergelijking met secundair subfertiele vrouwen. 
Gemiddeld genomen was de kans op een spontane zwangerschap binnen 1 jaar nadat de 
indicatie voor IVF of ICSI was bepaald, minder dan 10%, maar deze kon oplopen tot 25% voor 
vrouwen met de meest gunstige voorspellende factoren. 
Hoofdstuk 5
Factoren van invloed op de zwangerschapskans met IVF 
Dit hoofdstuk presenteerde de invloed van de patiëntkarakteristieken gerelateerd aan de 
verminderde fertiliteit, op de kans op een levend geborene na een eerste IVF behandeling. Tevens 
werd de invloed op de kans op zwangerschap met IVF van deze patiëntkarakteristieken 
gecombineerd met roken en de BMI. De verzamelde gegevens over levensstijl en zwangerschaps-
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uitkomsten werden verkregen uit een vragenlijst die werd gebruikt bij het OMEGA-project zie 
hoofdstuk 1. De onderzoekspopulatie bestond uit 8.457 vrouwen die tussen 1983 en 1995 minimaal 
één IVF behandeling hadden ondergaan in één van de destijds 12 IVF centra in Nederland.  
De gemiddelde kans op een levendgeborene in die periode was 15% per gestarte IVF cyclus. 
Met het stijgen van de leeftijd van de vrouw nam de kans op een levendgeborene na IVF af 
met 2% per jaar. De onafhankelijke invloed van meerdere variabelen is onderzocht:  Over het 
algemeen hadden rokers 28% minder kans op een levend geborene en een significant 
hogere kans op een miskraam in vergelijking met niet-rokers. Vrouwen met overgewicht (BMI 
≥ 27 kg/m2), hadden 33% minder kans dan vrouwen met een normaal gewicht (BMI 20-27 kg/
m2). De paren die IVF ondergingen vanwege een verminderde kwaliteit zaad hadden 30% 
minder kans op een levendgeborene per  eerste cyclus, in vergelijking met paren in twee 
andere diagnostische groepen (tubapathologie of overige oorzaken voor subfertiliteit). De 
duur van de fertiliteitstoornis en een eventuele zwangerschap in het verleden waren niet van 
invloed op de kans op een levendgeborene met IVF. 
Dit onderzoek over de eerste periode van IVF in Nederland gaf inzicht in de gemiddelde kans 
van slagen met IVF destijds, waarbij de invloed van aan subfertiliteit gerelateerde factoren en 
levensstijl factoren op de kans op een levendgeborene is bepaald. 
Hoofdstuk 6
Kans op een spontane zwangerschap ná stoppen met IVF 
We onderzochten de kans op een levend geborene, ontstaan uit een spontane zwangerschap, 
na afsluiting van de laatste IVF behandeling. De studie is uitgevoerd onder 8.669 vrouwen die 
in het verleden één of meerder IVF behandelingen hebben ondergaan (OMEGA-project, zie 
ook hoofdstuk 5) en die tot gemiddeld 5 jaar na de laatste IVF  behandeling gevolgd zijn. 
Binnen één jaar na het afsluiten van IVF, of binnen 1 jaar na de geboorte van een IVF kind, 
kreeg 7% van de vrouwen alsnog een kind via spontane conceptie. De kans op een spontane 
zwangerschap was afhankelijk van de oorzaak van de fertiliteitstoornis. Met het stijgen van 
de leeftijd van de vrouw nam de kans op een kind via spontane conceptie met 6% per jaar af. 
Er waren verschillen in het effect van de onderzochte factoren van invloed op de kans op een 
spontane zwangerschap voor paren die middels de laatste IVF een kind hadden gekregen, in 
vergelijking met paren die daarbij geen IVF-kind kregen. Voor paren met een niet succesvolle 
laatste IVF behandeling daalde de kans op een spontane zwangerschap met 20% indien de 
fertiliteitstoornis langer dan 6 jaar bestond en daalde met 29% indien vooraf meer dan 4 IVF 
pogingen hadden plaatsgevonden. Roken verlaagde de kans met 28%, overgewicht (BMI ≥ 
27 kg/m2) met 53%, cafeïne (≥ 4 koppen koffie per dag), deed de kans met 28% dalen en 
alcohol (≥ 3 glazen per week) verkleinde de kans met 43%. 
De invloed van de onderzochte factoren op de zwangerschapskans vóór en tijdens IVF bleek 
ook te gelden voor de kans een spontane zwangerschapskans ná stoppen met IVF. 
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Hoofdstuk 7
Invloed van angst en depressie op de kans op zwangerschap met IVF/ICSI
In een prospectieve studie werd de invloed van angst en depressie op de kans op 
zwangerschap met IVF/ICSI en de kans op het voortijdig staken van een behandeling 
onderzocht. Dit onderzoek werd uitgevoerd onder 783 vrouwen in 7 IVF klinieken tijdens 
een eerste IVF/ICSI behandeling. Voorafgaand aan de behandeling en kort vóór de punctie 
vulden zij een gevalideerde psychologische vragenlijst in. De uitkomsten van de vragenlijsten 
werden gecombineerd met de uitkomsten van de behandelingen, verkregen via de nationale 
cohort studie beschreven in hoofdstuk 2. De voorspellende waarde van angst en depressie 
werd berekend, nadat voor meerdere variabelen die de kans op een zwangerschap kunnen 
beïnvloeden (leeftijd van de vrouw, diagnostische categorie, primaire, dan wel secundaire 
subfertiliteit en de duur van de fertiliteitstoornis), werd gecorrigeerd. 
Angst en depressie voorafgaande aan een behandeling hebben geen invloed op de kans op 
zwangerschap en evenmin op de kans op een voortijdig afgebroken cyclus. Angststijging 
kort voor de eicel punctie, ten opzichte van het angst niveau enkele weken vóór de start van 
de behandeling, heeft eveneens geen invloed op de kans op zwangerschap.
Vrouwen die een eerste behandeling IVF/ICSI ondergaan kunnen gerustgesteld worden, 
hun gemoedstoestand heeft geen invloed op de kans op zwangerschap. 
Hoofdstuk 8
Risico op emotionele problemen na IVF of ICSI.
In dit hoofdstuk wordt beschreven of vrouwen met een verhoogd risico op het ontwikkelen 
van emotionele problemen na IVF/ICSI, voorafgaand aan de behandeling geïdentificeerd 
kunnen worden. Risicofactoren voor het ontwikkelen van emotionele problemen werden 
vastgesteld in een eerdere studie en opgenomen in een vragenlijst. “SCREENIVF” werd 
voorafgaande aan eerste IVF/ICSI en 6 weken na de punctie van een behandeling afgenomen 
bij 279 vrouwen. 
Het bleek dat 75% van de vrouwen juist geïdentificeerd kunnen worden op het al dan niet 
krijgen van emotionele problemen. De sensitiviteit van de test was 69%, dit betekent dat 
69% van de vrouwen die uiteindelijk emotionele problemen kregen met de test konden 
worden geïdentificeerd. De negatief voorspellende waarde van de test was hoog (89%), 
echter de positief voorspellende waarde was laag. Slechts 48% van de vrouwen met een, 
volgens SCREENIVF risicoprofiel, hadden inderdaad klinisch meetbare emotionele 
problemen. 
SCREENIVF kan gebruikt worden als een triage instrument en als hulpmiddel om te 
anticiperen op het risicoprofiel van vrouwen die starten met IVF. Vervolgens zou proactieve 
psychologische diagnostiek en begeleiding kunnen plaatsvinden ter preventie van 
voortijdige uitval of achteruitgang van psychisch welzijn. 
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Hoofdstuk 9
Kosten en oorzaken van werkverzuim tijdens IVF/ICSI 
De kosten van werkverzuim veroorzaakt door een eerste IVF/ICSI behandeling werden 
bepaald en de invloed van fysieke en de psychische klachten op het werkverzuim werd 
geanalyseerd. Het aan de IVF behandeling gerelateerde werkverzuim werd met behulp van 
een dagboekje bijgehouden door 384 vrouwen die werden behandeld in 8 verschillende IVF 
klinieken in Nederland. Voorafgaande aan de behandeling vulden zij ook een psychologische 
vragenlijst in (zie hoofdstuk 7). De uitkomsten van de behandelingen zijn verkregen uit de 
nationale cohort studie (zie hoofdstuk 2). 
Gemiddeld genomen was het werkverzuim 33 uur; 23 uur daarvan was gerelateerd aan de 
IVF/ICSI behandeling. Dit betekent een productiviteitsverlies door de IVF/ICSI behandeling 
van circa € 600 per behandeling. De belangrijkste reden voor het werkverzuim was voor 50% 
van de vrouwen fysieke en/of psychische klachten door de behandeling. Voor deze vrouwen 
waren de kosten voor het productiviteitsverlies het 4-voudige ten opzichte van de overige 
vrouwen die voornamelijk verzuimden vanwege ziekhuisbezoeken, welke gemiddeld 10 uur 
betroffen. Vrouwen die meer uren per week werkten hadden meer IVF gerelateerd 
werkverzuim. Hoog opgeleide vrouwen hadden minder IVF gerelateerd verzuim dan vrouwen 
met een gemiddeld opleidingsniveau. 
Om de kosten van werkverzuim door IVF te verminderen zou de focus op preventie van 
fysieke en psychische klachten moeten liggen. 
Hoofdstuk 10
Kostenanalyse van een IVF en ICSI behandeling
In dit hoofdstuk werden de kosten van een eerste IVF en een ICSI behandeling per behande-
lingsfase, per cyclus en per doorgaande zwangerschap beschreven. Ook de kosten van een 
behandeling met ingevroren “rest” embryo’s (cryo’s) werden berekend. De gegevens over de 
kosten zijn verkregen uit 4 IVF centra, 2 academische, 2 niet academische en één transport 
ziekenhuis. De behandelgegevens zijn verkregen via de IVF registraties van het nationale 
cohort onderzoek (zie hoofdstuk 2), via jaarverslagen van drie IVF centra en via de nationale 
infertiliteit registratie (LIR).
De gemiddelde kosten van een IVF en ICSI behandeling waren bijna € 2500. De totale kosten 
van de behandeling worden voor het merendeel bepaald door de kosten voor medicatie. Bij 
vrouwen vanaf 34 jaar stegen de gemiddelde kosten per doorgaande zwangerschap door 
hogere kosten voor medicatie (hogere gemiddelde doses per cyclus) en dalende kans op 
zwangerschap. De kosten van bewaring, ontdooiing en terugplaatsing van ingevroren 
embryo’s waren gemiddeld € 550. De kosten van een ICSI behandeling waren 8% hoger dan 
voor IVF door hogere kosten van apparatuur en arbeidsintensievere laboratorium procedures. 
De totale kosten per doorgaande zwangerschap per ICSI behandeling lagen echter lager dan 
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bij IVF vanwege de hogere kans op succes bij ICSI. Gemiddeld waren de kosten van een IVF/
ICSI behandeling € 10.250 per doorgaande zwangerschap.
Hoofdstuk 11 
Doelmatigheid van een IVF of ICSI behandeling
Dit hoofdstuk beschrijft een kosteneffectiviteit analyse van een behandeling IVF gestart bij 
paren die voldeden aan de NVOG richtlijn IVF (“direct- IVF”), in vergelijking met paren waarbij 
de behandeling één jaar langer zou worden uitgesteld. De berekening werd uitgevoerd met 
behulp van twee predictie modellen. Eén model is ontstaan uit een onderzoek naar de kans 
op zwangerschap één jaar na de start van IVF of ICSI in Nederland (zie hoofdstuk 2). Het 
andere model ontstond uit de studie naar de kans op een spontane zwangerschap op de 
wachtlijst voor IVF of ICSI (zie hoofdstuk 4). De prognostische factoren in de modellen waren 
leeftijd van de vrouw, diagnostische categorie, de duur en de aard van de subfertiliteit. De 
kosten van een IVF/ICSI behandeling zijn verkregen uit een steekproef van paren die een 
eerste IVF en ICSI behandeling ondergingen (zie hoofdstuk 10). De kosten van een behandeling 
IVF en de daaruit voortvloeiende kosten van een bevalling en de neonatale zorg werden 
vergeleken met de kosten indien de zwangerschap spontaan zou zijn ontstaan. Hierbij werd 
ook rekening gehouden met de grotere kans op een meerling met IVF/ICSI. 
De kosteneffectiviteit ratio is het verschil in kosten per levend geborene bij direct een 
behandeling IVF/ICSI in vergelijking tot de kosten bij één jaar uitstel van IVF, gedeeld door het 
verschil in kans op een levend geborene tussen de twee scenario’s. De kosteneffectiviteit 
ratio’s lagen tussen de € 10.000 en € 50.000 per levend geborene. Voor vrouwen met 
endometriose was de kosteneffectiviteit ratio net onder de € 10.000 vanaf 34 jaar. Voor alle 
andere diagnostische categorieën, ongeacht de leeftijd ligt de kosteneffectiviteit ratio hoger. 
Voor vrouwen met een onbegrepen subfertiliteit ligt de ratio op € 30.000 vanaf 32 jaar en 3 
jaar subfertiliteit. 
Uitstel van IVF bespaart kosten tegen een kleine vermindering van het totaal aantal zwanger-
schappen. De kosteneffectiviteit van IVF wordt bepaald door de diagnostische categorie, de 
leeftijd van de vrouw en de duur van de fertiliteitstoornis, maar ook van de maatschappelijke 
bereidheid om te betalen voor de kosten van een extra levend geborene. 
 
Hoofdstuk 12
Algemene discussie 
In dit hoofdstuk worden de antwoorden op de onderzoeksvragen en de belangrijkste 
conclusies en aanbevelingen gegeven:
1.  In Nederland was de kans op een doorgaande zwangerschap gemiddeld 24% na een 
eerste cyclus IVF/ICSI. Één jaar na de start van de behandeling was de kans 45%. 
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De zwangerschapskans met IVF/ICSI was voornamelijk afhankelijk van de leeftijd van de 
vrouw, voor een deel van de duur van de subfertiliteit en een eventuele eerdere 
zwangerschap en niet van de diagnostische IVF categorie. Het predictie model voor de 
kans op zwangerschap met IVF/ICSI zou gevalideerd moeten worden met gegevens van 
een nationale uniforme registratie van fertiliteitsbehandelingen en zou ook levensstijl 
factoren moeten bevatten. 
2.  Per IVF centrum verschilden de kansen op een doorgaande zwangerschap, één jaar na de 
start, tussen de 36% en 55%. Voor een klein deel worden de verschillen verklaard door de 
verschillen in patiënten populaties. Er zouden meer klinische en niet-klinische 
voorspellende variabelen geregistreerd moeten worden om meer duidelijkheid te krijgen 
over de verschillen tussen de IVF centra. 
3.  De gemiddelde kans op een spontane zwangerschap indien een IVF/ICSI behandeling 
met één jaar zou worden uitgesteld was 9%. Binnen één jaar na stoppen met IVF, was de 
kans op een spontane zwangerschap gemiddeld 7%. De kans op een spontane 
zwangerschap is zowel vóór als ná stoppen met een IVF behandeling, afhankelijk van de 
leeftijd van de vrouw, of ze ooit eerder zwanger is geweest, de oorzaak en de duur van de 
subfertiliteit. De counseling van paren op hun kans op een spontane zwangerschap zou 
gebaseerd moeten zijn op predictie modellen, waarin levenstijl factoren moeten worden 
meegenomen.  
4.  Rokende vrouwen en vrouwen met overgewicht (BMI ≥ 27 kg/m2) hadden 30% minder 
kans op een zwangerschap met IVF. Eveneens werd de kans op een spontane 
zwangerschap na stoppen met IVF verlaagd door roken, overgewicht, cafeïne en alcohol. 
Een grote prospectieve studie naar de invloed van levenstijl factoren tijdens fertiliteits-
behandelingen zou nog uitgevoerd moeten worden.
5.  Angst en depressie vóór en tijdens een IVF behandeling, verkleinden niet de kans op een 
IVF zwangerschap en had eveneens geen invloed op de kans op een voortijdig afgebroken 
behandeling. “SCREENIVF”, afgenomen voorafgaand aan een eerste IVF behandeling gaf 
in 75% van de vrouwen juist aan of zij wel of niet risico liepen op psychische problemen 
na een behandeling. De sensitiviteit van de test zou nog verbeterd kunnen worden. Bij 
onderzoek naar de invloed van negatieve emoties en fertiliteit zou onderzoek naar 
samenhang met levensstijl factoren niet mogen ontbreken. 
6.  De gemiddelde kosten van een IVF/ICSI behandeling waren € 10.250 per doorgaande 
zwangerschap. 
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 De kosten van werkverzuim door IVF, waren € 600 per eerste cyclus. Door lichamelijke en 
psychische klachten te voorkomen, zouden de kosten van het werkverzuim door IVF 
aanzienlijk verminderd kunnen worden.  
 Voor vrouwen uit alle diagnostische categorieën boven de 32 jaar lagen de kosteneffec-
tiviteit ratio’s voor direct IVF in vergelijking met uitstel van IVF met 1 jaar, in een range 
tussen de € 10.000 en € 25.000 per levend geborene. Behalve voor vrouwen met een 
onbegrepen subfertiliteit. Om in dezelfde range te vallen zouden zij bovenop de drie jaar 
die de huidige richtlijn aangeeft, de IVF behandeling minstens nog één jaar langer 
moeten uitstellen.
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Dankwoord
De eerste documenten over een op handen zijnd onderzoek naar de effectiviteit van de 
richtlijn IVF die ik gevonden heb dateren uit 1996. Dat was ver voordat ik erbij betrokken 
raakte. Mede dankzij de inspanningen van Didi Braat werd de subsidie voor het wachtlijst 
onderzoek naar de kosteneffectiviteit van IVF binnengehaald. Bij de start van het onderzoek 
ging het voor mij nog slechts om het verzamelen van de landelijke registraties van IVF 
 behandelingen, zonder het uiteindelijke doel om te promoveren. De samenwerking en 
 betrokkenheid van zoveel mensen hebben echter de morele druk hoog genoeg opgevoerd 
om het promotietraject voort te zetten. 
Iedereen die wetenschappelijk of vriendschappelijk betrokken is geweest bij de totstand-
koming van het proefschrift wil ik bedanken en enkelen in het bijzonder. 
Allereerst: beste Didi, dankzij jouw vastberadenheid, jouw positieve instelling en je  enthousiasme, 
kon ik niet anders dan doorzetten. Dank voor je vertrouwen in het onderzoek en in mij. Je hebt 
gelijk gehad, het is best goed geworden. De vele uren in de trein of auto van Nijmegen naar 
Utrecht en Rotterdam werden nuttig besteed; daarbij was het ook altijd gezellig. 
Beste Dik, je was een stabiele factor tijdens dit onderzoek, dank voor je aanwezigheid bij 
ieder overleg. Jouw wetenschappelijke kennis overkoepelde alle betrokken disciplines. Je 
creatieve inbreng was van bijzondere betekenis. Ik heb dankbaar gebruik gemaakt van je 
deskundigheid en je nauwgezetheid. Je was niet snel tevreden, maar nadat jij er nog eens 
naar had gekeken, werd het altijd beter. 
Beste René, jouw aandeel in dit proefschrift was enorm door je uitgebreide expertise van 
onderzoek in de fertiliteit en je onuitputtelijke inzet. Het is bewonderenswaardig dat je het 
overzicht hebt gehouden over onze complexe gegevensbestanden, mede gezien het feit dat 
je jouw aandacht moest verdelen over nog vele andere onderzoekers in Nederland. 
Jouw vermogen en geduld om mij iets uit te leggen heb ik zeer gewaardeerd. Dank voor het 
wekelijks telefonisch overleg; het heeft er uiteindelijk toe geleid dat ik het onderzoek wist af 
te ronden.
Beste Chris, als onderzoeker naar de interactie tussen psychologische factoren en behandeling-
en in de fertiliteit, heb je inmiddels je sporen verdiend. Ik ben blij dat dit onderzoek daar deel 
van uit maakt. Bedankt voor je begeleiding gedurende het hele traject en dank voor al je 
 inspanningen zodat ook het artikel “SCREENIVF” nog in het proefschrift terecht is gekomen. 
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Beste Clazien, ik bewonder de grondigheid waarmee je het onderzoek naar de kosten en het 
werkverzuim tijdens IVF hebt uitgevoerd. Dank dat ik daarvan ook de vruchten heb mogen 
plukken. Achteraf gezien had een dubbelpromotie er wel ingezeten. 
Beste Leona, bedankt voor je kritische commentaren tijdens de werkgroep vergaderingen en 
je bijdrage aan het onderzoek naar de kosten en het werkverzuim van IVF. 
Beste Claudine, dank voor je inzet om de landelijke IVF gegevens tot één geheel te maken. 
Nu besef ik pas hoe druk je moet zijn geweest met deze data, terwijl je ook nog jouw eigen 
promotieonderzoek aan het afronden was. 
Beste Floor, dank voor je inbreng als onderzoeker pur sang, het was altijd even schrikken 
wanneer ik je uitgebreide commentaar op de manuscripten terugkreeg, maar het heeft wel 
tot opmerkelijke artikelen geleid.
Beste Thea, bedankt voor je heldere, bondige opmerkingen. Altijd treffend, nooit overbodig. 
Beste Reini, onze gemeenschappelijke interesse in factoren van invloed op de fertiliteit heeft 
ons samengebracht. Het is maar goed dat we van tevoren niet hebben geweten dat het 
 artikel over de spontane zwangerschappen na IVF zich zo lang zou voortslepen. Bedankt dat 
je hebt doorgezet. 
Beste Pieternel, het lijkt niet alleen een eeuwigheid geleden dat wij hebben samengewerkt, dat 
is het ook. In tussentijd is er veel gebeurd. Ik dank je voor jouw aanzet tot mijn allereerste artikel 
over lifestyle en IVF. Hiermee heb jij een belangrijke richting gegeven aan dit proefschrift.
Aan alle mede auteurs: ik dank jullie voor jullie inzet en commentaar: 
Beste Suzanne en Anne Marije, destijds enthousiaste wetenschappelijke stagiaires, nu beiden 
al een eigen carrière in de gezondheidszorg. 
Beste Jesper, dank voor je constructieve commentaar, de scherpte die jij meegaf aan het 
 artikel over stress en IVF, was net wat het nodig had. 
Beste Jan, bedankt voor de niet-aan-onderzoek-gelabelde-tijd, die ik toch als zodanig kon 
gebruiken. Mooi, dat we toch samen een publicatie op onze naam hebben staan. 
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Beste Evelien, Kees, en Curt: het is al lang geleden dat we het eerste artikel voor dit proef-
schrift schreven. Bedankt voor jullie bijdragen. 
Beste verpleegkundigen, analisten, secretaresses, embryologen, gynaecologen en andere 
medewerkers van de afdeling voortplanting: bedankt voor jullie collegialiteit en persoonlijke 
belangstelling. De combinatie van onderzoek en kliniek viel mij niet altijd mee. Dankzij jullie 
was de praktijk altijd een welkome afwisseling met het werk achter de computer. 
Beste Rianne, bedankt voor je steun aan het onderzoek. Van tevoren wisten we dat het een 
onderzoek van grote getallen zou worden, waarvoor zelfs een secretaresse mocht worden 
aangesteld. Het begon met het informeren van 600 gynaecologen. Daarop volgde  uiteindelijk 
een gegevensbestand van meer dan 9000 nieuwe IVF paren op een landelijke wachtlijst. 
Vervolgens voerde je alle gegevens in van het uitgebreide vragenlijstonderzoek onder ruim 
1000 vrouwen. Zonder jouw hulp was dit alles nooit gelukt.
Beste Mark, status F, het databestand programma dat lijkt te dateren uit de tijd van de 
 ponstypistes, is onlosmakelijk met je verbonden. Bedankt dat we gebruik konden maken van 
je kennis en het doorspelen ervan aan Elly, die er daarna net zo handig mee werd als jij.  
Ik dank alle IVF centra, transport- en satelliet-klinieken voor de vruchtbare samenwerking. 
Geheel belangeloos hebben vele secretaresses en verpleegkundigen, fertiliteitartsen en 
 gynaecologen van de verschillende afdelingen voortplanting in het land zich ingezet voor 
mijn onderzoek. 
Geachte leden van de manuscript commissie: ik dank jullie hartelijk voor het lezen en 
 beoordelen van het proefschrift. Ik vind het oprecht jammer dat jullie niet allen aanwezig 
kunnen zijn bij de verdediging.
Beste onderzoekers uit de kantoortuin, ook al zat ik er maar zelden, ben ik van een andere 
generatie en ging ik nooit mee lunchen of mee op weekend, jullie gaven me toch het gevoel 
dat ik erbij hoorde. Bij het vieren van een publicatie en het komen en gaan van medewerkers 
en stagiaires werd ik nooit vergeten. Dank daarvoor.
Beste oud-collega’s uit Zwolle, mijn kennismaking met de fertiliteit was bij jullie in het Sophia 
ziekenhuis. Met veel plezier denk ik terug aan de achteraf gezien zeer bewogen eerste jaren 
als fertiliteitarts waarin ik trouwde, kinderen kreeg, door de week een alleenstaande ouder 
was en twee keer verhuisde in 3 ½ jaar tijd. 
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Bedankt mede IVF-artsen. Het was een komen en gaan: Marieke, Martin-Jan, Katja, Esther, 
Ilse, Anika, Marijke, Selma, Joyce en Corien. Bedankt voor jullie collegialiteit en  innemende 
 persoonlijkheden en humor. 
Bovenal bedankt collega, partner-in-crime en paranimf, Gwendolyn. Patiëntenzorg gaat altijd 
vóór op onderzoek, maar jouw tijd komt eraan.
Sportieve maatjes van Langszij, altijd maar weer uitleggen dat ik geen tijd had om te trainen 
ging vervelen, maar dank dat jullie me niet zijn vergeten. Ik ben er straks weer, zal niet  meteen 
op kop rijden, maar over een tijd moeten jullie weer rekening met me gaan houden.
Lieve familie en vrienden, bedankt voor jullie aandacht-op-maat voor de voortgang van het 
onderzoek. Nu het af is, wil ik er alles over kwijt. 
Lieve pa en ma, voor jullie heb ik het afgemaakt, al hebben jullie daar nooit op  aangedrongen. 
Het was al goed zoals het was. Bedankt daarvoor.
Juul en Noor, lieve meiden, ik ben blij dat ik geen gynaecoloog ben geworden, dan waren 
jullie er namelijk niet geweest en een leven zonder jullie is niet voor te stellen.
Allerliefste Jos, de enige echte wetenschapper van ons twee. Ik heb dankbaar gebruik 
 gemaakt van je vermogen om in oplossingen te denken. Wat zal ook jij blij zijn dat het af is. 
Na lang aandringen heb je toegezegd om paranimf te worden, daar maak je me nog 
 gelukkiger mee. 
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